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Visceral pain management is a major clinical problem since the lack of effective and safe 
drugs. The development of chronic visceral hypersensitivity frequently occurs in patients with 
a history of intestinal damage. Indeed, 20-50% of patients affected by Inflammatory Bowel 
Diseases (IBDs) manifest a chronic abdominal pain also in the remission phase of colitis. 
Despite the large number of sufferers, the mechanisms that drive the development of chronic 
abdominal pain remain largely unresolved and this presents a major barrier to progress in the 
development of new therapies. The present work aimed to: a) setup an animal model of 
chronic visceral pain closely related to the clinical manifestations for studying the 
pathophysiological mechanisms involved and looking for novel possible treatments; b) 
evaluate the efficacy of adenosine A3 receptor (A3AR) agonists in reducing post-inflammatory 
visceral hypersensitivity in rats; c) assess gut microbiota involvement in the persistence of 
visceral pain after the resolution of inflammation. 
For these purposes we induced chronic visceral hypersensitivity in rats by the intra-rectal 
injection of dinitrobenzene sulfonic acid (DNBS, 30 mg in 0.25 mL EtOH 50%). Visceral 
pain was assessed by measuring the Visceral Motor Reflex (VMR) and the Abdominal 
Withdrawal Response (AWR) to Colo-Rectal Distension (CRD). Animals anxiety and 
depressive-like behaviour were investigated after DNBS injection. Histological and molecular 
characterization of bowel endothelium, enteric and central nervous system was carried out. As 
a consequence of the intestinal damage induced by DNBS, animals developed a visceral 
hypersensitivity which persisted also after colitis remission on days 14 and 21 up to 3 months. 
Visceral hypersensitivity was accompanied by depressive, but not anxiety behaviour in the 
animals. On day 14 a pharmacological characterization of pain by commonly used pain-
relieving drugs (intraperitoneally vs intrathecally injected) revealed a mixed nociceptive, 
inflammatory and neuropathic pain originated by both the peripheral and central nervous 
system. At this time point, gut histological analysis highlighted a partial restitution of the 
tunica mucosa, transmural collagen deposition, infiltration of mast cells (MCs) and 
eosinophils, and upregulation of SP-nerve fibres which were surrounded with eosinophils and 
MHC-II-positive macrophages. At spinal cord level, a significant morphological activation of 
both microglia and astrocytes (Iba1- and GFAP-marked respectively), as well as an increased 
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number of astrocytes, was observed in the dorsal horn. The same cellular framework was 
found in the ventral horn. With the aim to individuate possible novel pharmacological 
approach, the acute effects of A3AR agonists (MRS5980 and Cl-IB-MECA) were evaluated 
over time after DNBS injection and compared to the clinically-used drug linaclotide. A3AR 
agonists significantly reduced DNBS-evoked visceral pain both in the post-inflammatory (14 
and 21 days after DNBS injection) and persistence (28 and 35 days after DNBS) phases. 
Efficacy was comparable to that of linaclotide. Patch-clamp recordings showed that A3AR 
agonists inhibited Cav2.2 in DRG neurons isolated from either control or DNBS-treated rats, 
this pharmacodynamic effect was confirmed by testing the selective Cav2.2 blocker 
PD173212 that fully reduced abdominal hypersensitivity to control values. 
Among the factors involved in the complex physiology of the gut-brain axis, the microbiota 
plays a role of primary importance. Recent findings have linked microbiota alterations to 
gastrointestinal disorders characterized by abdominal pain. To investigate the microbiota 
capacity of modulating visceral sensitivity the effect of Faecal Microbiota Transplantation 
(FMT) from DNBS donors (in the post-inflammatory phase) to naïve rats has been evaluated. 
To prepare the animals to the FMT, they were pre-treated with antibiotics. The effect of FMT 
on visceral sensitivity, intestinal histology, permeability, immune response and 
neurotransmitters levels was studied. The faecal content was processed for assessing 
monoamines and the plasma for tryptophan metabolites. As expected, the antibiotic treatment 
induced an increase in visceral sensitivity in the animals. This effect was completely reverted 
by the re-colonization of intestine with a healthy microbiota, as well as by administering the 
vehicle. By contrast, the FMT from DNBS donors led to a further increase in visceral 
sensitivity in the animals. Three weeks after the interruption of the treatments this 
hypersensitivity progressively decrease again. This behavioural trend correlated with 
modifications in the gut microbiota. Studying possible mechanisms of this phenomena we 
highlighted that the effect induced by FMT was not related to an inflammatory response, 
neither to changes in gut permeability or monoamines levels in the gut. A significant 
reduction of tryptophan was observed in all the animals underwent the antibiotic treatment 
and the FMT (irrespective to the donor), as well as the DNBS donors (wherein it correlates 
with an increase in the production of 5-HT). Finally, to evaluate the therapeutic effect of 
FMT, 7 days after DNBS injection, the animals have been subjected to FMT from healthy 
controls. The transplant of a healthy microbiota in DNBS-treated animals counteracted the 
persistence of visceral pain after the colitis resolution, confirming an active involvement of 
microbiota in post-inflammatory visceral pain.    
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In conclusion, this work highlighted the complex nature of post-inflammatory visceral pain 
whose study required a multidisciplinary approach. Within this scenario, A3AR agonists 
appear to be a promising resource for visceral pain management. The results obtained with the 
FMT strengthen the hypothesis of a direct involvement of microbiota in post-inflammatory 





























1. Visceral Pain definition and features 
 
1.1. Pain 
Pain is the most common question for people to seek health care. Traditionally, pain has been 
viewed as a symptom for which a cause is diagnosed, and pain is eliminated by control or 
cure of the cause (McCaffery and Beebe, 1989). As its best, pain is the body‘s natural alarm 
system, warning us of injury. It prompts us to stop a harmful behaviour or look for medical 
attention. When pain persists, it is often a sign that the body‘s alarm system has broken down 
which means the pain signals are still active (The American Pain Foundation, 2010a). 
Untreated pain can have serious physiological, psychological and social consequences. It can 
limit the ability to sleep, perform everyday tasks and exercise. It also reduces mobility and 
appetite, aggravating other health problems. From the psychological point of view, it can lead 
to depression and anxiety which often reinforce the sensation of pain and place added strain 
on relationships (The American Pain Foundation, 2010b). 
Besides, if we look at the definition of pain given by International Association for the Study 
of pain (IASP): ―Pain is an unpleasant sensory and emotional experience associated with 
potential or actual tissue damage or described in terms of such damage‖, we realize that pain 
is always subjective and it means that psychosocial and spiritual concerns can modify the 
sensation of it (Woodruff, 2004). A person‘s response to pain is shaped by age, emotional 
state, sociocultural factors, past experiences with pain, the patient‘s knowledge of pain and 
the meaning of pain itself (Burke et al, 2011). The term ‗total pain‘ refers to the etiological 
components of pain in addition to the noxious physical stimulus, that affect the patient‘s 
experience of pain: fear, social isolation, spiritual crisis, dependency, helplessness, anger and 
frustration (Radwany and Von Grueningen, 2012).   
Several classification systems are available in the pain literature according to several 
variables, including its duration (acute, convalescent, chronic) and its pathophysiologic 
mechanisms (nociceptive, inflammatory, neuropathic) (Cherny et al., 1994). Moreover, on the 






1.2. Visceral pain 
Visceral pain is by definition pain sensed as arising from the internal organs of the body. It 
results from the activation of nociceptors of the thoracic, pelvic, or abdominal viscera 
(Kennedy and Abd-Elsayed, 2019). There are multiple etiologies for visceral pain, including: 
• Inflammation (acute and chronic),  
• Mechanical irritants (e.g., kidney stones); 
• Infection; 
• Disruption of normal mechanical processes (e.g., gastrointestinal dysmotility); 
• Neoplasms (benign or malignant); 
• Alterations in nerves carrying sensations from the viscera;  
• Ischemia. 
Visceral structures are highly sensitive to distension (stretch), ischemia and inflammation, but 
relatively insensitive to other stimuli that normally evoke pain such as cutting or burning 
(Aziz, 2019). Although there are many commonalities in the processing of somatic and 
visceral pain, there are also several important clinical distinctions (Kennedy and Abd-Elsayed, 
2019). Firstly, pain cannot be evoked from all viscera. Besides injury to the viscera does not 
necessarily cause pain. Visceral pain is perceived more diffusely than noxious cutaneous 
stimulation with respect to location and timing, owing to relatively few visceral afferents with 
extensive receptive fields (Procacci et al., 1986). Pain from different visceral organs can have 
differing areas of presentation, e.g. bladder to perineal area, heart to left arm and neck, left 
ureter to left lower quadrant and loin. This diffuse nature and difficulty in locating visceral 
pain is due to a low density of visceral sensory innervation and extensive divergence of 
visceral input within the Central Nervous System (CNS). Subsequent development of 
symptoms may entail referred pain to parietal somatic structures within the same metameric 
field as the affected organ. Spatial discrimination of visceral pain is thus typically referred to 
superficial structures to produce secondary hyperalgesia of superficial or deep body wall 
tissues due to viscera-somatic convergence into shared spinal levels (discussed later) 
(Machmahon and Koltezenburg, 2006; Sikandar and Dickenson, 2012). This ―referred pain‖ 
is better localized and therefore difficult to differentiate from pain of somatic origin. 
Furthermore, visceral pain is often associated with marked autonomic phenomena, including 
pallor, profuse sweating, nausea, muscle tension, gastrointestinal (GI) disturbances and 
changes in body temperature, blood pressure and heart rate (Procacci et al., 1986). The table 
below lists the general characteristics of visceral pain in humans, underlying the difference 





Machmahon S.B., Koltezenburg M. Wall and Melzack’s Textbook of Pain, 2006. 
 
 
1.3. Chronic visceral pain 
It has been estimated that ~40% of population experience a chronic or persistent pain from 
internal organs. Traditionally, chronic visceral pain has been categorized as either ―organic,‖ 
caused by a pathological lesion that is detectable by standard diagnostic measures, or 
―functional,‖ where the etiology remains obscure and may be due to yet undefined changes in 
visceral sensitivity at either the peripheral or central level (Kennedy and Abd-Elsayed, 2019). 
Abdominal pain is the most common visceral pain and results in more than 15 million office 
visits per year. Chronic abdominal pain affects at least 10%–15% of the general population 
and is a characteristic feature of functional bowel disorders, such as irritable bowel syndrome 
(IBS), the inflammatory bowel diseases (IBDs), and is a growing problem associated with 
chronic opioid use (Longstreth et al., 2006; Mansfield et al., 2016;  Regueiro et al., 2017)  
 
1.4. Visceral pain in IBS 
The IBS is the most commonly diagnosed chronic gastrointestinal disease. Prevalence rates of 
IBS vary between 1.1% and 45%, based on population studies from countries worldwide 
(Longstreth et al., 2006). According to the Rome III criteria, IBS is defined based on the 
presence of chronic/recurrent abdominal pain or discomfort at least three days per month in 
the past three months associated with two or more of the following: (1) improvement with 
Somatic Visceral 
 
 Can be superficial (skin, muscle) or  
deep (joints, tendons, bones) 
 Nociceptors are involved 
 It is well localized 
 Usually described as throbbing or aching 
  
 
 Involves hollow organs and smooth muscle 
nociceptors that are sensitive to stretching or 
hypoxia and inflammation 
 Pain is usually referred, poorly localized, vague 
and diffuse 
 May be associated with autonomic symptoms 
(e.g. pallor, sweating, nausea, blood pressure 




defecation; (2) onset associated with a change in frequency of stool; and (3) onset associated 
with a change in form (appearance) of stool. These criteria should be fulfilled for the previous 
three months with symptom onset at least six months before diagnosis (Longstreth et al., 2006). 
Rome III criteria subtype IBS according to the predominant bowel habit as IBS with 
constipation (IBS-C), IBS with diarrhea (IBS-D), mixed type, and unclassified (Longstreth et 
al., 2006). To this end, the definition of bowel-habit type is based on the patient‘s description 
of the stool form by referring to the Bristol Stool Scale (Lewis et al., 1997). Nevertheless, IBS 
symptoms cannot be explained by structural abnormalities, and specific laboratory tests or 
biomarkers are not available for IBS. Therefore, IBS is classified as a ―functional‖ disorder 
whose diagnosis depends on the history of manifested symptoms (as above described) 
(Cervero et al., 2004). IBS patients can be further divided into two categories: sporadic 
(nonspecific) and postinfectious or inflammatory bowel disease-associated (PI-IBS). Meta-
analyses suggest that gastroenteritis increases the risk of developing IBS sixfold, making it 
one of the strongest risk factors for IBS. PI-IBS shows clearly that acute inflammation 
followed by mucosal healing can cause the development of chronic IBS symptoms (El-Salhy 
et al., 2012; El-Salhy et al. 2014; Cairns et al., 2014). Early studies suggested adverse 
psychological features were less common in PI-IBS, but other studies suggest that 
hypochondriasis, anxiety, depression and somatization are important risk factors for 
developing PI-IBS, as they are for all IBS subtypes (Coyle et al., 1998; Sweitzer et al., 1999; 
Stuesse et al., 2001; Bandell et al., 2004; Larauche et al., 2008; Cairns et al., 2014). The 
prognosis for PI-IBS seems to be similar to other IBS subtypes (Tanga et al., 2004). 
Nevertheless, PI-IBS is a useful model for understanding mechanisms in IBS because it has a 
defined mode of onset making it easy to separate cause from effect. Regarding the 
pathophysiological mechanisms of IBS, though routine histologic examinations do not show 
significant colonic mucosal abnormalities in the majority of IBS patients, however, recent 
quantitative histologic, immunohistochemical, and ultrastructural analyses have indicated 
subtle organic alterations in these patients, like an increase in histamine levels in the gut 
(Morales-Soto and Gulbransen, 2018). 
 
1.5. Visceral pain in IBD 
IBDs which are comprised of two main types, ulcerative colitis (UC) and Crohn's disease 
(CD), affects approximately 3.6 million people in the United States and Europe (Longstreth et 
al., 2006). Although considerable progress has been made in recent years, a major gap in 
knowledge of the pathogenesis of chronic visceral hypersensitivity in IBD patient remains and 
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consequently effective treatments are still lacking. IBD is characterized by chronic or 
relapsing immune activation and inflammation within the gastrointestinal (GI) tract that 
markedly alters GI function (Schirbel et al., 2010). When the gut is inflamed, there is 
breakdown of intestinal barrier function, abnormal secretion, changes in the patterns of 
motility, and visceral sensation, which contributes to symptom generation (diarrhoea, 
cramping, and pain) (Srinath et al., 2012).  
Although abdominal pain has been traditionally associated with inflammatory flare-ups in 
IBD, a large subset of patients that suffer from IBD eventually develop chronic abdominal 
pain even after achieving clinical remission. This condition, called comorbid IBS (loosely 
termed ―IBS-IBD‖), is present in up to 46%–59% of patients with Crohn‘s disease and 36%–
38% of patients with ulcerative colitis in remission (Keohane et al., 2010; Minderhoud et al., 
2004; Halpin et al., 2012). Abdominal pain linked to these disorders is common in adults and 
pediatric patients and is a major contributing factor to their low quality of life and high 
morbidity. As a result, the Food and Drug Administration (FDA) now requires the use of 
abdominal pain as a patient-reported outcome to assess the efficacy of new therapies for 
Crohn‘s disease (Regueiro et al., 2017). The mechanisms that drive the development of 
chronic abdominal pain remain largely unresolved and this presents a major barrier to 
progress in the development of new therapies. Current therapies for IBD primarily focus on 
controlling inflammation with amino salicylates, corticosteroids, immunomodulators, and 
biologic agents. Although these agents clearly benefit the treatment of active inflammation, 
they do not address abdominal pain (Colombel et al., 2017) Opioids are the current frontline 
therapy for chronic abdominal pain, but chronic opioid use has serious complications and 
produces a condition called narcotic bowel syndrome that is characterized by abdominal pain 
(Camilleri et al., 2017). This is a serious and growing issue that requires a more sophisticated 





Symptoms in IBD and IBS 
Spiller and Major, Nature Reviews Gastroenterology & Hepatology, 2016 
 
1.6. Visceral pain comorbidities  
Visceral pain is reported to be frequently associated with both somatic and psychiatric disorders. 
Among the somatic comorbidities, the association between IBS and fibromyalgia is the most studied, 
with the IBS-symptoms occurrence in an estimated 48% (range, 32%–77%) of patients with 
fibromyalgia. Six studies examining the presence of IBS in patients with chronic fatigue syndrome 
reported a high degree of overlap, ranging from 35% to 92% (median, 51%) found that 38% of IBS 
patients self-reported back pain, 18% reported premenstrual syndrome, and 10% 
reported dysmenorrhea (Whitehead et al., 2001). All of these incidence rates are significantly higher 
than those in other gastrointestinal patients. Anxiety and depression are the most commonly reported 
psychiatric comorbidities in chronic visceral pain syndromes (Garakani et al., 2003; Frissora and 
Koch, 2005; Whitehead et al., 2007; Spetalen et al., 2009). This complex link between visceral 
sensation and psychological perceptions are mediated via the brain–gut axis. Moreover, stress-related 
changes in bowel habit can attest to the fact that the brain can influence gut function and sensation 
(Park et al., 2008). Several clinical studies have suggested that psychosocial comorbidity is a major 
contributor to the severity and impact on quality of life of visceral pain disorders such as IBS and 
somatic pain disorders such as fibromyalgia (Gupta and Silman, 2004; Boudewijn van Houdenhove 
and Egle, 2005; Resendiz-Figueroa et al., 2008; Mikocka-Walus et al., 2008). These findings are 
reinforced by a considerable volume of experimental research that links stress, anxiety, and depression 
to altered GI sensory and motor function as well as altered pain processing. Indeed, successful 
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management of patients with visceral pain disorders requires careful attention to these psychosocial 
factors, often in consultation with mental health professionals (Moloney et al., 2015). Depression and 
anxiety are also common in patients affected by IBD. A recent systematic review of 86 studies found 
that adults with IBD are more likely to develop anxiety and depression before IBD onset, and rates of 
anxiety and depression are higher in patients with IBD than in the general population, and higher in 
those with active IBD compared with inactive IBD (66.4% versus 28.2% respectively for anxiety, and 
34.7% versus 19.9% for depression). Antidepressants are often used to treat the anxiety and depression 
that is commonly experienced by patients with IBD and IBS, wherein they have also been shown to be 
effective in treating associated gastrointestinal symptoms (Macer et al., 2017).  
 
2. Visceral pain assessment in patients 
 
2.1. Pain rating scales 
―…but when you cannot measure it, when you cannot express it in numbers, your knowledge 
is of a meagre and unsatisfactory kind‖. —Lord Kelvin Lecture ―Electrical Units of 
Measurement‖,1893 
A multitude of different instruments is currently used to assess chronic abdominal pain in IBS 
patients. Intensity is not the only factor important in the experience of pain, since pain occurs 
within a context. Pain intensity is influenced by the meaning of the pain to the patient and its 
expected duration (Turk and Melzack 1992). Pain is rarely caused by psychological factors 
but is associated with psychological and emotional effects such as fear, anxiety and 
depression. Moreover, in many cases, like GI diseases, pathology does not correlate well with 
pain (Wiesel et al., 1984; Boden et al., 1990; Turk and Melzack 1992). For these reasons, 
valid and reliable assessment of pain is essential for both clinical trials and effective pain 
management. To date, four commonly pain rating scales are available and used (Williamson 
and Hoggart, 2005; Mujagic et al., 2015). 
● Visual Analogue Scale (VAS)  
● Numerical Rating Scale (NRS) 
● Verbal Rating Scale (VRS) 
● Faces Rating Scale 
The VAS is presented as a 10-cm line, anchored by verbal descriptors, usually ‗no pain‘ and 
‗worst imaginable pain‘. The patient is asked to mark a 100 mm line to indicate pain intensity. 
The score is measured from the zero anchor to the patient‘s mark. Using a millimetre scale to 
measure the patient‘s score will provide 101 levels of pain intensity. The NRS is a 11, 21- or 
15 
 
101-point scale where the end points are the extremes of no pain and pain as bad as it could 
be, or worst pain. There is no published information about the distribution or error of data 
obtained using the NRS. However, the scale is interval level and can provide data for 
parametric analysis. The VRS comprises a list of adjectives used to denote increasing pain 
intensities. The most common words used to be: no pain; mild pain; moderate pain; and 
severe or intense pain. For ease of recording these adjectives are assigned numbers. These 
rank numbers can lead to the misapprehension that intervals between each descriptor are 
equal, but this is not the case (Jensen and Karoly, 1992) and could be a source of error. Facial 
expression drawings (‗‗faces scales‘‘) are a popular method of pain severity assessment in 
pediatric populations. Faces scales use a series of facial expressions to illustrate a spectrum of 
pain intensity. Numerous face-based rating scales are available (Chambers et al., 1999). A 
multitude of different instruments is currently used to assess chronic abdominal pain 
in IBS patients. Of these questionnaires, the validated IBS-Symptom Severity Scale includes 
the broadest measurement of pain-related aspects. Anyway, the multitude of different 
instruments to measure chronic abdominal pain in IBS makes it difficult to compare endpoints 
of published studies (Mujagic et al., 2015).  
The complexity of visceral nociceptive processes, as illustrated above, has imposed a challenge in 
assessing visceral perception in IBS. Traditionally, visceral perception has been tested by 
delivering a certain controlled sensory stimulus and measuring the nociceptive response 
evoked by it. The GI tract contains afferents that encode a wide range of intensities and 
modalities of stimulation including electrical, mechanical, thermal, and chemical (including 
nutrient) stimuli (Keszthelyi et al., 2012). Choosing the correct stimulation method or 
interpreting differential responses to multiple stimuli may be of superior relevance in 
delineating pathological mechanisms. For instance, electrical stimulation is often thought of 
as non-physiological and therefore of limited use in assessing GI sensation. Furthermore, 
manipulation of the environment in which a sensory stimulus is given, before and after 
nutrient infusion or heterotopic stimulation, for instance, can yield important physiological 
and pathophysiological information above and beyond that gained purely from quantitative 
sensory testing alone (Mayer et al., 2009). With respect to the assessment of visceral 
perception, perhaps the most important aspect is the objectivity and robustness of the 
measuring the magnitude of the pain response, used as primary endpoint for the experiment. 
Measurement of the pain response using verbal scores and scales to assess perceptive intensity 
and thresholds of nociception is largely influenced by subjective components, making it prone 
to reporting bias. Brain imaging and neurophysiological measurements, on the other hand, 
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theoretically offer a more objective assessment of nociceptive responses. However, these 
outcome measures are also greatly affected by cognitive-affective mechanisms, posing a 
challenge to the search for a surrogate marker of altered visceral perception in IBS 
(Keszthelyi et al., 2012). 
 
2.2. Perceptional response to mechanical stimuli (rectal distension) 
Until recently, employing gut distensions has most widely been used to test visceral 
perception in IBS. Lowered rectal pain threshold is a hallmark of IBS patients (Bouin et al., 
2002). It has been reported that 35–60% IBS patients exhibit increased visceral sensitivity to 
rectal balloon distension (Delvaux, 2002; Ludidi et al., 2012; Piche et al., 2010).  
Both rectal and sigmoid distensions have been employed, although the overwhelming 
majority of studies have applied rectal distensions. In fact, the more accessibility and the 
grater content of sensitive afferents make the rectum an ideal target in assessing visceral 
nociception (Kyloh et al., 2011). Rectal visceral sensitivity can be tested by using 
polyethylene bags in conjunction with a barostat. The barostat is a device that maintains a 
constant pressure within an air-filled polyethylene bag and can measure variations in rectal 
tone by recording changes in the intra-rectal pressure and volume (van der Schaar et al., 
1999). Rectal distension can be done according to a certain protocol, during which different 
pressures are applied to the rectal wall. During this procedure, the intensity and quality of 
perception can be measured by means of rating scales. Several different distention protocols 
have been applied to assess visceral perception in IBS (Keszthelyi et al., 2012). The lowered 
sensory thresholds seen in IBS have been shown to be elicited by rapid rates of rectal 
distension, whereas in the majority of patients the perception threshold during slow rectal 
distension pressure is not different from that in normal control subjects. It has also been 
postulated earlier that rapid phasic distensions preferentially stimulate serosal afferents 
(Lembo et al., 1994). These afferents are particularly chemosensitive to inflammatory and 
enteroendocrine mediators such as serotonin (5-HT), which suggests a role for nociception in 
conditions in which sensitization of visceral afferents is involved (Hugon, 1973). 
Furthermore, complex distension protocols with non-random presentation of stimuli such as 
double random staircase distension reduce psychological response bias by making the 
stimulus unpredictable to the subject (Mayer et al., 2008), which is desirable considering that 
IBS patients may be particularly prone to such bias due to anticipatory anxiety. However, 
these complex protocols usually require more distension levels and increasing the number of 
17 
 
interrogations about sensations may introduce bias or errors in a fatigued and stressed or 
disinterested participant (Keszthelyi et al., 2012). 
During rectal distension, several parameters of visceral sensitivity can be collected to assess 
perceptional status. These include perceived intensity of the stimulus, extent of the 
viscerosomatic referral area and the threshold at which different sensations (pain, discomfort, 
urge) appear during the distension protocol (Posserud et al., 2007). These components of 
visceral perception are not uniformly used by various groups, making comparison of study 
results troublesome (Keszthelyi et al., 2012). As for the intensity of perception, different 
scales including numeric rating scales, verbal rating scales, verbal descriptor scales, 
magnitude estimation, and visual analog scales are employed. Visual analog scales have 
emerged as having psychometric properties that are superior to the other pain scaling methods 
because they fulfill multiple criteria for ideal pain measurement and assessment (Price et al., 
2007). These criteria include ratio scale properties, high test-retest reliability and 
repeatability, the capacity to detect small differences, internally consistent measures of 
clinical and experimental pain, sensitivity to variables that increase or decrease pain, detection 
of individual differences in pain sensitivity, and ease of use (Price et al., 1994). The majority 
of the research groups investigating visceral perception using the barostat techniques have 
focused on identifying the thresholds for perception in IBS patients because these have been 
shown to be lowered compared with healthy volunteers. However, threshold measurements of 
pain perception are limited since they fail to assess alterations in pain intensity that may occur 
over a wide range of noxious intensities. On the other hand, investigation of the perceived 
intensity of the given stimulus as well as recording the viscerosomatic referral area can give 
extra information on processing of visceral stimuli (Mertz et al., 1995; Posserud et al., 2007). 
In addition to lowered thresholds to visceral stimuli, marked alterations in somatic referral 
patterns in response to balloon distension of the colon have been described in patients with 
IBS. This is a strong indication for altered spinal processing of visceral sensory information 
and is a manifestation of central sensitization (Kingham and Dawson, 1985; Keszthelyi et al., 
2012). Currently, distension paradigms differ in duration and type of inflation (tonic vs. 
phasic), level of bias (ascending vs. randomized distension), and measurement of response 
magnitude (perceptual threshold or rating). Despite the fact that not all patients exhibit 
hypersensitivity to rectal distensions, the barostat procedure appears to be a reliable and valid 
approach to assess visceral nociception. The barostat has also shown robust changes 
following administration of a narcotic analgesic even in small crossover samples, further 
supporting the measure's validity for assessing pain perception (Delvaux et al., 1999; Lembo 
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et al., 2000). It is also important to note that these perceptual alterations were independent of 
changes in compliance or tone (Bradette et al., 1994). Evidence from crossover studies points 
to considerable reliability and validity for rectal distensions to testing visceral perception, 
reviewed extensively by Mayer et al. (2008). Furthermore, the barostat method in conjunction 
with verbal reporting has shown to have high sensitivity and specificity for detecting visceral 
hypersensitivity in IBS patients (95.5 and 71.8%, respectively) (Bouin et al., 2002). 
Noteworthy, visceral sensitivity studies are generally performed in the fasted state. However, 
bowel symptoms in IBS patients often exacerbate after food consumption (Simren et al., 
2001). There is ample evidence that GI nutrient content may either be the source of or 
contribute to abnormal, painful, or uncomfortable visceral perception in IBS (Ragnarsson and 
Bodemar, 1998). Rectal and colonic perception thresholds in IBS patients have been shown to 
be lowered following intraduodenal infusion of fat. Furthermore, a liquid meal was shown to 
enhance rectal sensitivity in IBS, with a fatty meal producing more pronounced effect 
compared with a carbohydrate meal (Simrenet al., 2007; Keszthelyi et al., 2012). It has been 
postulated that enteroendocrine cells in the intestinal mucosa respond to changes in luminal 
contents by releasing mediators such as cholecystokinin and 5-HT, which in turn activate 
specific receptors on primary afferent nerve terminals. Cholecystokinin, a peptide released in 
response to intake of fat, has been postulated to sensitize mechanoreceptors because it has 
been demonstrated to increase rectal nociception in healthy volunteers (Sabate et al., 2002). 5-
HT, on the other hand, could also be a mediator of meal-induced nociception as higher 
postprandial levels of 5-HT have been reported in IBS patients (Bearcroft et al., 1998). 
Therefore, testing of visceral sensitivity in IBS patients in a postprandial state can also have 
an added value in assessing visceral perceptional status (Keszthelyi et al., 2012). 
 
2.3. Perceptional response to non-mechanical stimuli 
Besides mechanical stimulation, a number of other stimulation modalities have been used to 
assess visceral sensitivity. Transmucosal electric nerve stimulation, for instance, induces 
perception by nonspecific stimulation of afferent pathways without the involvement of a 
specific receptive unit. However, whereas IBS patients had lower sensory thresholds to 
mechanical stimulation of the small intestine compared with controls, thresholds to electrical 
intestinal stimulation were similar in IBS patients and controls (Accarino et al., 1992). A 
disadvantage of using electrical stimulation is the nonspecific activation of nerve endings, 




Thermal stimulation of the gut can be provided via intraluminal bags by recirculating water at 
adjusted temperatures. Thermal stimuli are also potentially applicable in conjunction with 
mechanical and electrical stimuli for the evaluation of visceronociceptive responses. It has 
been demonstrated that, similarly to mechanical stimuli, IBS patients also demonstrate lower 
thresholds to thermal stimulation of the rectum (Li et al., 2004). Chemical stimuli have been 
used widely to study pain mechanisms. Capsaicin is commonly applied as a sensitizing 
stimulus in studies of somatic pain. Hammer et al. (1998) demonstrated that intestinal 
capsaicin infusion resulted in a sensation of warmth and burning, in addition to the generation 
of cramps. This cramping sensation was independent of changes in bowel motility or 
biomechanics and the authors concluded that capsaicin was acting directly on 
mechanosensitive afferents. In addition to capsaicin producing these unique sensory 
characteristics, it was also noted that the time to first sensation of a second capsaicin infusion 
was significantly reduced, suggesting the induction of peripheral sensitization of capsaicin-
sensitive afferents (Hammer et al., 1998). Capsaicin has therefore also been successfully used 
to evaluate chemical hypersensitivity in functional dyspepsia (Fuhrer et al., 2011). On the 
other hand, drawbacks of chemical stimuli include relative long latency time to onset of 
effects, compared with other stimulation modalities, and the fact that these effects are often 
not reproducible (Ness and Gebhart, 1990). Therefore, validation of results using chemical 
stimulation in IBS is still warranted. 
 
2.4. Brain Imaging and fMRI 
In the past decade, accumulating evidence on visceral nociceptive processes has emerged 
from results of brain imaging studies. The most commonly used brain imaging entity, 
functional magnetic resonance imaging (fMRI), is based on the difference in the magnetic 
properties of oxygenated and deoxygenated blood, specifically the difference in decay time of 
the magnetic resonance signal from oxyhemoglobin and deoxyhemoglobin, referred to as the 
blood oxygenation level-dependent technique. This difference in signal characteristics allows 
for the localized detection of regional cerebral blood flow (rCBF). These regional changes in 
blood flow, volume, and oxygenation of hemoglobin derive from changes in neuronal activity 
and, thus, regions of activation may be identified by subtracting rCBF during a control 
condition from blood flow during a stimulus condition or by correlating regional blood flow 
with the intensity or time course of a stimulus or its perception (Turner, 1992). A major 
advantage of fMRI is that it is non-invasive and non-cumulative, allowing subjects to be 
studied repetitively. fMRI has an excellent spatial resolution (2–5 mm), especially in the more 
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superficial layers. Limitations are seen in the deeper structures, such as the brain stem and 
thalamus, owing to pulsation artifacts. The temporal resolution is poor (1–3 s), and therefore 
fMRI is not a specific tool for investigating the neuronal activity directly related to the painful 
stimuli. Since the exogenous brain activity takes place within the first 150 ms poststimulus, 
the response may miss the fast-occurring activity and model, instead, the endogenous activity 
rather than brain responses due to pain. Anyway, comparison of images recorded during 
resting and active periods following administration of a nociceptive stimulus, for instance 
rectal distension, reveals regions of increased cortical activity, and these measures have been 
used to increase understanding of the functional properties of the brain (Keszthelyi et al., 
2012). 
Another technique, Positron emission tomography (PET) scanning, utilizes biological 
molecules synthesized with radiolabeled isotopes, such as 
15
O-labeled water to monitor 
regional changes in cerebral blood flow. The most commonly used in visceral pain research is 
H2
15
O. In the normal brain, rCBF is closely coupled to regional cellular metabolism; 
therefore 
15
O-labeled water serves as a reliable monitor of cerebral interneuronal activity 
(Heiss and Herholz, 2006). Alterations in rCBF can then be mapped to specific intracerebral 
structures and foci, using either MRI or a computerized stereotactical method. PET has 
excellent spatial resolution (2–5 mm) and allows the operator to tag important biological 
molecules that bind to targeted receptor groups or glucose metabolism in active neuronal 
tissue. PET is superior in imaging radiopharmaceuticals and/or other ligands because it offers 
the ability to study receptor distribution and explore the site of action. However, the temporal 
resolution of PET is poor (minutes), and since the subject receives a considerable dose of 
radiation, group analyses are needed for meaningful results, interpreting endogenous brain 
activity following pain rather than exogenous brain activity following painful stimulation. 
Another major disadvantage is the expense and limited availability of a PET scanner 










Schematic overview of assessment of visceral perception in irritable bowel syndrome (IBS) 





3. Visceral pain pathways 
The perception of pain involves the integration of neurobiological pathways within the 
enteric, peripheral, and central nervous systems (Schirbel et al., 2010). The gastrointestinal 
tract differs from all other peripheral organs. An extensive intrinsic nervous system, termed 
enteric nervous system (ENS) controls digestive and defensive functions of the intestine even 
when it is completely separated from the central nervous system (CNS). The ENS, however, 
is not autonomous. Indeed, neuronal control of gastrointestinal function is an integrated 
system involving interactions between local enteric reflexes, reflexes that pass through 
sympathetic ganglia and reflexes that pass from the gut and back through the CNS (Furness, 
2012). 
 
3.1. Enteric nervous system 
The rich sensory innervation of the gastrointestinal tract comprises intrinsic sensory neurones 
contained entirely within the gastrointestinal wall, intestine-fugal fibres that project to 
prevertebral ganglia, and vagal and spinal afferents that project into the CNS (Grundy, 2002). 
The ENS regulates and coordinates almost all aspects of intestinal function including gut 
motility, transport of fluid and electrolytes, secretion of mucins, production of cytokines, and 
the regulation of epithelial barrier function (Furness, 2012). Each of the aspects of physiology 
are compromised in IBDs and IBS patients, whereby it is not surprising that there is an 
increasing amount of research interest in elucidating the role of the ENS in the pathogenesis 
of these GI disorders (Lakhan and Kirchgessner, 2010). Enteric ganglia are organized into two 
major ganglionated plexuses, the myenteric (Auerbach's) and submucosal (Meissner's) plexus. 
They contain a variety of functionally distinct neurons, including primary afferent neurons, 
interneurons, and motor neurons, synaptically linked to each other in microcircuits (Furness, 
2012). The cell bodies of vagal and spinal visceral afferents are contained within the nodose 
and dorsal root ganglia. Central projections of these neurones enter the brain stem and spinal 
cord, respectively, and make synaptic connection with second order neurones that distribute 
visceral information throughout central neuronal structures (Joshi and Gebhart, 2000) 
Projections from the nucleus tractus solitarus are mainly to hypothalamic and limbic 
structures associated with behavioural and emotional aspects of sensory processing. The 
peripheral terminals of vagal and spinal afferents locate in mucosal layers, muscle, and in the 
serosal and mesenteric attachments (Berthoud and Neuhuber, 2000). Nerve terminals in the 
serosa and in muscle convey mechanosensory information relevant to distension and 
contraction of the bowel wall. However, the afferent information conveyed by vagal and 
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spinal mechanosensitive afferents is very different, as revealed by direct electrophysiological 
recordings of afferent traffic en route to the CNS (Sengupta et al., 1990). Vagal afferents have 
low thresholds of activation and reach maximal responses within physiological levels of 
distension. In contrast, spinal afferents, although many have corresponding thresholds for 
activation, are able to respond beyond the physiological range and encode both physiological 
and noxious levels of stimulation. This different stimulus response profile is consistent with 
the hypothesis that vagal afferents are involved in physiological regulation while spinal 
afferents are responsible for mediating pain. However, recent evidence implicates vagal 
afferents both in the mediation of sensation and in the modulation of sensory experience. The 
morphological appearance of afferent terminals in the gastrointestinal wall, visualised by 
fluorescent microscopy, suggests that these endings may also subserve an ―efferent‖ 
sensorimotor function. Gastrointestinal afferents are thought to have collateral branches that 
supply blood vessels and innervate the enteric ganglia where they have the potential to 
modulate blood flow and enteric reflex pathways as a consequence of release of transmitters 
from their varicose nerve terminals (Sternini et al., 1992). Besides, viscerofugal neurons have 
cell bodies within the myenteric plexus, but have projections out of the gut wall, via extrinsic 
nerve trucks, to prevertebral ganglia. These viscerofugal neurons sense and receive 
information regarding mechanical distension of the intestine and transmit this information to 
postganglionic sympathetic visceromotor neurons in the prevertebral ganglia (Furness et al., 
2012). In addition, enteric neurons are supported by enteric glial cells (EGCs), that can 
modulate enteric neuron function (Furness et al., 2012; Morales-Soto and Gulbransen, 2018). 
Enteric glia forms a cellular and molecular bridge between enteric nerves, entero-endocrine 
cells, immune cells, and epithelial cells, depending on their location (Sharkey et al., 2015). 
EGCs function can be profoundly changed by many factors, such as pro-inflammatory 
cytokines, bacteria, and neurotransmitters. Thus, EGCs may undergo dynamic processing 
under pathological conditions and serve overlapping functions such as modulating intestinal 
barrier function, mucosal immunity and enteric neurotransmission via releasing various 





Arrangement of the primary afferent neurones within the intestine 
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3.2. Peripheral visceral neurotransmission 
Afferent fibres innervating viscera project to the CNS through autonomic sympathetic and 
parasympathetic nerves - a dual sensory innervation (McSwiney, 1944; Cervero, 1994). Some 
spinal afferents travel along hypogastric, lumbar colonic and splanchnic nerves to terminate in 
thoracolumbar regions as part of sympathetic innervation, traversing both prevertebral and 
paravertebral ganglia en route to the spinal cord (Sengupta and Gebhart, 1995). Vagal and 
pelvic afferents respectively terminate in the brainstem and lumbosacral cord and contribute 
to parasympathetic innervation. Visceral fibres can serve ‗sensory‘ and ‗afferent‘ functions: 
the former can evoke conscious sensations and the latter regulate autonomic flow (Langley, 
1903). Accordingly, sensory afferents innervating the gastrointestinal and urinary tracts serve 
regulatory functions of the gut (e.g. absorption, secretion, propulsion) and contribute to 
consciously evoked sensations such as pain and fullness (Janig et al., 1996). Visceral sensory 
afferents are almost exclusively thinly myelinated Aδ-fibres and unmyelinated C-fibres. 
However, the distinction between nociceptive afferents and non-nociceptive afferents is not 
clear in visceral neurotransmission compared to somatic nociception, given the functional 
division of mechano-sensitive visceral receptors into two physiological classes (Sengupta and 
Gebhart, 1994; Janig et al., 1996). ‗High-threshold receptors‘ in organs such as the heart, 
oesophagus, colon, ureter and uterus respond only to noxious mechanical stimuli. ‗Low-
threshold receptors‘ are intensity-encoding and thus respond to a range of innocuous to 
noxious stimuli. An important contrast with somatic nociception is the role of low-threshold 
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Aβ-fibres, which only convey innocuous mechanical sensations in normal conditions 
(Sikandar and Dickenson, 2012). 
Viscera are also innervated by so-called ‗silent‘ nociceptors, more accurately designated as 
mechanically insensitive afferents (MIAs). These can acquire mechanosensitivity following 
inflammation and have been thoroughly characterised in significant proportions in rodent 
pelvic and splanchnic innervations of colorectum and in human microneurographic studies of 
cutaneous C-afferents (McMahon and Koltzenburg, 2019). 
In addition to the enteric nervous system, gut epithelium is another site for detecting dietary, 
microbial, and inflammatory stimulus. Among the epithelial cells, serotonergic entero-
chromaffin (EC) cells are proposed to fulfil this role by acting as chemosensors. Studies 
conducted on cultured intestinal organoids showed that EC cells express specific 
chemosensory receptors, are electrically excitable, and modulate serotonin-sensitive primary 
afferent  nerve  fibers  via  synaptic  connections, enabling them to detect and transduce 
environmental, metabolic, and homeostatic information from the gut directly to the nervous 
system (Bellono et al., 2017). Recently, a research group of Pittsburgh demonstrated that 
extrinsic primary afferent neurons (ExPANs) link visceral pain to colon motility through a 
spinal reflex in mice. Indeed, proper colon function requires signals from ExPANs located in 
spinal ganglia. Besides, ExPAN stimulation initiates myenteric neuron activity and 
subsequent colon contractions, but only in the presence of an intact spinal cord, confirming 
the presence of a sensory-parasympathetic spinal circuit regulating colonic motility. The 
described circuit demonstrated how visceral pain is linked to colon motility and explain why 
pain and dysmotility co-occur in GI disorders (Smith-Edwards et al., 2019). Anyway, these 
results complicate further the network at the base of visceral sensitivity and might preclude 
the possibility of achieving a selective modulation of pain. 
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3.3. Viscerosomatic convergence  
The neurophysiological convergence of visceral and somatic afferent inputs to the CNS is 
thought to underlie referred visceral pain, where noxious stimulation of viscera triggers pain 
referred to somatic sites (Cervero, 1983; Mertz et al., 1995). Viscerosomatic convergence 
may occur as a result of the scarcity of visceral afferent fibres with spinal cord terminations. 
In fact, the relative contribution of visceral afferent fibres to the total spinal cord afferent 
input is less than 10%. Visceral afferent terminals also show extensive divergence and 
intraspinal distribution compared to cutaneous afferents (Gebhart, 2000). Because of 
viscerosomatic convergence, somatic injury and visceral inflammation can respectively alter 
central processing of visceral and somatic inputs (Cameron et al., 2008). Axons can send 
peripheral terminals to anatomically distinct segments to produce pain sensations distant to 
the primary site (Coderre et al., 1993). Viscerosomatic convergence also accounts for altered 
central nociceptive processing through sensitization of primary afferent pathways, ultimately 
modifying neuronal input at sites of convergence in the spinal cord or higher centres (Ness 
and Gebhart, 1991). This convergence of visceral and somatic messages may be one reason 
for visceral pains often accompanying somatic pain conditions or vice versa. In addition there 
can be viscero-visceral convergence whereby pain from one organ is referred to another 










Innervation of the rat GI tract  
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3.4.Central modulation of visceral pain 
The ascending fibers of the second order neurons are organized into the spinothalamic, the 
spinoparabrachial, and the spinoreticular tracts, depending on where the cell body of the third-
order neuron is located (Almeida et al., 2004). The final primary synapse occurs at cell bodies 
within the brain. For the spinothalamic tract, the 3rd order neuron is within the thalamus, 
which acts as the primary hub for the central pain matrix (Morton et al., 2016). The thalamus 
is somatotopically organized such that noxious signals from the spinal cord are sent to 
specific regions of the primary somatosensory cortex for the localization of the signal. In 
contrast, the cortical localization for visceral pain is typically less precise since the ascending 
signal often innervates the spinal cord at multiple levels and pain signals from visceral and 
somatic sources may be transmitted by the same 2nd order spinal neuron (viscerosomatic 
convergence). Within the central pain matrix, the thalamus signals to brain regions that 
process the emotional component of the pain signal, such as the amygdala, insula, anterior 
cingulate cortex, hippocampus, and nucleus accumbens (Wilder-Smith, 2011; Bushnell et al., 
2013). In healthy individuals, activation of the central pain matrix provides the appropriate 
behavioral responses (unpleasant emotion, guarding, and/or immobilization of the affected 
site) to promote recovery and to learn avoidance to prevent future injury (Navratilova and 
Porreca, 2014). Descending antinociceptive brainstem pathways are also activated by the 
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central pain matrix to decrease noxious signalling at the dorsal horn of the spinal cord by 
changing the excitability of the 2nd order neuron within the spinal cord (Heinricher et al., 
2009; Denk et al., 2014). In fact, pain modulation of the central nervous system occurs via 
descending pathways, with multiple areas involved, e.g. the amygdala and hypothalamus. The 
periaqueductal gray region (PAG) plays an important role within this pathway through its 
projections to the medulla, which relay descending inhibitory signals to ascending pain 
pathways. Another proposed mechanism arises from the nucleus raphe magnus and nucleus 
reticularis, which are collections of cells derived from the rostral ventromedial medulla 
(RVM). This system projects to the spinal and medullary dorsal horns to modify nociceptive 
signals. Profound anti-nociceptive effects occur when opiates are injected into these brain 
regions in animal models (Giamberardino, 2009). The RVM receives input from the PAG and 
is thought to be a joint final relay center in a network of descending inhibitory pathways of 
nociception from central sites. The RVM forms connections with primary pain afferents in the 
second and third order neurons that transmit nociceptive signals to higher brain centers 
(Cervero and Laird, 2009). The PAG also projects to the amygdala and other cortical sites that 
regulate emotion. Emotional responses, stress, and anxiety are believed to play a significant 
role in the integration and processing of pain. Synaptic plasticity in the amygdala was found 
in a rat model of visceral pain (Neugebauer et al., 2004). Moreover, it has been demonstrated 
that altered central processing of visceral stimuli in IBS is at least in part mediated by 
symptoms of anxiety and depression, which may modulate the affective–motivational aspects 
of the pain response. Indeed, patients with IBS experienced significantly more pain and 
discomfort upon rectal distensions in the scanner, despite unaltered rectal sensory thresholds. 
Anxiety and depression scores were associated with these subjective stimulus ratings, but not 
with rectal sensory thresholds. Anxiety symptoms in IBS were significantly associated with 
pain-induced activation of the anterior midcingulate cortex and pregenual anterior cingulate 
cortex. Depression scores correlated with activation of the prefrontal cortex (PFC) and 
cerebellar areas within IBS. Group comparisons revealed significant activation in the IBS 
versus controls in the anterior insular cortex and PFC (Elsenbruch et al.,  2010).  
 
3.5.Gut-Brain axis 
The ―gut-brain axis‖ is a theoretical model depicting bidirectional neural pathways linking 
cognitive, emotional and autonomic centres in the brain to neuroendocrine centres, the enteric 
nervous system and the immune system. Bodily visceral functions (e.g. digestion, nutrient 
resorption, gaseous exchange, excretion) require complex regulation in which the CNS is 
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highly integrated with the peripheral and enteric nervous systems and hormonal controls. 
Accordingly, altered brain-gut interactions can contribute to autonomic dysregulation of the 
gut and associated pain and perceptual changes in visceral disorders like IBS (Mayer, 1999). 
Vagal afferents project to the nucleus tractus solitarius (NTS) in the brainstem with cell 
bodies in nodose ganglion. Spinally-converging visceral afferents terminate in the dorsal horn 
with second order neurones projecting to higher centres through the dorsal column pathway 
(DC), parabrachial pathway and spinothalamic tract, as previously described (Hunt and 
Mantyh, 2001). Studies involving DC lesions have shown suppressed inhibition of 
exploratory behaviour induced by noxious visceral stimulation and inhibition of potentiated 
visceromotor reflexes evoked by colorectal distension during inflammation (Palecek and 
Willis, 2003). Superficial dorsal horn projections mostly form the spinoparabrachial pathway, 
associated with autonomic and affective responses to painful stimuli (Bester et al., 1995). 
Along with NTS projections from vagal afferents, spinoparabrachial projections are 
transmitted to limbic and cognitive higher centres including parts of the brain involved in 
affect, such as the amygdala, hypothalamus and periaqueductal grey (PAG) (Bester et al., 

















Ascending and Descending pathways in visceral nociception (in rodents).  
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4. Chronic visceral pain mechanisms 
Distinct from the well-established protective and adaptive functions of acute pain, pain 
persisting beyond tissue healing is maladaptive and serves no known physiological function. 
In contrast to acute pain, the mechanisms involved in the development and maintenance of 
persistent pain are not fully understood and visceral pain complexity make this research 
further difficult. The study of events immediately after acute gastrointestinal diseases, like 
infections or inflammations, showed a number of abnormalities that can persist even after 
overt remission of inflammation and can be involved in the chronicization of symptoms like 
pain. These abnormalities include increased gut permeability, immune response, increased 
mucosal serotonin availability, sensitized enteric nerves and altered gut microbiota (Spiller 
and Major, 2016). Anyway, a single factor is not likely to be responsible for the several 
presentations of chronic visceral pain (Sinagra et al., 2012). 
 
4.1. Increased gut permeability 
Acute gastroenteritis produces an increase in gut permeability in all infected individuals, both 
adults and children. This change lasts at least 12 weeks and up to 4 years in some individuals 
with PI-IBS. The increased permeability persisted even in patients whose bowel habit had 
returned to normal, which might indicate that increased permeability increases susceptibility 
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to IBS symptoms but is not sufficient to cause symptoms without other factors (Johansen 
et al., 1989; Spiller et al., 2000). On the other hand, elevated small and large intestinal 
permeability in both PI-IBS and IBS cases was detected without an obvious infectious 
precipitant (Dunlop et al., 2006). Such evidence does suggest that increased permeability 
might represent a common pathway for other factors to influence the gut. Furthermore, the 
real-life stress of public thesis defence, which more closely models the stressors patients 
associate with exacerbation of their IBS symptoms, has been shown to increase small bowel 
permeability, an effect that seemed to be blocked by the mast cell stabilizer cromoglycate 
(Vanuytsel et al., 2014). Rat studies, which enable improved control of other variables, clearly 
show that permeability is increased by psychological stress (induced by water avoidance or 
crowding), acting via mucosal mast cells and vasoactive intestinal peptide (Keita et al., 2013). 
Most of these changes can be mimicked by corticotropin-releasing factor (CRF) injections 
and blocked by CRF antagonists in these rat models (Larauche et al., 2009). If permeability 
tests represent barrier function, then such effects imply increased exposure of the immune 
system to bacterial and food antigens. This process could lead to immune activation that 
further deranges barrier function. Such abnormalities have also been indicated in IBD: 
genome-wide association studies on the aetiology of IBD have implicated a range of genetic 
loci related to pathways of epithelial barrier function (Khor et al., 2011). Increased gut 
permeability is reported in both disease-free relatives and patients with Crohn‘s disease or 
ulcerative colitis, supporting the hypothesis of its role as a predisposing factor with many 
causes (Buning et al., 2012). In patients with IBD-IBS mucosal permeability is markedly 
elevated compared with both healthy individuals and patients with IBD without IBS-like 
symptoms (Vivinus-Nebot et al., 2014). Given the similar symptoms, it is perhaps not 
surprising that being diagnosed as IBS increases the risk of subsequently being diagnosed 
with IBD (Larsson et al., 2012). Whether incident cases of IBD in people with prevalent IBS 
represent delayed diagnosis or evolution of the same condition cannot be determined. Plainly, 
other risk factors, either genetic or environmental, are needed in addition to increased 
permeability before IBS or IBD manifests (Spiller and Major, 2016).  
 
4.2.  Abnormal serotonin availability 
Serotonin, or 5-hydroxytryptamine (5-HT), is contained in enterochromaffin cells found in the 
intestinal crypts. 5-HT stimulates motility and secretion of water into the lumen (Mawe et al., 
2013). These effects are terminated by transport into enterocytes and neurons by the serotonin 
transporter (SERT), whose impairment in inflammatory conditions can lead to excess mucosal 
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serotonin availability. Increased rectal enterochromaffin cell numbers have been reported in 
PI-IBS after C. jejuni infection and in IBS-D, associated with a tenfold increase in 5-HT 
release in biopsy samples, which correlated with pain severity (Dunlop et al., 2003; Cremon et 
al., 2011). The striking clinical benefit of inhibiting 5-HT synthesis with a THP-1 inhibitor or 
blocking 5-HT3 receptors with 5-HT3 receptor antagonists in IBS-D, does confirm that 
increased 5-HT availability has a role in symptom generation (Andresen et al., 2008; Garsed 
et al., 2014). Postprandial plasma levels of 5-HT has been found to be elevated in PI-IBS and 
IBS-D. The increased levels might reflect either increased release or impaired reuptake by 
SERT, which is decreased in the platelets of patients with IBS-D (Dunlop et al., 2005; 
Atkinson et al., 2006). Human studies of the role of 5-HT in IBD are more limited. Increased 
enteroendocrine cell numbers staining for 5-HT and peptide YY have been seen in 
lymphocytic colitis. However, both an increase and decrease in numbers of these cells have 
been reported in Crohn‘s disease and ulcerative colitis. When frank ulceration occurs, the 
enterochromaffin cells are destroyed, their numbers decrease and 5-HT levels fall, but 
increases in enterochromaffin cells can occur during intestinal regeneration, hence the 
confusion in the literature (Magro et al., 2002; El-Salhy et al., 2012; Massironi et al., 2016). 
In IBD-IBS, enterochromaffin cell numbers are normal but such patients show increased 
TPH-1, the rate-limiting enzyme in serotonin synthesis, possibly implying greater 5-HT 
turnover than those without symptoms (Minderhou et al., 2007). Moreover, a role for 
serotonin in inflammation-induced neurogenesis has been shown in experimental models, 
being enhanced by 5-HT4 receptor agonists and inhibited by 5-HT4 receptor antagonists 
(Belkind-Gerson et al., 2015).  
Abnormalities in the metabolism of tryptophan were found in different GI disease, including 
IBDS and different types of IBS, resulting in a dysregulation of serotonin synthesis. There are 
neural processes in the gastrointestinal tract which can be influenced by local alterations in 
serotonin concentrations with subsequent relay of signals along the scaffolding of the brain-
gut axis to influence neurotransmission at central level (Agus et al., 2018). In the gut, the 
three major Trp metabolism pathways leading to serotonin, kynurenine, and indole derivatives 
are under the direct or indirect control of the microbiota. Interesting is the ability of 
microbiota to control host tryptophan metabolism along the kynurenine pathway, thereby 
simultaneously reducing the fraction available for serotonin synthesis and increasing the 
production of other neuroactive metabolites (O‘Mahony et al., 2015; Kennedy et al., 2017). 
Since gut microbiota is clearly affected in both IBS and IBDs, a long-term dysregulation in 
serotonin metabolism due to gut dysbiosis was proposed as possible mechanism for visceral 
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symptoms persistence in these patients, though there are poor evidence about this correlation 
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4.3. Dysbiosis in gut microbiota  
A growing body of preclinical and clinical evidence supports a relationship between the 
complexity and diversity of the microorganisms that inhabit our gut and health status. Under 
normal homeostatic conditions this microbial population helps maintain intestinal peristalsis, 
mucosal integrity, pH balance, immune priming and protection against invading pathogens. 
Furthermore, these microbes can influence centrally regulated emotional behaviour through 
mechanisms including microbially derived bioactive molecules (amino acid metabolites, 
short-chain fatty acids, neuropeptides and neurotransmitters), mucosal immune and 
enteroendocrine cell activation, as well as vagal nerve stimulation. Furthermore, the gut 
microbiota regulates several host biochemicals with know neuromodulatory properties, 
including endocannabinoides, neuropeptides and biogenic animes (Sjogren et al., 2012).  
Post-infectious IBS (PI-IBS), which bears close resemblance to IBS-D, is a surprisingly 
common result of acute gastroenteritis (primarily of bacterial aetiology) with a reported 
incidence of between 5–32% (Thabane et al., 2009). Small intestinal bacterial overgrowth 
(SIBO), defined by an excessive amount of bacteria in the small intestine, may be a cause of 
IBS. SIBO arises when the homeostatic mechanisms that regulate enteric bacterial 
populations are compromised. Small intestinal dysmotility and reduced gastric acid secretion 
are the most common predisposing processes. Studies in IBS patients have revealed delayed 
transit, intestinal dysmotility, and abnormalities in the migrating motor complex—all of 
which could account for a predisposition to SIBO (Dukowicz et al., 2007; Aziz et al., 2017). 
The reduction in microbial richness shown with rifaximin therapy may be responsible for its 
modest clinical benefit in diarrhoea-predominant IBS patients, but SIBO was not tested in 
these patients and the underlying mechanism of action remains to be clearly defined. 
Antibiotics significantly alter gut microbial ecology (namely a collapse in diversity) and 
disrupt interactions with host metabolism (Perez-Cobas, 2014). A consequence of this is the 
frequent disturbance in bowel habit, particularly with broad-spectrum antibiotics (5–62%), 
and numerous animal and human studies provide evidence of the role antibiotics play in IBS 
pathogenesis (Goldenberg et al., 2015). 
Preclinical studies have shown that mice raised in a sterile environment from birth, and as 
such, without gastrointestinal bacteria (germ-free), exhibit an exaggerated stress response 
(Clarke et al. 2013; Sudo 2012; Sudo et al. 2004), and a blunted response to inflammatory 
pain (Amaral et al. 2008). Similarly, antibiotic-induced alteration of gastrointestinal 
microbiota decreased visceral pain-related response elicited by intraperitoneal acetic acid 
injection or intracolonic capsaicin infusion in mice (Aguilera et al. 2015), and also decreased 
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visceral sensitivity in naïve rats (Hoban et al. 2016). Further studies demonstrated that early 
life exposure to antibiotic alters microbial composition and leads to enduring effects on 
visceral pain in rodents (O‘Mahony et al., 2009). Evidence that this also occurs in adulthood 
was shown in a prospective study in which consecutive patients prescribed antibiotics for 
non-GI complaints were more than three times as likely to report chronic bowel symptoms as 
controls (Maxwell et al., 2002). Recently, faecal matter from IBS patients characterised by 
hypersensitivity to colorectal distension was transplanted to germ-free rats, and the response 
to colorectal distension was enhanced in these animals (Crouzet et al. 2013). While preclinical 
evidence for the efficacy of prebiotics in manipulating visceral hypersensitivity is limited, 
there is evidence for a role of the microbiota in regulating response to visceral pain through 
probiotic administration. In contrast to the provocative preclinical evidence for a role for gut 
microbiota in visceral pain, clinical studies remain inconclusive with a large ‗non-responder‘ 
population in many probiotic trials (Larauche et al. 2012c; Kannampalli et al. 2014). On the 
other hand, cohorts are not always well-characterized when microbiome is studied in a disease 
context. Yet, the use of drugs such as proton pump inhibitors or laxatives, which are more 
often used by patients with IBD or IBS, has a large impact on the gut microbiota composition. 
Considering these effects, correction for these medications is essential for identifying disease-
associated microbial features and avoiding false positive associations due to changes in GI 
acidity or bowel mobility. Nevertheless, numerous studies have shown alterations in the gut 
microbiota in both IBS and IBD. Moreover, although the gut microbiota composition has 
been described as stable across individuals in different population cohorts even in the 
presence of high inter individual taxonomic variation, a large number of microbial pathways 
were shown to be disrupted in patients with IBD or IBS (Vich Vila et al., 2018).  
This change might be secondary to changes in a range of factors that are now understood to 
influence the gut microbiota, such as diet, medical treatment, mucosal immune response, gut 
transit and redox potential within the gut lumen, but dysbiosis might also contribute to 
symptoms (Rajilic-Stojanovic et al., 2015). The loose stool induced by both IBS-D and IBD 
exerts selective pressure on gut microorganisms. Thus, enterotypes associated with loose stool 
include taxa with the capacity for rapid growth or adherence to the mucosa, features that 
promote avoidance of washout (Vandeputte et al., 2016). A meta-analysis of studies of 
patients with Crohn‘s disease shows that, although there are many disparities between often 
underpowered studies, there is a consensus that Bacteroidetes and Enterobacteriaceae are 
increased in abundance whereas Firmicutes are decreased (Wright et al., 2015). An increase 
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in Bacteroidetes has also been observed in PI-IBS. However, differences in the gut microbiota 
between IBD and IBS were found (Jalanka-Tuovinen et al., 2014).  
Evidence suggests that dysbiosis in IBD might, in large part, reflect the response of a complex 
microbial community to the environmental stress of intestinal inflammation. In the healthy 
gastrointestinal tract, a radial oxygen gradient exists due to the diffusion of oxygen from the 
host mucosa into the gut lumen (Marshall et al., 2004; Dunlop et al., 2006; Vicario et al., 
2010). Accordingly, bacteria adherent to the colonic mucosa have higher oxygen tolerance 
and catalase expression relative to faeces-associated species (Vicario et al., 2010). As 
inflammation is an oxidative state, it might be expected to promote the outgrowth of 
aerotolerant taxa such as Proteobacteria and Actinobacteria. Indeed, the mouse pathogen 
Citrobacter rodentium has been shown to gain a fitness advantage by promoting epithelial 
aerobic respiration and increasing oxygenation of the mucosal surface (Vanuytsel et al., 
2014). Alternatively, several lines of evidence have shown that intestinal inflammation 
induces the production of small molecules that serve as terminal electron acceptors for 
facultative anaerobes such as Enterobacteriaceae (Soderholm et al., 2002). Thus, metabolic 
alterations associated with inflammation and/or pathobiont colonization might act as 
microbial stressors and promote the outgrowth of dysbiotic species. The heterogeneity of IBS 
inevitably means that reports of disturbed gut microbiota have been conflicting. In one study, 
patients with IBS with a similar gut microbiota to healthy individuals had higher scores for 
depression than patients whose gut microbiota differed (Jeffery et al., 2012). This finding 
raises the possibility of grouping patients with IBS into those whose symptoms predominantly 
relate to central processing and psychological factors, and those with a gut-predominant 
aetiology who have abnormal gut microbiota. The role of diet in determining the gut 
microbiota should not be forgotten. Patients with both IBS and IBD symptoms modulate their 
diet in important ways, often avoiding foods high in fermentable oligosaccharides, 
monosaccharides, disaccharides and polyols (FODMAPs) (Anderson et al., 2015).  
However, it is yet unclear how, or to what extent, microbiota confined to the gastrointestinal 
tract can influence visceral pain behaviour (Moloney et al. 2016). A number of different 
receptor types are involved in the process of peripheral sensitisation including the TRPV 
family, proteinase-activated receptors, cholecystokinin receptors, serotonin receptors, 
cannabinoid receptors as well as an array of ion channels including ATP-gated ion channels, 
voltage-gated sodium and calcium channels and acid-sensing ion channels (Akbar et al. 
2009). The gastrointestinal microbiota can activate these receptors directly or indirectly 
through immune responses at the mucosal surface during infection, inflammation and 
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autoimmunity (Cassel et al. 2008; El Aidy et al. 2014; Kamada et al. 2013; Mazmanian et al. 
2005; Round and Mazmanian 2009). Also, a number of different molecules, including formyl 
peptides and protease, polyunsaturated fatty acid (PUFA), SCFA, as well as hormones and 
neurotransmitter were found involve in the effects of microbiota (Husebye 1997; Cummings 
and Macfarlane 1997; Cenac et al. 2008; Vergnolle 2009; Lyte 2013, 2014; Cani et al. 2013; 
Cenac et al. 2015). However, the extent to which these mechanisms either individually or 
collectively have a role in the aetiology of visceral pain remains unaddressed. Gastrointestinal 
microbiota can also stimulate the release of the body‘s natural pain-suppressing biomolecules 
including opioids from innate neutrophils and monocytes, endocannabinoids from colonic 
tissue as well as other pain modulators including monoamines (Muccioli et al. 2010; Boue et 
al. 2014; Oleskin and Shenderov 2016). 
Recently the role of spinal microglia in the mediation of visceral pain has received some 
attention (Saab et al. 2006; Bradesi 2010). Microglia are critically involved in neuronal events 
at various stages in development and adulthood, including synaptic remodelling to improve 
neuronal network signalling (Schafer et al. 2012; Schafer and Stevens 2015). In contrast, the 
absence of a complex host microbiota led to increased microglial populations, defects in 
microglia maturation, activation state and differentiation, alterations to microglia morphology 
(with longer processes and increased branching, terminal points and clubbing at synaptic 
boutons) and a compromised immune response to bacterial or viral infection (Erny et al. 
2015). The observed alterations in microglial phenotype were reversed with recolonisation of 
gut microbiota, following 6-week cohabitation of germ-free mice with control mice. The 
findings from this study have redefined the ideology that the relationship between our 
microbiota, immune system and neurodevelopment is moot in adulthood, as a healthy and 
diverse gastrointestinal microbiota is essential for the continuous preservation of healthy 
microglia and proper brain function throughout our lifespans (Cryan and Dinan 2015). It is 
plausible that such events also occur to spinal microglia. However, to date, no studies have 
investigated the effects of gastrointestinal microbiota modulation on spinal microglia 
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4.4. Altered gut immune response  
The GI tract has a complex innate and adaptive mucosal immune system that is capable of 
monitoring the luminal content for a diverse array of innocuous antigens including 
commensal microbiota and food antigens (oral tolerance) versus invasion of the host by 
potentially toxic pathogens. The immune cells that reside in the intestine mucosa, mesenteric 
lymph nodes, and Peyer‘s patches make up the gut-associated lymphoid tissue (GALT). Cells 
of the GALT, dendritic cell, macrophages and B-cells make up the antigen-presenting cells 
and shape the responses of a heterogeneous population of T cells. Such response can be 
tolerogenic against commensal bacterial antigens or immunogenic against invading 
pathogens. Together, the cells of the GALT play a role in both innate and adaptive immunity 
and are pivotal for maintaining immune homeostasis in the gut. The maintenance of a delicate 
balance between tolerance and immune system activation is key for overall gut health with 
abnormalities in this equilibrium leading to pathologies of the gut including IBD, CD, and 
food intolerances (Mann and Li; 2014; Reboldi and Cyster, 2016; Vitale et al., 2016). 
Significant increases in the number of T lymphocytes, macrophages and mast cells, 
enteroendocrine cells, and IL‐1β mRNA expression were observed in submucosal biopsies of 
PI‐IBS patients compared with healthy volunteers (Spiller et al., 2000; Gwee et al., 2003; 
Wang et al., 2004).  
Immune cells contribute significantly to both neuropathic and inflammatory pain: on one 
hand, distinct immune cell types release mediators that act on the terminals of nociceptors to 
drive peripheral sensitization; on the other hand, in the CNS, microglia, astrocytes and T cells 
modulate neurotransmission and spinal cord pain circuitry to drive central sensitization. 
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In acute inflammation, pain often parallels the immune response and diminishes with 
resolution of inflammation. In chronic diseases such as rheumatoid arthritis and colitis, 
persistent immune triggers such as cytokines mediate long-lasting pain. In this regard, 
multiple studies have shown that cytokine and chemokine signalling pathways impact pain-
like behaviours in animal models of inflammatory and neuropathic pain (White et al., 2005; 
Cook et al., 2018). 
TNF is one of the most important cytokines mediating pain sensitization in the periphery. In 
the CNS, microglia and astrocytes also release TNF, which acts on CNS neural circuitry to 
modulate pain signalling (Ferreira et al., 1988; Jin et al., 2006; Ji et al., 2014). IL-1β is a 
cytokine produced downstream of the inflammasome and is involved in driving pain 
sensitivity in a number of diseases including gout and rheumatoid arthritis. IL-1β was one of 
the first cytokines demonstrated to cause hyperalgesia upon both local challenge and systemic 
administration in mice (Ferreira et al., 1988; Fukuoka et al., 1994). Both tumor necrosis 
factor-α (TNF-α) and interleukin-1β (IL-1β) levels were found increased in the spinal cord of 
animals after the induction of colitis by TNBS. In these animals the colonic inflammation is 
strictly associated with the development of persistent post-inflammatory 
visceral hypersensitivity (Lu et al., 2019). IL-6 and the chemochines are also mediators of 
neuroimmune communication in pain and are involved in both peripheral and central pain 
sensitization (Xu et al., 1997; Jiang et al., 2016; Cook et al., 2018). IL-17A is one of the main 
cytokines driving inflammation and pathology in several autoimmune and inflammatory 
diseases (Pinto et al., 2010; McNamee et al., 2011). Neutralizing endogenous IL-17A 
prevented pain-like behaviours in mice, with this effect being mediated via the expression of 
TNF, IL-1β and CXC-chemokine ligand 1 (CXCL1) and neutrophil recruitment34. IL-17A 
was also observed to directly induce rapid phosphorylation of protein kinase B and ERK in 
DRG cell cultures, which contain nociceptors (Richter et al., 2010).  
Besides, IL-10, a key anti-inflammatory cytokine, possesses anti-nociceptive properties 
(Milligan et al., 2005; Krukowski et al., 2016). IL-10-mediated suppression of pain may 
involve both its inhibitory effect on the expression of pro-algesic cytokines such as TNF, IL-6 
and IL-1β and a direct effect on neurons (Shen et al., 2013). Despite this, the serum levels of 
either IL-5, IL-6, IL-10, and TNF-α were found significantly higher in patients with IBS 
compared to healthy controls (Liebregts et al., 2007; Vara et al., 2018). In rats, a similar colon 
pattern of cytokine mRNA levels was observed in the post-inflammatory phase of colitis: 
higher IL-6 and IL-10 and no modifications of TNF- production (Salameh et al., 2019).  
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Gram-negative bacterial infections are also frequently painful. LPS, which is a major 
component of Gram-negative bacterial cell walls, induces pain when injected into mice. 
Recent work suggests that LPS can directly act on nociceptors, as nociceptors express Toll-
like receptor 4 (TLR4), which mediates LPS detection (Diogenes et al., 2011; Meseguer et al., 
2014). In a mouse model of urinary tract infection with uropathogenic Escherichia coli, pelvic 
pain has been found driven by LPS in a TLR4- dependent fashion independent of bacterial 
colonization or inflammation (Rudick et al., 2010). LPS-induced systemic immune activation 
leads to visceral hyperalgesia in rats (Nozu et al., 2017). In accordance, TLR4 blockage 
counteracted visceral hyperalgesia associated to a high-fat diet in mice (Tramullas et al., 
2016).  
It has been also demonstrated that neuronal signalling via the secreted neuropeptides CGRP 
and substance P could generate immediate vasodilation, increasing blood flow and oedema 
independently of the immune response in a process called neurogenic inflammation. Innate 
and adaptive immune cells also express receptors for CGRP, substance P and other 
neurotransmitters, indicating a role for complex neural–immune communication through these 
neuropeptides to potently regulate innate and adaptive immunity. Substance P has a robust 
effect on monocytes and macrophages and induces their release of proinflammatory 
cytokines, including IL-1, TNF and IL-6, via ERK–p38 MAPK-mediated NF-κB activation 
(Lotz et al., 1988; Sun et al., 2008; Lim et al., 2017). CGRP has a predominantly anti-
inflammatory effect on myeloid cells, inducing the downregulation of cytokine production, 
oxidative burst synthesis and antigen presentation and the upregulation of the 
antiinflammatory cytokine IL-10 in macrophages and dendritic cells (DCs) (Nong et al., 1989; 
Yaraee et al., 2005; Baliu-Pique et al., 2014; Russell et al., 2014). One intriguing area that 
remains to be characterized is the impact that the mechanisms described above have on pain. 
Nociceptor interactions with neutrophils have been less well characterized, but recent studies 
show a key role for nociceptors in regulating neutrophil recruitment and activation 
(Strausbaugh et al., 1999; Baral et l., 2018). Yet, a tight interplay between nociceptors and 
mast cells has long been postulated owing to their anatomic co-localization. Mast cells are 
found in close apposition to nerve fibres in barrier tissues, particularly CGRP– and substance 
P+ neurons (Stead et al., 1987; Arizono et al., 1990; Alving et al., 1991). Increases in the 
number of nerves–mast cell contacts have been reported in models of inflammatory and 
allergic diseases, as well as in parasitic infection of the colon. Both Substance P and CGRP 
alone are sufficient to cause mast cell activation, degranulation and release of inflammatory 
mediators including histamine, leukotrienes, tryptases, PGD2 and TNF (Arizono et al., 1990; 
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Jarvikallio et al., 2003; Yosipovitch et al., 2016). Like mast cells, DCs have been found to be 
in close contact with nociceptors in peripheral tissues. Indeed, nociceptor regulation of DCs 
has an important role in modulating immunity (Riol-Blanco et al., 2014; Kashem et al., 2015).  
The increased numbers of T and mast cells in mucosal biopsies of IBS patients significantly 
correlated with abdominal bloating frequency and symptoms of dysmotility‐like dyspepsia 
(Chadwick et al., 2002; Cremon et al., 2009). In addition, mast cells were found to be located 
in closer proximity to nerve fibers in IBS patients vs controls while the number of mast cells 
in close proximity to nerves significantly correlated with the severity and frequency of 
abdominal pain and discomfort (Barbara et al., 2004).  
Analysis of the supernatants obtained after incubation of mucosal biopsies revealed that the 
supernatants from IBS patients contained increased amounts of pro‐inflammatory mediators, 
such as histamine, serotonin, polyunsaturated fatty acid metabolites and proteases (Cenac et 
al., 2007; Buhner et al., 2009; Cenac et al., 2015). Each of these mediators can contribute to 
aberrant visceral pain perception as in vitro studies revealed that the marked increase in 
intracellular calcium in rat DRG neurons was at least partially inhibited by the application of a 
5‐HT3 antagonist, histamine 1 or 2 receptor antagonists, and a protease antagonist (Nasser et 
al., 2014). In vivo, supernatants from colonic biopsies of IBS patients, but not controls, caused 
somatic and visceral hyperalgesia and allodynia in mice, when administered into the paw or 
colon, respectively (Cenac et al., 2007). Although the evidence for aberrant immune 
activation seems overwhelming in PI‐IBS, care must be taken when interpreting these results 
as the evidence supporting persistent immune cell infiltration or low‐grade inflammation in 
IBS is conflicting. Indeed, various research groups found no differences in immune cell 
numbers or cytokine mRNA expression in mucosal biopsies of PI‐IBS and IBS patients 
compared with healthy volunteers (Mearin et al., 2009; Braak et al., 2012; Wouters et al., 
2016a; Bennett et al., 2016). Braak et al. even reported decreased numbers of mast cells, 
macrophages and T cells in the colonic mucosa of 66 IBS patients compared with 20 healthy 
volontaries (Braak et al., 2012). Also, at mRNA level, decreased levels of genes linked to 
chemokine function or IL‐10 were detected among IBS patients (Macsharry et al., 2008; 
Chang et al., 2012).  More recently, Bennet et al. found no differences in cytokine mRNA 
expression levels in sigmoid colon biopsies when analyzing 109 IBS patients vs healthy 
volunteers (Bennett et al., 2016).  These reports which fail to demonstrate immune infiltration 
in the colorectal mucosa of PI‐IBS patients, also fail to demonstrate a correlation between 
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4.5. Altered enteric nervous signalling  
Acute inflammation damages enteric nerves and disconnects them from their gut targets. As 
nerves regrow, they sprout and subsequently undergo complex remodelling in the process of 
reconnecting with their targets. This process has been clearly described in experimental model 
of colitis (Byers et al., 2003; Simpson et al., 2008; Liebregts et al., 2009). 
In the enteric nervous system, inflammation causes a rapid loss of enteric neurons and 
viscera-fugal neurons. Of the remaining enteric neurons, specific subpopulations located in 
the myenteric and submucosal ganglia become hyperexcitable and synaptic transmission 
between them is facilitated. These changes in neuronal function result in decreased secretion 
and disrupted motility (Mawe et al., 2009). In the prevertebral ganglia, although synaptic 
input from viscera-fugal neurons is reduced, sympathetic viscera-motor neurons are actually 
hyperexcitable. Many of the neuronal changes evident during inflammation are still present 
after resolution of inflammation, with hyperexcitable enteric neurons and facilitated synaptic 
transmission still evident in the post-inflammatory state. This hyperexcitability results in 
increased neuronal activation in the nucleus of the solitary tract or the dorsal horn of the 
spinal cord, respectively (Mawe et al., 2009; Spiller and Major, 2016). In whole-animal 
studies, this process translates to enhanced pain responses to either gastric or colorectal 
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distension. In this context, an increased density of colonic afferent central terminals was also 
observed, as there is a sprouting of these terminals into different regions of the dorsal horn of 
the spinal cord. This plasticity results in increased numbers of dorsal horn neurons in the 
spinal cord being activated in response to noxious colorectal distension. Many of these 
changes are still present or are even enhanced following resolution of inflammation (Brierley 
and Linden, 2014). Histochemical studies of nerves in diseased terminal ileum resected from 
patients with Crohn‘s disease show anatomical distortion with abnormal varicosities and a 
chaotic increase in staining for a wide range of neuropeptides (Belai et al., 1997). 
Tachykinergic innervation of the submucosal blood vessels increases markedly in ulcerative 
colitis (de Fontgalland et al., 2014). Increases were also seen in nerves co-expressing 
substance P and transient receptor potential cation channel subfamily V member 1 (TRPV1), 
with a decrease in somatostatin-expressing nerves. An earlier study in patients with IBD-IBS 
showed increased TRPV1-positive nerves with a strong correlation between number of 
TRPV1-positive fibres and pain. The same group also investigated patients with IBS and 
found an increase in total nerve fibres, including those staining for substance P, mast cells and 
lymphocytes. Multivariate regression analysis showed that TRPV1-immunoreactive fibres 
and mast cells were related to the abdominal pain score, suggesting that these nerve fibres 
might contribute to visceral hypersensitivity (Akbar et al., 2008; Akbar et al., 2010). The 
occurrence of such changes in both IBS and IBD suggests a common explanation for pain 
occurrence, though the mechanisms by which these signalling alterations perpetuate over time 
are not elucidated (Spiller and Major, 2016). 
 
Neuroplasticity of afferent pathways during and after resolution of gut inflammation 
Brierley and Linden, Nature Reviews Gastroenterology & Hepatology, 2014 
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Major populations of glia that contribute to chronic pain. 
Morales-Soto and Gulbransen, Cellular and Molecular Gastroenterology and Pathology, 2019 
 
Glia (from Greek γλοία meaning 'glue') pertains to non-neuronal cells in the central (CNS) 
and peripheral nervous system (PNS) that nourish neurons and maintain homeostasis. In 
addition, glia are now increasingly appreciated as active regulators of numerous physiological 
processes initially considered exclusively under neuronal regulation (Grubišić and 
Gulbransen, 2016). 
Multiple distinct types of glial cells expressing are encompassed by the term ‗enteric glia‘. 
These diverse populations of cells reside within myenteric and submucosal ganglia 
(intraganglionic), within inter-ganglionic nerve fibre tracts, below the mucosal epithelial cells 
(subepithelial), and are associated with nerve fibres interspersed between smooth muscle cells 
(intramuscular) (Gulbransen and Sharkey, 2012). Current theories suggest that neuronal 
plasticity involving the sensitization of visceral afferent sensory nerve fibers and broad 
alterations to the brain-gut axis contribute to the development of chronic abdominal pain. 
Much of this theory is based on evidence demonstrating changes in neuronal sensitivity, firing 
patterns, and network activity in the periphery, brain, and spinal cord. Although little is still 
known regarding the mechanisms that drive these alterations to neurons and their networks, it 
is increasingly clear that these properties are regulated by glia (Morales-Soto and Gulbransen, 
2019). Enteric glia regulates enteric neurons activity and interacts with various non-neuronal 
cell types in the gut wall such as enterocytes, enteroendocrine and immune cells and is 
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therefore emerging as important local regulators of diverse gut functions. The intricate 
molecular mechanisms that govern glia-mediated regulation are beginning to be discovered, 
but much remains unknown about the functions of enteric glia in health and disease. Reactive 
enteric glia, as with reactive astrocytes, display a marked hypertrophy, increased proliferation 
and vary expression of both cytoplasmic and surface proteins under certain conditions 
(Grubišić and Gulbransen, 2016). Notably, under pathological conditions, enteric glia can 
transform into antigen-presenting cells that promote inflammation by attracting immune cells. 
Moreover, enteric glia can modulate enteric neural circuits in a number of ways, including 
terminating the actions of neurotransmitters from synapses, supplying neurons with 
neurotransmitter precursors and by generating neuroactive substances (Gulbransen and 
Sharkey, 2012; Sharkey et al., 2015). 
Recently, a research group in Chicago demonstrated that the intestinal inflammation induced 
by DNBS in rats alters the ENS functionality by affecting the interaction between enteric 
neurons, nociceptors and glia. In that context the activation of enteric glia resulted to be 
actively involved in visceral hypersensitivity (Delvalle et al., 2018). Interestingly glia 
activation, triggered by the intestinal damage, persists even in the remission phase of colitis 
(Ippolito et al., 2015), spreading vertically to the dorsal root ganglion where it was found an 
increased coupling between satellite cells and neuron that was positively correlated with 
visceral pain (Huang et al., 2010; Hanani et al., 2010). This upward activation of glia along 
the sensitive pathways would suggest an involvement of central glia in the persistence of pain 
after the peripheral damage resolution.  
Indeed, it is now acknowledged that the development of central sensitization engages not only 
neuronal, but also glial processes (Dodds et al., 2016). Within the CNS, glia is the non-
neuronal, immune-like cell population that constitute the vast majority of cells. Glia 
comprises satellite glial cells in the ganglia, and microglia, astrocytes and oligodendrocytes 
within the spinal cord and brain. The anatomical co-localization of astrocytes and microglia in 
the spinal cord, combined with pre- and postsynaptic neurons, forms a key site of interaction 
termed the ‗tetrapartite synapse‘ (Deleo et al. 2006; Ren and Dubner, 2015). In this context, 
the reactivity state and control of astrocytes and microglia is critical in maintaining healthy 
CNS activity. Many of the proinflammatory responses of glia are important in protecting 
against challenges that disrupt the homeostatic balance of the CNS (Maier and Watkins, 
1998). However, under certain conditions, glial reactivity is not advantageous and can instead 
be detrimental to neuronal function, such as during the manifestation of persistent pain. In 
response to strong or persistent receptor stimulation, microglia switch from a surveillance 
46 
 
state to an active response state, and astrocytes transition from a regulatory to reactive state (Ji 
et al., 2013). Under these circumstances, the release of proinflammatory mediators by glia can 
contribute to ongoing nociception, by inducing long-lasting plastic changes of synaptic 
connectivity that enhances the transmission of ascending nociceptive information (Milligan 
and Watkins, 2009; Grace et al., 2014). Glial proliferation, morphological changes and 
increases in protein expression can persist for months after initial injury, even beyond tissue 
healing (Beggs et al., 2012; Schwaller et al., 2015). Moreover, proinflammatory mediators 
and glial-derived neurotransmitters can reciprocally stimulate glia in an autocrine and 
paracrine manner, thereby amplifying a positive feedback loop of unfavorable activity 
(Anderson et al., 2004; Shiga et al., 2011; Zhang et al., 2014).  
Many studies are also investigating the impact of early-life stressors, such as maternal 
separation or injury, on long-lasting glial alterations in the adult. Such events can be the ‗first 
hit‘ that primes glia to over-respond and be detrimental in restoring ‗second hit‘ immune 
challenges later in life. The hypothesis is that adverse life events provoking long-term 
heightened glial reactivity may lead to greater sensitivity to future harmful stimuli. Priming of 
spinal glia may also provide an explanation for why some people are predisposed to 
developing IBS as result of gastrointestinal inflammatory or infections. In fact, the initial 
scenario of gastroenteritis preceding IBS could represent the ‗first hit‘ of irritation that 
sensitizes the neuroimmune system, later contributing to disease progression. The relevance 
of inflammation in glia priming could also explain why IBS symptoms were reported in ~40% 
of patients with IBDs in apparent remission (Halpin and Ford, 2012). 
The studies on glia and IBD employed rodent models of di- or trinitrobenzene sulfonic acid-
induced colitis and chronic pancreatitis. In these preclinical models, marked increases in 
reactivity were described for microglia in the spinal cord and hippocampus, and activated 
satellite glia in the dorsal root ganglia. This is associated with an upregulation of TNFα levels, 
and closer apposition between satellite glial cells and primary afferent neurons in the dorsal 
root ganglia via enhanced neuron–glia gap junction coupling. Microglia activaction was 
associated with an increased visceromotor reflex activity and abdominal withdrawal reflex to 
graded colonic distension. Intracerebroventricular, intrathecal or systemic minocycline (a 
microglia inhibitor) or intrathecal administration of an anti-TNFα antibody attenuated pain 
behaviors in these animals (Riazi et al., 2008; Huang et al., 2010; Kannampalli et al., 2014; 
Song et al., 2014; Liu et al., 2012). In support of the direct involvement of microglia in 
visceral pain, the injection of fractalkine (a microglia activator) reproduced the visceral 
nociception in naïve rats (Milligan et al., 2005). Unlike microglia, the role of spinal astrocytes 
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in visceral pain has been poorly investigated, though both these cell types were found 
activated in chronic pain conditions (Li et al., 2019; Ji et al., 2019). 
In summary, heightened spinal glial reactivity and proinflammatory signaling may contribute 
to ongoing peripheral inflammation, as well as enhancing pain by central sensitization. This 
raises another interesting question as to whether centrally derived neurogenic inflammation, 
generated in part by neuroimmune signaling, contributes to the perpetuation of other 
inflammatory diseases. Indeed, neurogenic inflammatory processes have been implicated in 
the exacerbation of IBD, cystitis and endometriosis. In this setting, enhanced afferent 
signalling in response to the tissue insult may facilitate lesion development by a positive 
feedback loop (Dodds et al., 2016). Although the link between glia activation and visceral 
pain persistence has to be further clarified, these preliminary results support the pro-
nociceptive role of glia in mediating visceral hyperalgesia and make it a promising target for 
controlling chronic visceral pain.  
 
 
Glia and Visceral Pain.  
Dodds et al., Translational Psychiatry, 2016. 
 
4.7. Stress 
While the previous description was presented as a ―bottom-up‖ model of sensitization leading 
to chronic visceral pain, direct sensitization of the central pain matrix can drive a ―top-down‖ 
mechanism wherein stress and negative emotions can promote enhanced perception of 
nociception in the absence of overt peripheral injury (Scarinci et al., 1994; Lampe et al., 
2003; Maizels et al., 2012; Racine et al., 2012). The body's response to stress is composed of 
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two parallel systems: the quick ―flight or fight‖ of the sympatho-medullary axis and the 
slower hypothalamic-pituitary-adrenal (HPA) axis. The sympathetic response to acute stress 
mobilizes epinephrine and norepinephrine to change blood-flow away from the skin and GI 
tract toward the muscles along with providing a burst of energy and a dampening of pain 
perception to allow the individual to run or fight for survival. The neuroendocrine response 
mediated by the HPA axis causes release of cortisol in humans or corticosterone in rodents 
(CORT) to mobilize glucose reserves to restore homeostasis after an acute stressor, or to 
cause long-term changes in metabolic function and neuronal sensitivity following chronic 
stressors. Typically, the sympathetic response will habituate to repeated stressors, whereas the 
HPA response may or may not habituate depending on the type, duration, and variability of 
the stressor (Greenwood-Van Meerveld and Johnson, 2017). As implied by the name, the 
HPA axis is initiated when paraventricular nucleus of the hypothalamus secretes 
corticotropin-releasing hormone (CRH) into the hypophyseal portal circulation in response to 
a stressor. After binding to corticotrophs in the anterior pituitary, CRH causes the release of 
adrenocorticotropic hormone into the systemic circulation after being cleaved from its acid 
precursor protein, proopiomelanocortin. After binding in the adrenal cortex, 
adrenocorticotropic hormone induces de novo synthesis of CORT from a cholesterol-derived 
steroid precursor, which then enters systemic circulation bound to a carrier protein (cortisol 
binding globulin). In addition to its metabolic functions, CORT binding to its high affinity 
mineralocorticoid receptor (MR) and low affinity glucocorticoid receptor (GR) within brain 
regions such as the hippocampus, the paraventricular nucleus of the hypothalamus, and some 
cortical regions induces negative feedback to terminate the response of the HPA axis, while 
binding at the amygdala opposes the feedback inhibition by increasing CRH expression and 
facilitation of the stress axis (Sapolsky et al., 1983; Reul and de Kloet, 1985; Herman and 
Cullinan, 1997; Schulkin et al., 1998; Shepard et al., 2000). In particular, the central nucleus 
of the amygdala (CeA) integrates viscerosensory signaling with neuroendocrine and 
autonomic responses to stressors and is primed to influence both stress and pain signaling. 
(Myers and Greenwood-Van Meerveld, 2010; Johnson and Greenwood-Van Meerveld, 
2015; Johnson et al., 2015). Exposure to chronic stress causes neuronal remodelling in 
specific regions and the net effect of this neuronal remodelling is the exacerbation of pain 
perception and the promotion of chronic pain symptomatology due to the loss of anti-
nociceptive and anti-stress signalling within the central pain matrix combined with facilitation 
of nociceptive and stress-responsive signalling. These remodelled pain circuits also impinge 
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on the function of key brainstem regions that modulate descending pain inhibition 
(Greenwood-Van Meerveld and Johnson, 2017).  
Clinically, the effect of chronic stress on visceral pain is best illustrated by the high co-
morbidity of anxiety, depression, and other psychiatric disorders with functional pain 
disorders, such as IBS (Drossman et al., 2011; Hooten, 2016). Because there are multifactorial 
mechanisms that can induce chronic visceral pain, further research is necessary to identify 
specific mechanisms underlying the development of chronic stress-induced visceral pain. 
Neuroimaging studies in IBS patients have shown that there is altered brain activation in 
response to a nociceptive stimulus suggesting central sensitization (Weaver et al., 2016). In 
particular, the amygdala has been found to consistently demonstrate altered activation to 
visceral stimulation in IBS patients (Greenwood-Van Meerveld and Johnson, 2017). 
To understand the central pathways and cellular mechanisms underlying changes observed in 
the human brain and to design novel therapeutics for stress-induced visceral pain, there are 
multiple rodent models of stress. The Wistar Kyoto rat is a spontaneous or genetically-
induced model in which a high anxiety trait is associated with elevated colonic sensitivity as 
demonstrated by an increased visceromotor response (VMR) induced by low levels of CRD 
(Greenwood-Van Meerveld et al., 2005; Gibney et al., 2010; Bravo et al., 2011; Johnson et 
al., 2012). In other models, adult animals are exposed to stressors such as restraint stress, 
water avoidance stress, and a chronic variable stress (Gué et al., 1997; Bradesi et al., 2005; 
Winston et al., 2010) In these models, there is an increase in plasma CORT resembling that 
seen in IBS patients and an increase in visceral sensitivity (Leserman and Drossman, 2017). 
On the other hand, animal models of early-life stress were used for longitudinal studies aimed 
at understanding the life-long effects of early life adversity on visceral pain perception. 
Preclinical studies in these rodent models have provided important experimental evidence to 
suggest that brain circuits are primed by exposure to stress or pain during early life, 
predisposing individuals to chronic pain disorders as adults (Greenwood-Van Meerveld 
and Johnson, 2017). 
 
4.8. Genetic predisposition 
The number of documented IBD susceptibility loci continues to increase, with more identified 
as regional datasets are combined enabling comparison of geographically distant populations 
(Liu et al., 2016). These loci include NOD2, IRGM, ATG16L1 and IL23R genes dealing with 
the detection and response to gut bacteria. By comparison, the understanding of IBS genetics 
lags far behind, although there are a number of initiatives such as the international network 
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GENIEUR (Genes in Irritable Bowel Syndrome Europe; www.GENIEUR.eu) aiming to 
improve the phenotyping and power of future studies. Most studies have been investigations 
of candidate genes and have been underpowered (Czogalla et al., 2015). However, this meta-
analysis did support the link between IBS and polymorphisms in the TNFSF15 gene, a 
member of the TNF superfamily that influences interferon production (Zucchelli et al., 2011; 
Swan et al., 2013; Czogalla et al., 2015). This gene was found to be a risk factor for Crohn‘s 
disease in an analysis of 86,640 Europeans and 9,846 Asians with a relative risk of 1.14 (Liu 
et al., 2015). This data supports the idea that an excessive response to immune stimulation 
could predispose to both IBD and IBS. However, the same IBS study that showed the link 
with TNFSF15 found no association with 30 other IBD genes, reinforcing the argument that 
IBD requires other less common factors than are required for IBS (Zucchelli et al., 2011). 
This aspect might explain why IBS (an incidence of 1 in 10) is 100 times more prevalent than 




Potential shared mechanisms in IBS and IBD in remission.  
Spiller and Major, Nature Reviews Gastroenterology & Hepatology, 2016. 
 
5. Visceral pain therapy 
Although some visceral pain disorders are not life-threatening, they still contribute 
significantly to a large segment of healthcare resource consumption and have a considerable 
negative impact on lives with psychological distress, disturbance of work and sleep and 
sexual dysfunction (Hungin et al., 2003). For this reason, the treatment of visceral as well as 
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somatic pain is progressively becoming independent of the accompanying disease and pain 
itself is regarded as a syndrome, rather than a symptom or by-product of illness (Cervero and 
Laird, 1999). 
Patients with visceral pain present unique challenges because the pain is often poorly 
localized and is associated with strong autonomic reactions and changes in visceral 
function. Pain management, in turn, may further alter visceral function, with opioid effects on 
the gastrointestinal tract providing a good example. These unintended treatment effects on 
visceral function can exacerbate the pain or lead to additional discomfort, thus showing that 
rational and effective pain management needs to be based on an understanding of the 
anatomic and physiologic basis of visceral function and pain (Gebhart and Bielefeldt, 2016).  
Since IBS symptoms do not have an apparent structural or biochemical explanation, the 
therapy included psychotherapy- behavioural therapy, nutrition and drug treatment of the 
predominant symptoms (bulking agents, antidiarrheals, antispasmodics and tricyclic 
antidepressants). Currently, the most efficacious therapies against visceral hypersensitivity are 
mainly directed to treat bowel dysfunction, while drugs able to directly target the related-pain 
are still unsatisfactory (Camilleri and Boeckxstaens, 2017). 
As previously described, there is clinical overlap between IBD and IBS, with IBS-like 
symptoms frequently reported in patients before the diagnosis of IBD, and a higher than 
expected percentage reports of IBS symptoms in patients in remission from established IBD. 
So, the therapeutic approach for IBD and IBS pain relieving is often the same (Schirbel et al., 
2010; Furness, 2012).   
 
5.1. Dietary interventions 
Food is often a trigger of abdominal symptoms in patients with IBS, and the mechanisms 
evoked by food ingestion have been reviewed extensively elsewhere (Bohn et al., 2013; Farré 
et al., 2013). In relation to colonic function, these triggers include stimulation of colonic 
motility through a vagally mediated reflex, inhibition of colonic water absorption and 
stimulation of colonic transit and high amplitude propagated contractions by carbohydrates 
that reach the colon and their metabolic products. On the other hand, deficiency of fibre in the 
diet is often considered as a factor predisposing to constipation, which may then cause 
abdominal pain (Burkitt et al., 1976; Suares et al., 2011).  
A number of different diets are now promoted to treat IBS symptoms, and these include 
regimens that exclude carbohydrates, fermentable foods, gluten, and substances that might 
create food-related antibodies (Camilleri et al., 2008).  The more commonly employed by 
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patients are diets low in Fermentable Oligo-, Di-, Mono-saccharides And Polyols 
(FODMAPs) and excluding gluten (Werlang et al., 2019). There are numerous evidences that 
the intake of FODMAPs is associated with development of symptoms of IBS, including pain. 
The proposed mechanisms include increasing water retention in the small intestine through 
the osmotic effects of the molecular entities and rapid fermentation by intestinal bacteria, 
leading to production of gas and short chain fatty acids with luminal distension resulting in 
sensations of pain and bloating and stimulation of abnormal motility (Gibson et al., 2015).
 
The low-FODMAP diet intervention for IBS patients consists of 3 distinct phases: the 
restriction or elimination phase, the re-introduction or re-challenge phase, and the 
maintenance or personalized phase (Staudacher and Whelan, 2016; McIntosh et al., 
2016). During the initial phase, patients eliminate FODMAPs from their diets. Importantly, 
the low-FODMAP diet is meant to last only 4 to 6 weeks, and it is essentially a method to 
determine whether symptoms are related to specific foods. It is not designed for long-term 
use. During the second phase, after noting symptom improvement or resolution, foods 
containing FODMAPs are reintroduced gradually, with the goal of identifying tolerance to 
individual ingredients and specific symptom triggers among fermentable carbohydrates. This 
phase lasts several weeks, if not longer, as foods are slowly reintroduced. After reviewing and 
interpreting results from the food re-challenge phase, the goals of the third phase are to 
continue the intake of foods that were well-tolerated and to restrict foods that produced 
symptoms. As the tolerance to different FODMAPs can change over time, patients can 
attempt to reintroduce their trigger foods a few months after symptom control if they so desire 
(Böhn et al., 2015).  
Systematic review and meta-analysis have documented the greater benefit of low FODMAPs 
diet over control treatment for overall symptom severity and severity of abdominal pain and 
bloating (Böhn et al., 2015; Marsh et al., 2016; Eswaran et al., 2016). The mechanism of 
benefit is assumed to relate to reduced colonic fermentation or greater microbial diversity and 
reduced total bacterial abundance (Halmos et al., 2015; Valeur et al., 2016). More 
specifically, a recent study of 20 patients with diarrhoea-predominant IBS (IBS-D) or IBS-M 
reported that low FODMAP diet decreased serum levels of proinflammatory interleukin (IL)-
6 and IL-8, as well as levels of faecal bacteria, like Actinobacteria, Bifidobacterium and 
Faecalibacterium prausnitzii, as well as faecal total SCFAs and n-butyric acid compared with 
baseline (Hustoft et al., 2016). Lower levels of Bifidobacteria were confirmed with low 
FODMAP diet in other study (Staudacher and Whelan, 2016). Conversely, increased 
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Actinobacteria richness and diversity were demonstrated in another study on IBS patients 
(McIntosh et al., 2015).  
In general, the low FODMAP diet remains controversial, and it still presents short-term and 
long-term limitations, including a high level of restriction that may be required in individual 
patients, the need for monitoring by an expert dietician, potential for developing nutritional 
deficiencies, potential for changes in gut microbiota, lack of predictors of response as well as 
relative efficacy compared with other dietary, psychological or pharmacological interventions 
for IBS (Molina-Infante et al., 2016).  
Even the elimination of gluten from the diet of IBS patients has demonstrated efficacy beyond 
patients with celiac disease (Biesiekierski et al., 2011; Biesiekierski et al., 2013; Vazquez-
Roque et al., 2013). The main limitations of the current literature on gluten-free diets for IBS 
lie in small study sample sizes and concern for contamination of the vehicle of gluten 
exposure. To this point, a large meta-analysis reviewing 1726 studies evaluating the efficacy 
of a gluten-free diet on the management of IBS recently found insufficient evidence to 
recommend this diet for IBS symptoms, as findings were not statistically significant (Dionne 
et al., 2018). Isolation of gluten from the diet without also removing other potential symptom-
driving substances is both difficult to study and nebulous for IBS patients. It is possible that 
many IBS patients improve on a gluten-free diet, as it also reduces fructan intake, a significant 
component of modern wheat products (Skodje et al., 2018).
 
 
Proposed mechanisms of FODMAP ingestion and symptoms in IBS 
Werlang et al., Gastroenterol Hepatol (N Y), 2019 
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5.2. Probiotics supplementation 
The World Health Organisation define probiotics as ―live microorganisms, which when taken 
in adequate amounts, confer a health benefit on the host‖. Probiotics, derived from the Latin 
―for life‖, have been used in fermented foods for millennia. The ancient Egyptians are known 
to have consumed fermented milk products, Laban Rayeb and Laban Khad, as early as 9000 
years ago, with fermentation growing in popularity due to its ability to preserve food and also 
possibly as a digestion aid (Gogineni et al., 2013). 
Probiotics may exert their beneficial effects on the host through various mechanisms: (1) 
Pathogen suppression—competition for nutrients and mucosal space, and the production of 
bacteriocins (anti-bacterial proteinaceous toxins); (2) Improvement of barrier function—tight 
junction (spaces between adjacent epithelial cells) homeostasis; (3) Immunomodulation—
pathogen-associated molecular patterns (PAMPs) are sensed by dendritic cells which 
influence B and T cell regulation; and (4) Neurotransmitter production—a number of lactic 
acid bacteria are capable of producing serotonin and gamma-aminobutyric acid (GABA) 
which may influence the communication between the gut and brain (gut–brain axis) (Sánchez 
et al., 2017). 
The latest consensus definition of prebiotics by the International Scientific Association for 
Probiotics and Prebiotics defines them as ―a substrate that is selectively utilised by host 
microorganisms conferring a health benefit‖ (Gibson et al., 2017). Prebiotics such as inulin 
and inositol are found in foods including leeks, asparagus, Jerusalem artichokes, garlic, and 
onions (Slavin, 2013). Some of the most common prebiotics are described below. 
 Inulin: Belonging to the fructan family of dietary fibres, inulin is non-digestible. It is 
therefore able to pass through the small intestine intact and reach the colon. Here, 
inulin is fermented—particularly by Bifidobacterium species and other lactic acid-
producing bacteria—boosting the numbers of these health beneficial bacteria (Slavin, 
2013). Fermentation products of inulin offer colon cancer-preventing properties, and 
short chain fatty acids (SCFAs) are also produced during fermentation. 
 β-glucan: This exopolysaccharide is found naturally in cereal grains, bacteria, and 
fungi (Wang et al., 2017). It has been shown to have prebiotic properties on the 
growth of Bifidobacterium and Lactobacillus species (Russo et al., 2012). 
Fermentation of β-glucan by Bifidobacterium infantis, in particular, was shown to 
increase the production of SCFAs (Jaskari et al., 1998). 
 Fructooligosaccharides (FOSs): Present in wheat, honey, onion, garlic, and banana, 
FOSs are short-chain carbohydrates which resist digestion in the small intestine. In the 
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colon, they promote Bifidobacterium and are converted to SCFAs, and also contribute 
to faecal matter, improving bowel movement. Conversely, they inhibit the 
pathogen Clostridium perfringens in the colon (Belorkar et al., 2016). 
Synbiotics are products containing both prebiotics and probiotics, whereby they act 
synergistically. In a synbiotic, the prebiotic component is designed to selectively stimulate 
either growth or metabolism by the probiotic bacteria and may therefore be considered for use 
where there may be survival challenges for the probiotic alone (Pandey et al., 2015). In 
addition, they may also stimulate certain commensal bacteria in the GI tract (Markowiak et 
al., 2017). 
Scholarly reviews have appraised the potential effects of the intestinal microbiota on intestinal 
motility and sensation, autonomic nervous system, hypothalamic-pituitary-adrenal axis, 
enteric nervous system, mucosal barrier and neuroimmune signalling (Distrutti et al., 
2016). The interactions between the gut microbiota, stress and the central nervous system 
have emerged suggesting that visceral pain-related disorders may be candidates for symptom 
relief through therapeutic alterations of the microbiome (Moloney et al., 2016). These 
observations suggest that therapeutic interventions that alter the microbiome may have 
beneficial effects in patients with IBS.  
IBS patients were found to have an abnormal pro-inflammatory IL-10/IL-12 ratio, which was 
normalised—in conjunction with symptom alleviation—by the consumption of the 
probiotic Bifidobacterium infantis (O‘Mahony et al., 2005). Neural mechanisms involved in 
visceral pain perception also seem to be influenced by certain bacterial species, such as the 
induction of μ-opioid and cannabinoid receptors by Lactobacillus acidophilus (Quigley, 
2013). Earlier studies had shown that probiotics affect bowel function and bloating in patients 
with IBS-D treated with individual probiotics such as Bifidobacterium infantis or combination 
probiotics (Kim et al., 2003; Kim et al., 2005; Whorwell et al., 2006). Ford et al. reported 
benefit of probiotics over placebo for global symptoms in IBS (Ford et al., 2014a). However, 
the data do not provide sufficient information to specifically assess effect on abdominal pain. 
A 2015 systematic review and meta-analysis of probiotics in IBS included 15 trials, of which 
only 2 had sufficient data to assess effects on abdominal pain. These studies used 
combination Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) or E. 
coli (DSM 17252) alone as the probiotics compared with placebo (Enck et al., 2008; Enck et 
al., 2009; Didari et al., 2015). However, recent randomised controlled trials demonstrated no 
significant benefit of probiotics preparations over placebo in the treatment of pain in adults 
with IBS in contrast to the benefit observed in some (but not all) trials in children with regard 
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to frequency and intensity of abdominal pain, for example, with a combination of three 
Bifidobacterial species or a single bacterial species (Weizman et al., 2016; Spiller et al., 2016; 
Giannetti et al., 2017). Treatment with Lactobacillus paracasei in mice (Eutamene et al. 
2007) and the probiotic mix VSL#3 in rats (Distrutti et al. 2013) were both shown to be 
effective in ameliorating the maternal separation stress-induced hypersensitivity during 
colorectal distension. In a restraint stress-induced increase in visceral hypersensitivity to 
colorectal distension, Bifidobacterium lactis significantly attenuated the nociceptive response 
(Agostini et al. 2012), while Bifidobacterium infantis (McKernan et al. 2010), Lactobacillus 
paracasei NCC2461 (Verdu et al. 2006) and Lactobacillus reuteri (Kamiya et al. 2006) 
resulted effective in blunting nociceptive response during colorectal distension in naïve 
animals. VSL#3 was also shown to prevent visceral hypersensitivity induced by inflammation 
via intracolonic instillation of 4% acetic acid when given prophylactically (Dai et al., 2012), 
while Bifidobacterium infantis ameliorated visceral hypersensitivity to colorectal distension in 
the trinitrobenzenesulphonic acid-induced (TNBS) model of colitis in rats (Johnson et al. 
2011). Moreover, Lactobacillus rhamnosus and Bifidobacterium animalis ssp. lactis were 
shown to exhibit protective effects on intestinal barrier function in the TNBS model of colitis 
in mice by restoring barrier integrity, reducing inflammatory cytokines and increasing the 
levels of intestinal tight junction proteins (Laval et al. 2015; Martin et al. 2016). In summary, 
effects of probiotics in the treatment of abdominal pain appear to be strain dependent and may 
be more significant in children. Further studies are required to address which bacterial strains 
and which patients are most likely to respond. 
Besides, increasing research is revealing the interaction between psychiatric disorders 
including generalised anxiety disorder, major depressive disorder, and schizophrenia and IBS 
(Fadgyas-Stanculete et al., 2014). Both animal and human studies have demonstrated a link 
between altered gut microbiota and depression (Zhou and Foster, 2015). Worryingly, a UK 
study identified that IBS has the potential to cause fatal outcomes from suicide, with 
depression not accounting for all the variance in suicidal ideation (Miller et al., 2004). 
Probiotics capable of conferring mental health benefits through interactions with commensal 
gut bacteria have been coined ―psychobiotics‖. The psychophysiological effects of 
psychobiotics include psychological effects on emotional and cognitive processes, systemic 
effects on the hypothalamic–pituitary–adrenal axis, and neural effects via neurotransmitters 
and neurotrophic proteins (Sarkar et al., 2016). In a human study using functional magnetic 
resonance imaging (fMRI), 4 weeks of a multi-strain probiotic altered emotional processing 
compared to placebo (Tillisch et al., 2014). On the other hand, germ-free (GF) mice have an 
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exaggerated stress response with heightened levels of stress hormones—a finding that was 
reversed by treatment with Bifidobacterium infantis (Sudo et al., 2004). 
 
5.3. Non-absorbed antibiotic, rifaximin 
Rifaximin produced significant improvements in core symptoms of IBS-D in patients treated 
with up to three 2-week courses of therapy. With second repeat treatment, the most significant 
benefit was the relief of urgency and bloating, with borderline benefit on abdominal pain and 
stool consistency (Chey et al., 2015; Chang et al., 2015). The mechanism of benefit of 
rifaximin is still unclear. In the past, it was assumed that the benefit reflected beneficial 
effects on small bowel bacterial overgrowth or direct anti-inflammatory actions that countered 
effects of bacterial products (Pimentel et al., 2016). However, there is evidence that breath 
hydrogen measurements after lactulose or glucose load, a no-invasive method to diagnose 
SIBO, may reflect oro-caecal transit rather than bacterial overgrowth (Simrén and Stotzer, 
2006; Yu et al., 2011). A recent study appraised several potential mechanisms of action of 
rifaximin in the treatment of non-constipated patients with IBS, including permeability, 
expression of barrier proteins and faecal microbiome, but there were no significant effects 
relative to placebo (Acosta et al., 2016). In summary, the efficacy and the mechanism leading 
to relief with this non-absorbable antibiotic are unclear.  
 
5.4. Antispasmodics and prokinetics  
In addition to visceral hypersensitivity, abnormal GI motility is recognised as an important 
pathophysiological mechanism. Increased or decreased GI transit is indeed reported in IBS-D 
and IBS-C, respectively (Manabe et al., 2010). Moreover, patients with IBS develop increased 
small bowel motility in response to meal ingestion and the stress hormone, corticotropin-
releasing factor (CRF), associated with episodes of abdominal pain (Fukudo et al., 1998). As 
antispasmodics reduce GI contractility, these compounds may be beneficial in IBS and are 
indeed widely used in Europe. A European systematic review identified nine placebo-
controlled studies of antispasmodics in IBS, but many did not use standardised diagnostic 
criteria, and all were of low to intermediate quality since they were performed before the 
development of the Rome criteria for study design (Narducci et al., 1986; Tack et al., 2006). 
Abdominal pain was improved in seven of the studies, bowel symptoms improved 
significantly versus placebo in two studies and four of the studies reported global symptom 
severity improvement. Reviewers concluded that there is level II evidence suggesting that 
antispasmodics may improve abdominal pain, but that there is lack of evidence to support 
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global symptom improvement. Afterwards, a Cochrane review concluded that there was weak 
evidence for the benefit of some antispasmodics for abdominal pain and global symptom 
relief, although it was unclear which individual classes were effective (Quartero et al., 
2005).  Among the antispasmodics, the strongest data were for otilonium bromide. This 
compound targets L-type and T-type calcium channels, and muscarinic type 2 and tachykinin 
neurokinin (NK)-2 receptors, possibly contributing to its increased efficacy. The efficacy of 
otilonium bromide in IBS has been confirmed in four studies, including significant 
improvement of abdominal pain and bloating severity with otilonium bromide versus 
placebo, or reduction in the number of pain episodes and severity of abdominal distension, 
improved well-being and global assessment, but not in bowel symptoms (Baldi et al., 1991; 
Battaglia et al., 1998; Glende et al., 2002; Clavé et al., 2011).  
Antispasmodics are generally well tolerated, apart from anticholinergics which can cause 
atropine-like side effects, including constipation (Ford et al., 2008).  
Peppermint oil and its active ingredient, l-menthol, are smooth muscle calcium channel 
antagonists that may cause muscle relaxation and, therefore, serve as an antispasmodic. 
Peppermint oil and menthol also have κ-opioid agonistic properties that may alter gut 
sensitivity, have been reported to possess anti-inflammatory effects and have serotonergic (5-
HT3) antagonistic properties (Hawthorn et al., 1988; Juergens et al., 1998; Galeotti et al., 
2002; Walstab et al., 2014). Menthol, the active component in peppermint oil, is also widely 
used in medicinal preparations for the relief of acute and inflammatory somatic painful 
conditions. Recent evidence has indicated that this menthol-induced analgesia is mediated by 
activation of the temperature sensing ion channel, transient receptor potential ion channel 
melastatin subtype 8 (TRPM8) (Liu et al., 2013). TRPM8 has been identified on colonic 
primary afferent neurons, TRPM8 mRNA in colonic DRG neurons and TRPM8 protein on 
nerve fibres throughout the wall of the colon. It is expressed by nociceptive visceral afferents, 
where TRPM8 has antinociceptive properties (Harrington et al., 2011). Visceral 
hypersensitivity has been relieved in rat by a combination of essential oils from peppermint 
and caraway. In this effect seems involved mycobiome modulation (Botschuijver et al., 2018). 
In a systematic review and meta-analysis of five randomised controlled trials of an older 
formulation of peppermint oil that included 197 patients on the active treatment arm and 195 
on placebo, the analysis favoured peppermint oil (RR 2.23 (95% CI 1.78 to 2.81)) over 
placebo. Peppermint oil was significantly superior to placebo for global improvement of IBS 
symptoms and improvement in abdominal pain (Khanna et al., 2014). However, multicentre 
trial for testing a new formulation of peppermint oil with sustained release into the small 
59 
 
bowel showed no superiority over placebo, although pain, bloating and urgency were 
significantly reduced (Cash et al., 2016). 
 
5.5. Serotonin receptors agonist/antagonist 
Another neurotransmitter which seems to active visceral afferent fibers is serotonin (5-HT). 5-
HT released from EC cells may affect several subtypes of enteric neurones (intrinsic and 
extrinsic sensory neurones as well as motor and secretomotor neurones) and final effector 
cells (smooth muscle cells and enterocytes). The role of 5-HT in GI motility and pain 
perception is rather complex (Gershon and Tack, 2007; Kendig and Grider, 2015), and 
intervention in the 5-HT signalling pathway may, therefore, impact several mechanisms 
involved in IBS symptoms, including pain. Several serotonin receptor subtypes have been 
characterized, of which 5HT3, 5HT4, and 5HT1b are the most important for GI function (De 
Ponti, 2004). 5-HT4 receptors are another key target for pharmacological intervention. Their 
stimulation with agonists potentiates peristalsis initiated by 5HT1 receptor stimulation, they 
are therefore useful in constipation predominant form of IBS and in chronic constipation. The 
partial 5-HT4 agonist, tegaserod, has been proposed to reduce visceral sensitivity by 
inhibiting substance P expression in the dorsal horn of spinal cord (Bradesi and Mayer, 2007). 
Tegaserod has been demonstrated in several randomized, placebo-controlled trials to relieve 
global IBS symptoms as well as individual symptoms of abdominal discomfort, number of 
bowel movements and stool consistency (Ford et al., 2009a). One important aspect of partial 
agonists is that they may surrogate the functions of 5-HT when its release is impaired but may 
work as antagonists by opposing the effect of endogenous 5-HT (which is a full agonist) in 
case of 5-HT overload. In addition, partial agonists may help to overcome, at least in part, the 
problem of 5-HT4 receptor desensitisation. Noteworthy, 5-HT4 receptors are present in 
human atrial cells and when stimulated may cause atrial arrhythmias (Fayyaz and Lackner, 
2008). Indeed, tegaserod was pulled out of the market by because of the risk of heart attacks 
and strokes. Recently, FDA approved the reintroduction of Zelnorm (tegaserod) for the 
treatment of IBS-C, but with some restrictions (FDA, 2018). 
On the other hand, 5HT3 antagonists (alosetron and cilansetron) prevent the activation of 
5HT3 receptors on extrinsic afferent neurons and can decrease the visceral pain associated 
with IBS (Andresen et al., 2008). These agents also retard small intestinal and colonic transit 
and are therefore useful in diarrhea-predominant IBS. Several randomized, controlled trials 
have shown that alosetron relieves pain, improves bowel function, and provides global 
symptom improvement in women with diarrhea-predominant irritable bowel syndrome. 
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However, ischemic colitis and severe complications of constipation have been major concerns 
leading to voluntary withdrawal of alosetron from the market followed by remarketing with a 
comprehensive risk management program (Bielefeldt, 2016).  
Considering the limited availability of the serotonin 5-HT3 antagonists, the global market of 
drugs for diarrhoeal disorders is still led by agents developed 40–60 years ago, including 
opioid receptor agonists (eg, loperamide), bile acid binders (eg, cholestyramine) and tricyclic 
antidepressants (eg, amitriptyline) (Barbara et al., 2014).  
 
5.6. Antidepressants 
Visceral pain syndromes, including IBS, may be effectively treated by a variety of therapies 
that modulate the interactions between the central and enteric nervous systems. Clinical 
observations and preliminary data suggest that antidepressants may be efficacious for the 
treatment of these syndromes (Crowell et al., 2004). Tricyclic antidepressants (TCA) are the 
first-line pharmacologic treatment for symptom improvement in gut-brain axis disorders 
where pain is a prominent feature. Their mode of action is by 5-HT and NA reuptake 
inhibition in combination with additional receptor antagonistic properties (5-HT2A and 2C, 
muscarinic1, histamine1). There are slight variations comparing different TCAs from these 
aspects where the tertiary amines (amitriptyline, imipramine) are more prone to produce side 
effects from their greater antimuscarinic and antihistaminic actions compared to the secondary 
amines (desipramine, nortriptyline). These side effects, particularly sedation and constipation, 
can be used also to treat some aspects of IBS such as sleep disturbance and diarrhoea, if 
present. it was also shown that escitalopram, an SSRI, did not have the same positive effect 
on abdominal pain as TCAs, thus supporting the more limited use of SSRIs for treating pain 
due to their lack of NA effects. Anyway, it is important to consider that potential benefit with 
higher dosages of TCAs (particularly the tertiary amine agents) is compromised by their 
greater potential for side effects (Törnblom and Drossman, 2018). 
A recent review indicates that antidepressants may have even a beneficial effect on IBD 
course, given that psychological factors play an important role in IBD activity and 
antidepressants have been reported to have anti-inflammatory properties (Macer et al., 2017). 
A systematic review of animal models of colitis has found that desipramine and fluoxetine 
reduce the risk of colitis and improve inflammatory markers, with little evidence of adverse 
effects.4 (Mikocka-Walus et al., 2009) 
The efficacy of antidepressants on pain syndromes is best supported by reviewing meta-
analyses (Ford et al., 2009b). Nevertheless, these analyses have a number of flaws or 
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inconsistencies in the design, analyses of efficacy, safety, as documented elsewhere, leading 
to significant questions regarding the generalizability for this class of pharmacological agents 
(Ford et al., 2014b; Camilleri, 2015). The recent literature is questioning whether 
antidepressants are safe drugs when used over the long term for non-psychiatric indications, 
but several confounding factors may influence this link (eg, severity of depression and other 
psychiatric comorbidities) and causality has not been proven. For example, selective serotonin 
reuptake inhibitors (SSRIs) affect bone health, and there is epidemiological evidence of 
dementia with long-term antidepressant treatment, based on a population-based, retrospective, 
case-control analysis using the Taiwan National Health Insurance Research Database of 
patients enrolled from 2005 to 2011 (Yadav et al., 2008; Lee et al.,2016).  
 
5.7. Secretagogues 
Effects of the chloride channel activator, lubiprostone, on bowel function and pain scores in 
IBS-C have generally shown consistent efficacy for spontaneous bowel movement rate over 3 
months and somewhat reduced efficacy in relief of reduction in IBS pain and discomfort in 
the third month of a 3-month clinical trial (Johanson et al., 2008).  
One recent type of visceral analgesic relates to the functional effects of guanylate cyclase-C 
(GC-C) receptor stimulation in the gut (Waldman and Camilleri, 2018). The analgesic 
properties are mediated by a cascade of intracellular events starting with GC-C stimulation 
that gives rise to intracellular cyclic guanosine monophosphate (cGMP) production. cGMP 
transported to the extracellular space modulates the conduction properties of nociceptive 
neurons located in the submucosa. This concept is based on mechanistic studies in animal 
models and has been shown to be relevant in the treatment of the pain component of IBS 
(Johnston et al., 2010). The effect of GC-C stimulation on fluid excretion results in an 
accelerated gut transit that restricts its use to those patients with a bowel habit dominated by 
constipation. Linaclotide was the first substance available for clinical use after proving to be 
effective in IBS-C, followed by plecanatide that is available at some markets with the same 
indication (Chey et al., 2012; Rao et al., 2012; Miner at al., 2017). Linaclotide, appears to 
increase the proportion of adequate relief and global relief responders, as well as improving 
weekly frequency of bowel movements and reducing pain. It also relieved pain in patients 
with severe symptoms, as well as discomfort and bloating ratings during 12 weeks of 
treatment (Johnston et al., 2010; Rao et al., 2014; Castro et al., 2013). On the base of these 
evidence, US Food and Drug Administration's (FDA) recommend linaclotide for IBS-C 




5.8.  Peripheral Opioid Receptor Agonists/Antagonists 
Stimulation of the visceral μ-receptor has for long been the first-line treatment option in 
conditions involving chronic diarrhea, including IBS-D. From the historical use of opioids 
with both peripheral and central effects, the advent of loperamide, a μ-receptor agonist that 
does not penetrate the blood-brain barrier was a major break-through. One limiting factor has 
been that a substantial proportion of patients do not tolerate this treatment due to the 
development or aggravation of abdominal pain or constipation. Therefore, µ-opioid agonists 
are used during acute exacerbations of pain in patients with IBS (Hellström et al., 2011).  
A new therapeutic option, eluxadoline, has agonistic properties on μ- and κ-receptors, and 
antagonistic properties on δ-receptors. Animal studies showed promise that eluxadoline could 
reduce visceral hypersensitivity, one of the key pathophysiologic mechanisms in IBS, and 
normalize transit in diarrhea models where the combined μ- and δ- receptor effects 
normalized transit over a wider dose range compared with loperamide (Wade et al., 2012; 
Lacy, 2016). Due to a limited bioavailability after oral administration, the central effects of 
opioid receptor stimulation are avoided and clinical trials with treatment given for up to 
52 weeks have not shown signs of abuse potential or opioid withdrawal effects after treatment 
termination (Fujita et al., 2014; Fant et al., 2017). Eluxadoline, at 100 and 200 mg, resulted in 
greater improvements in bowel movement frequency and urgency, global symptoms, IBS 
symptom severity score, IBS quality of life and adequate relief (Dove et al., 2013). The 
adverse events of pancreatitis and sphincter of Oddi spasm led to specific exclusions of 
patients with a history of bile duct obstruction, pancreatitis, severe liver impairment or severe 
constipation, and in patients who drink more than three alcoholic beverages per 
day. Nevertheless, the FDA Adverse Event Reporting System received information on 99 
cases of pancreatitis, 39 cases of sphincter of Oddi spasm and 220 cases of abdominal pain 




5.9. Histamine receptor antagonist 
Mast cells and their mediators, in particular histamine, serotonin and proteases, are 
increasingly recognised as contributing to the pathogenesis of IBS (Camilleri and 
Boeckxstaens, 2016). Most insight in the role of inflammation in chronic abdominal pain 
comes from studies evaluating patients with postinfectious (PI)-IBS. Colonic biopsies of 
patients with PI-IBS reveal no signs of overt inflammation but show persistent minor 
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increases in epithelial T lymphocytes and mast cells, suggesting that long-term inflammatory 
changes may be responsible for colonic hypersensitivity. Yet, it has been found a significant 
correlation between mast cell density and pain perception in patients with IBD who were in 
remission (Wouters, 2016a). 
Of interest, histamine is released by IBS colonic biopsies and induces visceral 
hypersensitivity to colorectal distension in murine models. Recently, evidence was reported 
that histamine sensitises TRPV1 on neurons from murine DRG and on human submucosal 
neurons in rectal biopsies via activation of H1 receptors (HRH1) (Wouters et al., 
2016b). Moreover, supernatant of IBS biopsies sensitised murine DRG neurons, an effect also 
mediated via HRH1. H4 and H1 receptor antagonists dose-dependently reduce and even 
normalise post-inflammatory visceral hypersensitivity via different underlying mechanisms 
but with a synergistic effect (Deiteren et al., 2014).  
The mast cell stabiliser, ketotifen, was tested in a prior single-centre trial, and it increased the 
threshold for discomfort on rectal balloon distension in patients with IBS with visceral 
hypersensitivity, reduced global IBS symptoms and severe abdominal pain, and improved 
health-related quality of life (Klooker et al., 2010). The potential unblinding resulting from 
sedating effects of ketotifen raised questions about its therapeutic potential. As ketotifen also 
possesses HRH1 antagonistic properties and HRH1 has been implicated in visceral 
hypersensitivity, a follow-up study evaluating the HRH1 antagonist, ebastine, indeed showed 
a significant improvement in global relief and abdominal pain (Wouters et al., 
2016b). Ebastine is a second generation H1R antagonist free of any significant influence on 
the central nervous system as it does not penetrate the blood-brain barrier. Of interest, a recent 
study detected histamine levels in urine samples of patients with IBS that were modulated by 
a low FODMAP diet. Detection of histamine in urine or other samples may represent an 




5.10.  NK receptor antagonists 
Recently developed models have focused considerable attention on two sites of neural 
processing: primary afferents and the spinal dorsal horn (Wesselmann et al., 2009). 
Sensitization of the primary afferents has been shown to occur via changes in the intrinsic 
properties of sensory neurons that regulate excitability and in gene expression for nociceptive-
specific membrane proteins (Latremoliere and Woolf, 2009). Peripheral sensitization resulting 
from prolonged periods of stimulation also releases at least two central neural mediators, 
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glutamate and substance P (SP) that increase the efficacy of synaptic transmission between 
primary afferents and spinal neurons (central sensitization) (Wesselmann et al., 2009). NK1 
and NK2 receptors are abundantly expressed in the GI tract and mediate robust and long-
lasting contractions of smooth muscle in the gut. Inflammation of viscera increases central 
and peripheral NK1 receptor expression, and visceral hyperalgesia is attenuated in NK1 
receptor knockout mice. Receptor antagonists act peripherally and centrally to attenuate 
viscera motor responses induced by colorectal distention. Also, NK2 receptor activation is 
involved in stimulation of sensory nerves and activation of visceral reflexes. Based on these 
characteristics, NK2 receptor antagonists have been evaluated as treatments for IBS. In a 
phase II, dose-finding study, ibodutant, a highly selective NK2 antagonist with high oral 
bioavailability, revealed improvement in patients with IBS-D (Corsetti et al., 2015). A more 
recent multinational, double-blind, placebo-controlled study showed dose-dependent 
improvement of overall symptoms, abdominal pain and stool pattern in IBS-D in females, but 
not in males. The tolerability of the compound was reported to be excellent (Tack et al., 
2016). Recently, also the role of NK3 receptors in inflammation-induced gut hyperalgesia was 
recognized.  
Like SP, also glutammate has a clear role in nociceptive systems, though specific relevance of 
this neurotrasmitter in visceral pain systems are yet to be precisely defined, (Wesselmann et 
al., 2009).  
 
5.11. Gabapentenoids  
Gabapentenoids, pregabalin and gabapentin, agents are α2δ ligands that generally bind 
potently to an auxiliary protein associated with voltage-gated calcium channels, reducing 
depolarisation-induced calcium influx at nerve terminals which reduces the release of several 
excitatory neurotransmitters including glutamate, noradrenaline, substance P and calcitonin 
gene-related peptide, which are involved in pain mechanisms (Camilleri et al., 2007). 
Prevention of neurotransmitter release by pregabalin and gabapentin occurs only in pathologic 
states when calcium channels are being up-regulated and activated. Pregabalin and gabapentin 
are predominantly central acting analgesic (Dooley et al., 2000; Patel et al., 2000; Field et al., 
2006). Gabapentinoids have been shown to reduce visceral hypersensitivity in experimental 
animals as well as symptoms of irritable bowel syndrome in humans (Diop et al., 2002; Lee et 
al., 2005; Million et al., 2007; Houghton et al., 2007). Not only do gabapentinoids reduce 
nociceptive neurotransmission centrally but also improve bowel compliance to distention 
perhaps through blocking alpha-2 delta subunits in smooth muscle (Davis et al., 2012). 
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Pregabalin has been tested in pharmacodynamics studies in healthy controls and in patients 
with IBS, with inconsistent results on effects on colonic compliance and sensation thresholds 
(Houghton et al., 2007; Iturrino et al., 2014).  
 
6. New therapeutic opportunities 
 
6.1. Emerging pharmacological targets in visceral pain management 
As argued in the previous paragraphs, the mechanisms underlying pathophysiological events 
that produce chronic visceral pain are still poorly understood, so therapeutic targets for 
treating visceral pain provide a very active and rapidly changing field of research. Several 
chemical and molecular factors in the intestine have a potentially significant role in IBS, 
particularly in IBS-D, including mast cell products such as histamine, proteases and tryptase, 
and mucosal messenger RNAs (mRNA), proteins and microRNAs (miRNA) (Camilleri et al., 
2016b).  
Between the channels in the enteric nervous system, ASICs and KCQN result particularly 
important. The activation of acid sensing ion channels (ASICs) which respond to decreases in 
pH can also contribute to mechanic-sensation from viscera. In the GI tract, ASIC1a has an 
inhibitory effect, ASIC2 has mixed effects and ASIC3 appears excitatory (Page et al., 2005).  
Voltage-gated potassium channels are required for action potential firing and are also 
involved in spontaneous trains of action potentials after nervous system injury. Particularly 
KCNQ (Kv7) channels came into focus because of the anti-nociceptive effect of the specific 
KCNQ opener retigabine in animal models of neuropathic and visceral pain (Blackburn-
Munro et al., 2005; Hirano et al., 2007).  
The over-expressed colonic brain-derived neurotrophic factor (BDNF) has been reported to be 
associated with abdominal pain in patients with IBS. Functionally, TrkB (BDNF receptor), or 
BDNF knockdown significantly suppressed visceral hypersensitivity in mice (Wang et al., 
2016). On the contrary the glial cell line-derived neurotrophic factor (GDNF) family ligands 
(GFLs) resulted able to support survival, regeneration and functioning of several neuronal 
populations: dopaminergic, enteric, sympathetic, parasympathetic, motor, cholinergic neurons 
and of sensory neurons (Boucher et al., 2000). So, modulation of these peptides could be 
study in order to restore a normal visceral sensitivity.  
The role of Vascular Endothelial Growth Factor (VEGF) in pain is rapidly increasing. Its 
instillation into the mouse bladder promotes a significant increase in peripheral nerve density 
together with alterations in bladder function and visceral sensitivity. The VEGF pathway is 
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being proposed as a key modulator of neural plasticity in the pelvis and enhanced VEGF 
content may be associated with visceral hyperalgesia, abdominal discomfort, and/or pelvic 
pain (Malykhina et al., 2012).  
In the GI tract, another class of receptors highly studied belong to the family of protease-
activated receptors (PARs). PARs are expressed both on the apical and basolateral sides of 
intestinal epithelial cells, these receptors might be activated both by luminal proteases 
(including microbial proteases) and by tissue proteases. PAR activation causes visceral 
hypersensitivity, modifies intestinal motility and intestinal epithelial permeability. All these 
functions take an important part in IBS symptoms generation (Cenac et al., 2007). Trypsin 
and tryptase expression and release were increased in colonic biopsies from IBS patients 
compared with control subjects. Biopsies from IBS patients (but not controls) released 
mediators that sensitized murine sensory neurons in culture. Sensitization was prevented by a 
serine protease inhibitor and was absent in neurons lacking functional protease-activated 
receptor–2 (PAR2). Supernatants from colonic biopsies of IBS patients, but not controls, also 
caused somatic and visceral hyperalgesia and allodynia in mice, when administered into the 
colon (Cenac et al., 2007). According to this serpin superfamily, endogenous serine protease 
inhibitor, and leukocyte elastase turn out seems to have a novel and clinically relevant role in 
the crosstalk between neurons and T cells in the modulation of neuropathic pain (Vicuña et 
al., 2015). Recently, a study demonstrated that proteases, through the activation of PAR2, 
were able to induce the release of TRPV4 endogenous agonists, which were found up-
regulated in tissues from patients with IBS (Vergnolle et al., 2016). According to these 
evidence thermosensive ion channels, TRPV1 and TRPV4, resulted implicated previously in 
visceral mechanosensation. In fact, deletion of TRPV1 or TRPV4 impairs afferent fibre 
transmission of mechanical stimuli in the colon (Jones et al., 2005). TRPV1 and TRPA1 
showed a pivotal role in visceral hypersensitivity at the peripheral and spinal cord level during 
acute colitis and gastric disease. Further, histamine- or serotonin mediated visceral 
hypersensitivity depend on TRPV4 expression in sensory neurons (Cenac et al., 2010). 
TRPV4 appears as a common mechanism to several known mediators of visceral 
hypersensitivity (Kondo et al., 2009). Histamine can also sensitize the nociceptor transient 
reporter potential channel V1 (TRPV1) contributing to visceral hypersensitivity in animals 
(Cenac et al., 2010).  
In this contest, it is interesting to note that, unlike the other protease, elastase effects seem 
instead to involve another type of receptor, the toll-like receptor-4, but the exact mechanism is 
still unknown (Vergnolle et al., 2016). Toll-like receptors (TLRs) are critical pattern 
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recognition molecules of the innate immune system. Interestingly, innate immune receptor 
expression resulted changed in the gastrointestinal tract of animals with stress induced IBS-
like symptoms (McKernan et al., 2009).  
Growing evidence suggests that, in IBS, the epithelial barrier, gut microbiota, food antigens 
and bile acids elicit abnormal responses in the key regulators of sensorimotor functions, 
involving the hypothalamus–pituitary–adrenal (HPA) axis. Corticotropin releasing factor 
(CRF) receptor mediate the stress response, activating the hypothalamic-pituitary-adrenal and 
sympathic-adrenal axes. In animals both acute stress, colitis or central CRF administration 
increases colorectal distension-evoked nociceptive responses and in all the cases visceral 
hypersensitivity can be reversed by CRF1 antagonists. Yet, in human administration of CRF 
increases colonic motility and hypersensitivity to distension, effects that are exacerbated in 
patients with IBS (Taché et al., 2009). Other neuropeptides that have similar potential for a 
role in visceral pain sensation include CGRP, somatostatin and cholecystokinin (Wesselmann 
et al., 2009).  
Over recent years, increasing attention has been placed also toward the adenosine system, 
which represents a crucial link between the enteric neuromuscular layer and the immune 
components of the gut. Studies in rodents have shown a significant involvement of adenosine 
in the control of intestinal secretion, motility and sensation, via activation of A1, A2A, A2B 
or A3 purinergic receptors, as well as the participation of ATP in the regulation of enteric 
functions, through the recruitment of P2X and P2Y receptors (Antonioli et al., 2008). Great 
interest is focusing on the involvement of ATP and adenosine in the pathophysiology of 
intestinal disorders, with particular regard for inflammatory bowel diseases (IBDs), intestinal 
ischemia, post-operative ileus and related dysfunctions, such as gut dysmotility, diarrhoea and 
abdominal discomfort/pain. Current knowledge suggests that adenosine contributes to the 
modulation of enteric immune and inflammatory responses, leading to anti-inflammatory 
actions (Antonioli et al., 2008). Expression of nociceptive-specific P2X3 ATP receptors is up-
regulated in colonic nerve fibres of individuals with IBS (Burnstock et al., 2009). It is 
interesting to observe that P2X3 receptors seems not involved in sensory signalling under 
physiological conditions whereas they modulate visceral hypersensitivity during acute and in 
the post-inflammatory phase, although via different mechanisms of sensitization (Deiteren et 
al., 2015). Spinal microglial P2X4 receptors are also activated after visceral injury. The 
consequent microglia activation evokes inflammatory cytokines release that contribute to 
central sensitization (Burnstock et al., 2009). Furthermore, the activation of neuronal P2X7 
receptor-Pannexin-1 complex resulted as mediators of death of enteric neurons during colitis 
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(Gulbransen et al., 2012). Recent evidences suggest a P2X7-dependent-glutamate release in 
cerebro-cortical nerve terminals of neuropathic animals (Silverman et al., 2009; Mannelli et 
al., 2015). Opposite of ATP, the neurotransmitter adenosine seems mediate pain suppression. 
In fact, the spinally injection of two ectonucleotidases, able to generate adenosine in 
nociceptive neurons, showed long-lasting adenosine A1 receptor-dependent antinociceptive 
effects in inflammatory and neuropathic pain models (Zylka, 2011).  
 
6.2. Adenosine receptors  
The main focus for the development of adenosine targets as analgesics to date has been A1Rs 
due to its antinociceptive profile in various preclinical pain models. The usefulness of 
systemic A1R agonists may be limited by other effects (cardiovascular, motor), but enhanced 
selectivity for pain might occur with partial agonists, potent and highly selective agonists, or 
allosteric modulators. A2AR agonists exhibit some peripheral pronociceptive effects, but also 
act on immune cells to suppress inflammation and on spinal glia to suppress pain signalling 
and, therefore may be useful for inflammatory and neuropathic pain. A2BR agonists exhibit 
peripheral proinflammatory effects on immune cells, but also spinal antinociceptive effects 
similar to A2AR agonists (Sawynok, 2016). A3Rs are now demonstrated to produce 
antinociception in several preclinical neuropathic pain models, with mechanistic actions on 
glial cells, and may be useful for neuropathic pain. Endogenous adenosine levels can be 
augmented by inhibition of metabolism (via adenosine kinase) or increased generation (via 
nucleotidases), and these approaches have implications for pain. Endogenous adenosine 
contributes to antinociception by several pharmacological agents, herbal remedies, 
acupuncture, transcutaneous electrical nerve stimulation, exercise, joint mobilization, and 
water immersion via spinal and/or peripheral effects, such that this system appears to 
constitute a major pain regulatory system (Sawynok, 2016).  
It has been demonstrated that increasing endogenous adenosine levels through selective 
adenosine kinase inhibition produces powerful analgesic effects in rodent models of 
experimental neuropathic pain through the A3 adenosine receptor (A3AR, now known as 
ADORA3) signalling pathway (Little et al., 2015). These effects were prevented by blockade 
of spinal and supraspinal A3AR, lost in A3AR knock-out mice, and independent of opioid and 
endocannabinoid mechanisms. A3AR activation also relieved non-evoked spontaneous pain 
behaviours without promoting analgesic tolerance or inherent reward (Little et al., 2015). 
Also, A3AR agonists resulted effective in several models of chronic neuropathic pain, 
including that caused by chemotherapeutic agents, was also proved (Bennett et al., 1988; 
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Chen et al., 2012). Of particular interest are the highly selective A3AR agonists developed by 
Tosh et al. (2015) which lack the cardiovascular side effects known for other AR agonists, 
such as A1AR agonists which also provide pain relief (Luongo et al., 2012). Critically, 
engaging the A3AR mechanism did not alter nociceptive thresholds in non-neuropathy 
animals and therefore produced selective alleviation of persistent neuropathic pain states 
(Little et al., 2015).  
Exploring the mechanistic basis for the protective effect of A3AR agonists in chronic 
neuropathic pain, it has been found that pain relief is dependent on GABAergic transmission, 
but not cannabinoid or opioid receptors, in the spinal cord, and that both peripheral sensory 
neurons and brain are involved. Moreover, when peripherally administered A3AR agonists 
can correct the imbalance in dorsal horn cytokines, oxidative pathways, and glutamatergic 
transmission associated with the pain state. A3AR agonists are demonstrated to be also 
protective in other pain models, such bone cancer pain (Little et al., 2015; Varani et al., 2013; 
Yan et al., 2016). Thus, A3AR agonists promise to be safe and effective in the treatment of 
chronic neuropathic pain of various etiologies. 
Moreover, recently, we found that the selective stimulation of A3AR inhibits N-type voltage-
gated Ca
2+
 channels (Cav2.2) opening and decreases the electrically-evoked excitation of 
isolated rat dorsal root ganglia (DRG) neurons. This mechanism could explain the anti-
hyperalgesic effect of A3AR agonists across different models (Coppi et al., 2019).  
The possibility of targeting adenosinergic system also in visceral pain management is 
supported by preclinical evidence attesting the involvement of adenosine receptors in the 
analgesic effect of paeoniflorin in rats with neonatal maternal separation-induced visceral 
hyperalgesia (Zhang et al., 2009). Asano and Takenaga (2017) reported that the adenosine 
A2B receptor is involved in visceral hypersensitivity in animal models of IBS and blocking the 
A2B receptor suppresses both somatic and visceral pain. Additionally, the same research group 
reported that a specific inhibitor for each subtype of adenosine A2B receptor and 
phosphodiesterases mediated the inhibitory effect of aminophylline on maternal separation- 
and acetic acid administration-induced visceral hypersensitivity to colorectal distension 
(CRD) (Asano et al., 2017). Recently, Hou et al. (2019) demonstrated that the inhibitory 
effect of electroacupuncture on visceral pain is mediated by adenosine receptors activation in 
mice with inflammatory bowel disease. In this context, electroacupuncture also determine an 
increase in the expression of A1R, A2AR, and A3R and a decrease in the expression of A2BR in 
the colon tissue. A3R selective activation has an anti-inflammatory activity through the 
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inhibition of pro-inflammatory cytokine expression associated with the inhibition of NF-κB 
signaling pathways in murine DSS colitis in vivo (Ren et al., 2015).  
The efficacy showed by adenosine receptors modulation in visceral pain, joined with the 
recent evidence identifying adenosine A3 receptor as an effective and safe target for achieving 
pain relief in different models of persistent pain, put these receptors first in the list of possible 
new treatments for chronic visceral pain.  
On the other hand, contrasting data were reported about the involvement of A3R in the 
regulation of intestinal motility. Ren et al. (2015) reported that A3 receptors expression 
localized on epithelium, excluding a direct action on enteric nerves functionality (Ren et al., 
2015). Nevertheless, immunofluorescence showed a predominant distribution of A3 receptors 
in normal myenteric ganglia and an increased density during colitis (Antonioli et al., 2010). 
Yet, functional disruption of A3R in A3
−/−
R mice alters intestinal motility (Ren et al., 2011). 
The effect of A3R regulation on intestinal functionality is an important point to know in the 
development of therapies for visceral pain. 
 
7. Faecal Microbiota Transplantation (FMT)  
 
7.1. Faecal Microbiota Transplantation in IBS and IBD 
The complex interplay between genetic, microbial, and environmental factors is likely 
responsible for the phenotypic heterogeneity in IBS, and the successful treatment of different 
subsets may therefore require specific microbial manipulations (as introduced in the previous 
paragraphs). Host specificity has been suggested to be a desirable property for probiotic 
bacteria and is therefore recommended as one of the selection criteria (Rinkinen et al., 2003). 
Of the studies that found a statistically significant improvement in ―global symptoms‖ (14 out 
of 29 studies) and a clinically meaningful improvement in ―abdominal pain‖ (only 8 of all 35 
trials), the majority were multi-strain products (~2:1). Furthermore, only multi-strain trials 
found a clinically meaningful improvement in quality of life in IBS patients (Williams, 2008; 
Lorenzo-Zúñiga et al., 2014). The mechanisms underlying this difference in efficacy remain 
to be defined and are likely complex.  
However, in an in vitro intestinal epithelial cell inflammation model, MacPherson et al. 
demonstrated that, in comparison to single-strains, a multi-strain challenge resulted in a 
greater reduction of inflammation-modulated genes—findings that indicated a synergistic 
effect of bacterial combinations in resolving inflammation and maintaining cellular 
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homeostasis, which the authors concluded reinforces the rationale for using multi-strain 
probiotic formulations (Macpherson et al., 2017).  
The more frequent success of multi-strain probiotics in IBS may be owed to a synergistic 
effect on disease-modulated genes. Considering the advantages of combining multiple strains 
in respect to the use of a single bacterial strain, it is natural to question whether the transfer of 
a whole healthy microbiota could bring even more benefits.  
Faecal Microbiota Transplantation (FMT), also called faecal bacteriotherapy or stool/faecal 
transplantation, is the infusion or engraftment of liquid filtrate faeces from a healthy donor 
into the gut of a recipient to treat many diseases, including Clostridium difficile infection, 
IBD, obesity, and insulin resistance. Evidence for this range in therapeutic response is 
provided by studies using the somewhat controversial technique of transplantation of faecal 
matter from healthy donors to sufferers of functional gastrointestinal disorders (Choi et al. 
2016). In one study involving IBS and IBD sufferers (Borody et al. 1989), FMT was effective 
in 36% of the patients, mildly improved discomfort in 16% and non-effective in the rest 47%. 
Other clinical studies and case studies have utilised FMT for alleviation of chronic 
constipation (Andrews and Borody 1993), refractory IBS (Pinn et al. 2015) and IBD 
(Angelberger et al. 2013; Bennet and Brinkman 1989) with varied success. Another recent 
Open-Labeled Study on Fecal Microbiota Transfer in IBS patients confirmed improvement in 
abdominal pain which resulted associated with the relative abundance of Akkermansia 
muciniphila (Cruz-Aguliar et al., 2019). While such studies provide evidence for a role of 
microbiota in alleviating certain symptoms associated with gastrointestinal discomfort or 
visceral sensitivity, the studies provide little empirical data relating to long-lasting changes in 
gastrointestinal microbiota or alterations to immune, endocrine, inflammatory or 
neurotransmitter systems. Moreover, given the heterogeneity of chronic pain and the complex 
and diverse nature of the microbiome, individual interventions may be developed. 
Nevertheless, the principle of the gut microbiota as a therapeutic target has generated much 
enthusiasm. Prebiotic, Probiotic and FMT approaches have been tried in both IBD and IBS 
but understanding of cause–effect relationships continues to evolve. Several mechanisms 
underlying the therapeutic effects of FMT on chronic pain were proposed, including direct 
competition of pathogenic bacteria with commensal microbiota, protection of the intestinal 
barrier, restoration of secondary metabolism, and stimulation of the intestinal immune system 
(Guo et al., 2019). To date FMT is approved only for the therapy of Clostridium difficile 
infection, where the microbiota transplant is highly efficacious with the ability to restore 
healthy microbial ecology (Cammarota et al., 2016). The same efficacy has not been achieved 
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when FMT is employed for the treatment of other diseases. However, enteric microbiota 
alterations in other type of gastrointestinal disease, as colitis, might be more resistant to 
restoration than those in C difficile infection, possibly requiring more intense and prolonged 
therapy. Clostridium difficile infection is a pure ecological problem characterized by a defect 
in gut microbiota barrier properties (Leffler and Lamont, 2015; Gupta et sl., 2016). Besides, 
IBD is far more complex and involves a deregulation of the host-microbes cross talk. The 
goal of FMT in IBD is thus not only to correct the dysbiosis, but also to restore a normal 
dialog between the host immune system and the microbiota. Data are still scarce, but the 
results of the first studies suggest a complex effect of FMT in IBD (Pigneur and Sokol, 
2016). A recent study investigating the Fecal Microbiota Transplantation for Chronic Active 
Ulcerative Colitis (FOCUS) showed the efficacy and safety of multidonor, intensive-dosing, 
faecal microbiota transplantation in patients (Paramsothy et al., 2017). The efficacy of serial 
FMT has been demonstrated also in patients affected by chronic intestinal pseudo-obstruction 
in which bloating, and pain resulted effectively alleviated 2 weeks after FMT (Gu et al., 
2017). Increasing the dose and/or repeating FMT ameliorates the prognosis also in patients 
with IBS (El-Salhy et al., 2019).  
Although serious adverse events including bacteraemia and perforations have been reported, 
the majority of adverse events of FMT appear to be mild, self-limiting and gastrointestinal in 
nature. In some cases, a credible association was not established due to the lack of controlled 
data. Plainly, there is a need for standardized, randomized controlled trials to qualify and 
quantify the risks associated with FMT (Baxter and Colville, 2016). However, even if FMT 
for IBS has still a long way to go, the preliminary evidences are promising. Ongoing and 
future research should be oriented in understanding the best FMT protocol of treatment to 
employ for chronic visceral pain relief, since the literature is heterogeneous and not clear on 






Mechanisms underlying successful treatment of recurrent CDI with FMT 
Kelly et al., Gastroenterology, 2015a 
 
 
7.2. Faecal Microbiota Transplantation procedure 
The FMT procedure involves identification of a donor, screening of donor stool for 
pathogens, stool preparation (including cryopreservation if necessary), preparation of the 
recipient (antibiotic treatment and enteric cleansing), infusion of the donor stool and post-
procedural management of the patient, including the monitoring of adverse events. Hence, the 
treatment is somewhat unwieldy compared with antibiotic treatment alone.  
To reduce and prevent the occurrence of adverse events, strict donor screening tests of FMT 
are recommended (Choi et al., 2016; Cammarota et al., 2017; Wang et al., 2019). The 
guidelines in the United States and European consensus conference both suggest to use a 
donor questionnaire to meet the exclusion and inclusion criteria (Bakken et al., 2011; Smits et 
al., 2013; Cammarota et al., 2017; Vindigni and Surawicz, 2017). To evaluate any recent 
potentially harmful behaviors, screened donors should undergo an additional interview on the 
same day of the donation (Routy et al., 2018). Furthermore, standard donor screening 
protocols should be set up to lower the risks of infection transmission from the donor to 
recipient, and a suitable donor ought to receive both blood and stool examinations within 4 
weeks before donation (Cammarota et al., 2017). 
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The similarity of microbial species is expected between the recipient and his/her close 
relative; therefore, adaptive immunity in the mucosal immune system might present more 
tolerance towards the microbiota from the donor (Bakken et al., 2011). Nevertheless, 
additional clinical evidence has proven no association between donor and FMT outcomes 
(Weingarden et al., 2014; Shankar et al., 2014). Unrelated FMT volunteer donors may be 
more beneficial in cases where genetics play a contributing factor in the disease, like IBD 
(Kelly et al., 2015a).  
The optimal preparation of fecal material to manage remains to be determined. It had been 
debated whether fresh or frozen fecal material was the better choice for FMT at the beginning 
of the FMT practice. Currently, several randomized clinical trials and meta-analysis 
demonstrated that frozen FMT has the same efficacy as fresh FMT in clinical improvement of 
recurrent or refractory CDI (Lee et al., 2016; Wise, 2016; Tang et al., 2017). Fresh fecal 
material should be processed within 6 h of donor production, and it can be stored at room 
temperature until further processing. Approximately 50 g (minimum amount of 30 g) of fecal 
material is mixed with approximately 150 mL of sterile normal sodium chloride by blender. 
The mixture is filtered with a filter or gauze to clear away large particulate matter, which may 
obstruct the endoscope channel. Finally, the filtrate is infused into 60-mL syringes (generally 
4–5 tubes) and infused to the recipient's GI tract (Sokol et al., 2016; Cammarota et al., 2017; 
Vindigni and Surawicz, 2017).  
In recent years, several stool banks have been established worldwide in succession. Collecting 
stool from a set of prescreened donors, preparing and dividing the donated fecal material, and 
freezing aliquots of screened fecal material are processed in a stool bank. Additionally, the 
final fecal material must be strictly managed by clearly labeling, tracking, and storing at 
−80 °C. On the day of FMT, the fecal suspension is thawed in a warm (37 °C) water bath, and 
the normal saline solution is mixed to obtain an expected suspension volume. It is worth 
noting that repetitive thawing and freezing ought to be avoided, and infusion should be 
performed within 6 h of thawing (Cammarota et al., 2017; Vindigni and Surawicz, 
2017). Nevertheless, the appropriate volume of fecal infusion is difficult to define. Larger 
volumes of fecal material have shown better FMT outcomes in CDI patients, as demonstrated 
by a systemic review article, and up to a four-fold higher risk for failure was noted for 
infusion volumes less than 50 g compared to the larger volume (Gough et al., 2011).  
Regardless of the source of fecal material or chosen route of administration, patients 
undergoing FMT need support and education prior to treatment (Blackburn et al., 
2015). Recipient should not be administered with any form of antibiotics 12–48 h before 
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fecal infusion (Cammarota et al., 2017). Practical preparation for the FMT procedure is 
similar to that of any other endoscopic procedure, including a standard bowel preparation. The 
bowel should be virtually free of contaminated fecal material prior to the donor feces infusion 
to ensure a healthy graft (Blackburn et al., 2015). Some studies suggested loperamide use one 
hour before FMT in order to ensure that the transplanted feces stay at least 4 h long in the 
intestines (Brandt and Aroniadis, 2013; Evrensel and Ceylan, 2016; Goldenberg et al., 2018).  
The current administration of fecal material by means include upper GI route 
(via esophagogastroduodenoscopy, nasogastric, nasojejunal, or nasoduodenal tube), lower GI 
route (via colonoscopy or retention enema), and oral capsule. In general, FMT via the upper 
GI route can be administered in patients with an inflamed colon; however, the discomfort 
sensation during tube placement, risks of aspiration, and inability to evaluate the colon 
mucosa or to collect mucosa tissue samples are weak points. FMT via colonoscopy has 
superiority in recolonizing the entire colon with favorable bacteria, and bowel cleaning can 
probably reduce the number of residual organisms and spores to visualize the entire colon, but 
it is a relatively risky, expensive, and invasive procedure. FMT via retention enema is more 
affordable and less invasive than colonoscopy, but the donor fecal material cannot be 
delivered to the entire colon and is limited to the distal colon. Oral capsule for FMT 
administration has the advantages of less invasion and high patient acceptability, but the 
expense and large capsule burden are its disadvantages (Cammarota et al., 2014; Vindigni 
and Surawicz, 2017).  
If more was known about the elements in stool that make FMT work, it might be possible to 
develop a simpler FMT procedure. For instance, if only certain faecal bacteria are needed for 
successful FMT, the production of synthetic bacterial suspensions could be standardized, 
scaled up and potentially commercialized. Such a system would also reduce the risk of 
transferring potential pathogens such as enteric viruses and parasites that might be difficult to 
detect during routine microbiological screening of donor stool (Wang et al., 2019).  
Most clinical trials and systemic reviews presented that some minor adverse events, such 
as abdominal discomfort, diarrhea, constipation, and low-grade fever, were transiently noted 
after FMT, and uncommon severe side effects were often associated with the possible 
complications of endoscopy and sedation (Wang et al., 2019). Moreover, some case reports 
and cohort studies showed that small populations of patients experienced IBD flares after 
FMT (De Leon et al., 2013; Quera et al., 2014; Fischer et al., 2016). The definite mechanism 
of IBD flare after FMT is still unclear, although Quera et al. suggested that 
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transient bacteremia may result in altered intestinal permeability, resulting in a flare (Quera et 
al., 2014).  
 
 
The schematic diagram of fecal microbiota transplantation process 
Wang et al., Journal of the Formosan Medical Association, 2019 
 
 
8. Animal models of visceral pain 
Rats and mice are the most commonly used animal models used to assess colonic physiology, 
pathophysiology, and new treatment approaches for visceral pain. In general, there are 
multiple, well-established methodologies to universally quantify visceral nociception in rats 
and mice. The most commonly used technique involves recording devices such as 
electromyographic (EMG) electrodes or strain gauges implanted on the external oblique 
abdominal musculature, to quantify the number of reflex abdominal muscle contractions in 
response to graded colonic balloon distension. Measurement of isobaric distension pressures 
with a barostat offers numerous strengths, such as an objective assessment of pseudoaffective 
nociceptive reflexes, allowing for assessment of colonic compliance, as well as mimicking the 
approach used in clinical studies in which sensitivity is assessed in response to rectosigmoid 
distension. However, there are also weaknesses that must be considered in the data 
interpretation. For example, the animals may be exposed to stress during the procedure as a 
result of the novel laboratory environment or may be restrained to reduce movement artifact 
during EMG recording. An acclimatization period to the experimental environment has been 
shown to significantly reduce animal stress and allows for the assessment of visceral 
sensitivity in a freely moving animal. However, anesthesia will always be necessary to insert 
the colorectal balloon; it should be kept as brief as possible to avoid interference with the 
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nociceptive reflex. An additional approach to assess colonic sensitivity is by the visual 
assessment of the abdominal withdrawal reflex (AWR) in response to colorectal distension 
(CRD). A benefit of this technique is that the stereotyped nociceptive behavior is induced by a 
brief distension; however, the AWR is a subjective behavioral measure, requiring larger 
samples sizes to demonstrate significant differences between treatment groups. An alternative 
approach to the use of a colonic balloon distension paradigm is to directly stimulate visceral 
nociceptors through colonic infusion of algesic chemicals, such as capsaicin or mustard oil. 
Such substances produce spontaneous nocifensive behaviors (perianal licking, abdominal 
retraction or compression, and hindlimb stretching) and take advantage of spontaneous 
evoked nocifensive behaviors. A note of caution in the data interpretation is that the 
inflammatory component of the stimulus suggests that the model may more relevant to 
inflammatory pain rather than functional visceral pain (Greenwood-Van Meerveld et al., 
2015).  
 
8.1. Genetic/Spontaneous models of visceral hypersensitivity 
Knockout models provide the opportunity to investigate the role of a specific gene in the 
regulation of colonic sensitivity. For example, there is a significant decrease in colonic 
sensitivity to CRD in corticotropin-releasing factor (CRF)-1 receptor knockout mice, 
suggesting the importance of CRF in colonic sensitivity (Trimble et al., 2007). Further studies 
in knockout mice have demonstrated the importance of other signalling molecules and 
transporters in the regulation of colonic sensitivity, including brain-derived neurotrophic 
factor (BDNF), guanylate cyclase C (GC-C), serotonin (5HT), and interleukin 10 (IL-10), 
human excitatory amino acid transporter 2 (EAAT2), and the serotonin reuptake transporter 
(SERT) (Greenwood-Van Meerveld et al., 2015).  
Multiple studies have confirmed that the Wistar-Kyoto (WKY) rat has a hypersensitive 
response to colonic distension (Gunter et al., 2000). No single mechanism has been 
demonstrated to be responsible for the hypersensitive response in WKY rats. Recent studies 
have shown that both central and peripheral CRF receptors are differentially expressed and 
that selective CRF antagonists can inhibit colonic hypersensitivity (O‘Malley et al., 2010; 
Bravo et al., 2011; Johnson et al., 2012; Buckley et al., 2014). Interpretation of data in genetic 
models is complicated and represents a significant challenge. For example, gene deletion may 
affect the overall health of the animal along with endogenous compensatory and/or redundant 
mechanisms that mask the true effect of the loss of the gene. An issue with the WKY rats is 
that, the inbred nature of this strain may limit the translational relevance because they may 
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only model the pain experienced by a subgroup of patients with functional visceral pain 
(Greenwood-Van Meerveld et al., 2015). 
 
8.2. Early Life Stress models of visceral pain  
Increasing evidence from clinical studies suggests that a history of Early Life Stress (ELS) 
serves as a risk factor for the development of adult pathologies including but not limited to GI 
disorders such as IBS, with affected patients being two to four times more likely to report an 
adverse experience during childhood (Brierley et al., 2009). Despite the strong correlation 
between ELS and decreased health-related quality of life in adults due to GI-related 
abnormalities, the mechanism by which ELS underlies these changes is still unknown. 
Although the complex nature of the human ELS experience cannot be completely simulated in 
animal models, animal models of ELS are important tools to develop our understanding of 
how adverse neonatal experiences alter brain-gut communication that may lead to the 
development of abnormal visceral perception. The most well studied model of ELS is 
maternal separation (MS), which involves removal of pups from mother and nest, most 
commonly for 3 h/day on postnatal (PN) day 2–14 (Plotsky and Meaney, 1993). The purpose 
of this paradigm is to mimic childhood neglect and abuse through separation and subsequent 
alterations in maternal care, including altered licking and grooming behaviors and arched-
back nursing (Plotsky and Meaney, 1993). MS pups exhibit decreased weaning body weight 
at PND22 compared with controls that are left undisturbed in their home cage on PND2, 
potentially introducing the effects of malnutrition as a side effect of neglect in this ELS 
model. In adulthood, there are contradictory results on visceral sensitivity depending on the 
duration of separation. However, a 3 h/day separation has been shown to result in visceral 
hypersensitivity, as evidenced by an increased viscero-motor response (VMR) to CRD in 
male Long-Evans rats (Coutinho et al., 2002). This model is useful to investigate the 
relationship between ELS and subsequent development of visceral hypersensitivity, in 
conjunction with hyper-reactivity of the HPA axis, two commonly comorbid symptoms in 
disorders such as IBS (Dinan et al., 2006; Whitehead et al., 2010). The odor-attachment 
learning (OAL) model of ELS is a classical conditioning model that utilizes predictable or 
unpredictable odor-shock pairings to mirror an attachment to an abusive caregiver (Sullivan et 
al., 2000). Conditioning occurs from PND8-12 wherein rat pups are experiencing both a 
sensitive and a hyporesponsive period. These are evolutionary advantages that allow the pups 
to be more sensitive to maternal odors to find the dam in the cage for care and nursing 
(Sullivan and Wilson, 1994). Therefore, by utilizing an odor and modest shock, this model is 
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able to mimic patterned interactions between pup and dam. In adulthood, this is the first 
model that induces female-specific visceral hypersensitivity in adult Long-Evans rats. 
Following OAL, female rats with a history of unpredictable ELS exhibit an increased VMR to 
CRD, an effect that has been shown to be estrogen dependent (Chaloner et al., 2013). This 
model of ELS has far reaching relevance to translational research as it parallels the female 
predominance found in patients who experience visceral pain (Bradford et al., 2012). A third 
model of ELS, limited nesting, aims to mirror the neglect and abuse found in areas of poverty 
or lower socioeconomic standing (Gilles et al., 1996). From PND2 to PND9, all bedding 
material is removed, and the dam and pups are placed on a wire cage bottom with only a 
single paper towel for nesting material. This limitation of bedding material causes disruptions 
in normal maternal care similar to those exhibited by dams during the MS protocol, however, 
the limited nesting model does not require removal of pups from the dam at any time during 
the experimental paradigm. This advantage also eliminates differences in weaning weights 
seen in the MS model (Prusator et al., 2015). Another model of ELS utilizes neonatal colonic 
irritation using colonic infusion of mustard oil or repeated CRD in neonates (Al-Chaer et al., 
2000). Colonic irritation results in altered neuronal excitability and permeability within the 
colon, as well as visceral hypersensitivity of adult animals (Al-Chaer et al., 2000; Lin et al., 
2003; Chaloner et al., 2010). This model may be relevant in instances of repeated physical or 
sexual abuse, and potentially in patients who experience some type of colonic inflammation 
during childhood. Rodent models of ELS are pivotal tools in the investigation of the 
mechanisms that underlie visceral pain following early life trauma. However, ELS studies as a 
whole, as well as each paradigm, are not without challenges. Overall, the initial consideration 
of protocol, strain, and sex differences present major considerations (Greenwood-Van 
Meerveld et al., 2015).  
 
8.3. Stress-Induced models of colonic hypersensitivity in adulthood  
As a model of stress targeting only the amygdala, implantation of corticosterone (CORT) 
micro-pellets on the dorsal surface of the central nucleus of the amygdala (CeA) were initially 
shown to increase colonic sensitivity to innocuous distension (Greenwood-Van Meerveld et 
al., 2001). An interesting feature of this model is its relevance to patients with IBS based on 
imaging studies showing heightened activation of the amygdala in IBS patients in response to 
colonic distension (Naliboff et al., 2003; Wilder-Smith et al., 2004). Careful stereotaxic 
targeting of the CeA is necessary, since placement of the CORT micro-pellet in adjacent 
nuclei does not reproduce the colonic hypersensitivity (Myers et al., 2007).  
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Another model of stress is that induced by animal restraints. The most typical protocol is a 1- 
or 2-h acute stress protocol in which the animal either has its forelimbs wrapped with tape to 
restrict movement and grooming behaviour or is placed in a restraint apparatus (cage or tube) 
that prevents turning and grooming. A strength of the model is the robust and reproducible 
nature of the colonic hypersensitivity induced by restraint stress. This acute restraint stress 
induces an increase in colonic sensitivity to distension as measured by EMG or AWR 
quantification. A stronger model of stress-induced colonic hypersensitivity is that represented 
by the Water Avoidance paradigm. In this experimental model of stress, the rat is placed on a 
dry platform surrounded by water in attempt to mimic a psychological stressor. However, this 
model may also engage the fear neurocircuitry, which could evoke freezing behaviors in the 
colonic distension paradigm and affect interpretation of data using this model. With the 
exception of two studies (Larauche et al. 2012a, 2012b), water avoidance stress (WAS) 
protocols in rats induce colonic hypersensitivity to distension. A single exposure to WAS has 
been demonstrated to induce colonic hypersensitivity either immediately, within 60-min of 
the acute stressor, or after recovery from the stressor, 24-h poststress (Myers et al., 2012).  
To eliminate the possibility of rats habituating to a single repetitive stressor, several variable 
stress protocols have been developed that expose animals to a set of randomly presented 
stressors. The unpredictable nature of the stressors prevents acclimatization to the procedures. 
The duration of colonic hypersensitivity to distension, measured through EMG or AWR, was 
strain dependent with a duration of action of up to 48 h poststress. A common issue is that in 
rat models of stress-related visceral pain the nature of the stressors, including whether they are 
physical vs. psychological, acute vs. chronic, or predictable vs. unpredictable, can have a 
profound influence not only on the outcome of the investigation but also on the biological 
processes involved (Greenwood-Van Meerveld et al., 2015).  
 
8.4. Colonic irritation models of hypersensitivity  
Acetic acid has been used to induce colonic hypersensitivity to distension through two 
different mechanisms. Low-concentration (~1.0%) acetic acid produces a transient 
sensitization of colonic afferents (Langlois et al., 1994; Plourde et al., 1997). Higher 
concentrations of acetic acid produce a mild damage to the colon, producing inflammation-
associated hypersensitivity. In an attempt to produce a noninflammatory model of colonic 
hypersensitivity with potential translational relevance to IBS, Bourdu et al. (2005) 
characterized the effect of repeated butyrate enemas on both colonic hypersensitivity to 
distension and colonic histology. Six enemas of butyrate induced colonic hypersensitivity, 
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reversible with morphine and requiring C-fibers, without evidence of inflammation or 
histological damage (Bourdu et al., 2005). On the other hand, the colonic installation of a low 
volume of capsaicin or mustard oil induces pain through direct activation of receptors on 
afferents as well as establishing an acute inflammation through tissue damage and is typically 
used to evaluate the analgesic properties of novel therapeutics. Stereotypic pain behaviors, 
such as abdominal licking, stretching, retraction, or compressing on the cage floor, are 
counted for 20 –30 min after irritant administration (Greenwood-Van Meerveld et al., 2015).  
 
8.5.Models of post-infection/inflammatory visceral pain 
These models attempt to mirror the postinflammatory/infective hypersensitivity that develops 
in some IBS patients. In an attempt to model postinfective IBS, colonic sensitivity has been 
assessed in rat and mouse models following an acute bacterial gastroenteritis. In rats, 
Citrobacter rodentium induced a significant increase in AWR score, which was inhibited by 
treatment with a traditional herbal medicine or alosetron (Hu et al., 2013). In mice, 
Campylobacter jejuni infection caused long-term hyperexcitability of colonic DRG neurons 
(Ibeakanma et al., 2009). However, a clear increase in the EMG response to balloon 
distension was found only if the mouse was exposed to an additional stressor (Ibeakanma et 
al., 2011). Trichinella spiralis infection has also been used to produce a long-term colonic 
hypersensitivity to distension in rats and mice. At 8 wk postinfection, the EMG response to 
distension was significantly increased along with increases in glutamatergic receptor 
expression (Yang et al., 2009). Notheworty, additional precautions should be exercised when 
using the post-infective models to protect the experimenters from the pathogens (Greenwood-
Van Meerveld et al., 2015).  
Based on the current understanding of post-inflammatory- (PI-) visceral hypersensitivity (PI-
IBS), in an ideal animal model, the animals should not only completely recover from the acute 
intestinal infection or inflammation but also show intestinal features such as visceral 
hypersensitivity, motility dysfunction, and changes in permeability or secretion (Qin et al., 
2012). Owing to their low cost and rapid onset of disease, chemical models are considered 
invaluable to the study of various aspects of IBS (Hughes et al., 2009; Giamberardino, 2009).   
Among the irritants used to induced post-inflammatory IBS there are acetic acid, DSS, and 
TNBS. Following recovery from an acute colitis induced by these chemicals, determined by 
gross morphology, histology, and/or tissue immune activation markers (cytokines), these 
animals develop a hypersensitive response to colonic distension. The standard protocol for 
acetic acid-induced post-inflammatory colonic hypersensitivity is to administer and enema of 
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4% acetic acid, followed by a buffered saline enema, with colonic hypersensitivity lasting 7 
days post-enema. Strong evidence for post-inflammatory colonic hypersensitivity following 
DSS colitis is lacking in recent literature. Although hypersensitivity to distension was 
demonstrated at 10 days post-DSS administration (Chen et al., 2013), colonic sensitivity was 
similar to control animals at ~40 days post-colitis (Eijkelkamp et al., 2009). Besides, in rats, 
colonic hypersensitivity has been observed 14-112 days post-TNBS enema. 2,4,6-
trinitrobenzenesulfonic acid (TNBS) is a hapten that produces an acute colonic inflammation 
when administered as an enema in combination with 25–50% ethanol (EtOH). Ethanol is a 
prerequisite to break the colonic mucosal barrier to allow penetration of TNBS into the lamina 
propria where TNBS haptenize the localized colonic and gut microbial proteins to become 
immunogenic, thereby triggering the host innate and adaptive immune responses (Qin et al., 
2011). Although inflammatory changes in the colonic tissue can be measured within hours of 
the enema, most protocols investigate colonic sensitivity to distension, with EMG or AWR 
quantification, 3–7 days post-enema, which will represent different amounts of inflammatory 
damage depending on the concentration of TNBS and EtOH in the enema (te Velde et al., 
2006). Assessing colonic sensitivity in rats and mice with active colitis likely increases the 
risk for perforation by the balloon catheter due to the potential presence of ulcerated and/or 
necrotic tissue (te Velde et al., 2006). In general, TNBS model is associated with severe and 
sometimes bloody diarrhoea, weight loss and intestinal wall thickening however symptoms 
vary depending upon the type of rodent used, as well as the timing, dose and degree of 
exposure to TNBS used in the study (Qin et al. 2011). The features of IBS, such as visceral 
hypersensitivity, motility dysfunction, alteration in histopathology, and changes in 
permeability and secretion, have also been identified in the experimental animals after 
recovery from the initial inflammation induced TNBS (Qin et al. 2012). Moreover, both 
tegaserod and linaclotide have been shown to inhibit TNBS-induced post-inflammatory 
colonic hypersensitivity, providing evidence for the translational relevance of the model 
(Greenwood-Van Meerveld et al., 2006; Castro et al., 2013). All these evidences made TNBS 
the most commonly used model of pot-inflammatory IBS. TNBS is considered as a hazardous 
chemical due to its highly oxidative properties so 2,4-DiNitroBenzene Sulfonic acid (DNBS) 
is currently regarded as a preferred choice to induce IBS. Despite the numerous aspects 
similar to IBS patients found in the TNBS and DNBS models, the experimental protocols are 
variegated and poorly defined because of the great variability in the animal‘s responses to the 
damage (Giamberardino et al., 2009). Indeed, the recovery from the colitis does not guarantee 
the existence for colonic hypersensitivity to balloon distension (Zhou et al., 2009). Thus, the 
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acute effects of the initial inflammatory insult (loose stool/ diarrhoea, weight loss, occult or 
explicit bleeding) needs to be monitored during the recovery period to aid in predicting which 
animals may develop post-inflammatory colonic hypersensitivity. Optimally, colonic 
sensitivity to distension should be assessed before testing a therapeutic intervention with only 
those animals with verified colonic hypersensitivity being used for subsequent testing 
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AIMS OF THE STUDY 
 
The aims of the study are the establishment and the characterization of an animal model of 
persistent visceral pain closely related to the clinical manifestations in order to study the 
pathophysiological mechanisms involved and to research novel possible treatments.  
For these purposes we will set up a persistent visceral hypersensitivity in rats through the 
intra-rectal injection of 2,4-DiNitroBenzene Sulfonic acid (DNBS). Visceral pain persistence 
will be assessed by measuring the Abdominal Withdrawal Response (AWR) and the Visceral 
Motor Reflex (VMR) to Colo-Rectal Distension (CRD) weekly after DNBS injection. 
Anxiety- and depressive-like behaviour will be also assessed in these animals. The effect of 
systemic and/or intrathecal administration of spasmolytics, anti-inflammatory drugs, opioids, 
antiepileptics and antidepressants will be investigated in order to characterize the nature of the 
observed pain. Histological and molecular characterization of intestine will be carried out for 
evaluating colon damage, fibrosis, eosinophil infiltrate, mast cells concentration and 
substance P level. An immunofluorescence analysis will be performed to evaluate immune 
interaction with the peripheral afferents on colon and microglia (Iba-1 positive cells) and 
astrocytes (GFAP positive cells) number and morphology in the spinal cord.  
In the second part of this work we will study the effect of modulating adenosine A3 receptors 
on post-inflammatory visceral pain. We will evaluate the effect of acute intraperitoneal 
administration of a new highly selective A3 adenosine receptor agonists, MRS5980, and the 
golden standard, Cl-IB-MECA in DNBS treated animals. The involvement of A3 receptors 
activation and Ca
2+
 modulation in the anti-hyperalgesic effect of MRS5980 and Cl-IB-MECA 
will be studied by both behavioural tests and electrophysiological analysis on DNBS isolated 
DRG neurons. The efficacy of these molecules will be compared with a reference drug for 
IBS therapy, linaclotide.  
In the third part of the work the role of microbiota in post-inflammatory visceral pain will be 
studied. Firstly, the effect of Faecal Microbiota Transplantation (FMT) from DNBS-treated to 
naïve rats on visceral sensation will be investigated. To allow the transplant of the microbiota 
the animals will undergo an antibiotic treatment. To reduce the impact of antibiotics on 
visceral sensitivity we will test different protocols, and the least impacting will be used in the 
following experiments. Moreover, we will study the mechanisms underlying microbiota-
mediate visceral sensitivity alterations by exploring the effect of FMT on gut permeability, 
cytokines profile and neurotransmitters (5-HT and DA) levels. We will also assess the levels 
of tryptophan and kynurenine in the plasma and monoamines in the faeces. In parallel, the 
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analysis of microbiota composition will be performed. Finally, we will investigate the effect 
of transplanting a healthy microbiota in DNBS animals on the development of post-




























MATERIALS AND METHODS 
  
1. Animals 
For all the experiments described below, Male Sprague-Dawley rats (Envigo, Varese, Italy) 
weighing approximately 220-250 g at the beginning of the experimental procedure, were 
used. Animals were housed in CeSAL (Centro Stabulazione Animali da Laboratorio, 
University of Florence) and used at least 1 week after their arrival. Four rats were housed per 
cage (size 26 × 41 cm); animals were fed a standard laboratory diet and tap water ad libitum, 
and kept at 23 ± 1 °C with a 12 h light/dark cycle, light at 7 a.m. All animal manipulations 
were carried out according to the Directive 2010/63/EU of the European parliament and of the 
European Union council (22 September 2010) on the protection of animals used for scientific 
purposes. The ethical policy of the University of Florence complies with the Guide for the 
Care and Use of Laboratory Animals of the US National Institutes of Health (NIH Publication 
No. 85-23, revised 1996; University of Florence assurance number: A5278-01). Formal 
approval to conduct the described experiments was obtained from the Animal Subjects 
Review Board of the University of Florence. Experiments involving animals have been 
reported according to ARRIVE guidelines (McGrath and Lilley, 2015). All efforts were made 
to minimize animal suffering and to reduce the number of animals used. 
 
2. Induction of colitis 
Colitis was induced in accordance with the method described previously by Fornai et al. 
(2006) with minor changes. In brief, during a short anesthesia with isoflurane (2%), 30 mg of 
2,4-dinitrobenzenesulfonic acid (DNBS) in 0.25 ml of 50% ethanol was administered 
intrarectally via a polyethylene PE-60 catheter inserted 8 cm proximal to the anus. Control 
rats received 0.25 ml of saline solution.  
 
3. Drug administrations 
Morphine hydrochloride (S.A.L.A.R.S., Como, Italy) was subcutaneously (10 mg kg
-1
) and 
intrathecally (1 μg in 15μL) administered. Ibuprofen (100 mg kg
-1 
Carbosynth, Compton, UK) 
and otilonium bromide (20 mg kg
-1 
Carbosynth, Compton, UK) were orally administered. 
Pregabalin (Sigma-Aldrich, Milan, Italy) was intraperitoneally (30 mg kg
-1
) and intrathecally 
(100 μg 15μL) administered. Amitryptiline hydrochloride (Sigma-Aldrich, Milan, Italy), was 
intraperitoneally (15 mg kg
-1
) and intrathecally (60 μg 15μL) administered. Desamethasone 
(0.6 mg kg
-1 
Carbosynth, Compton, UK) was dissolved in 1% DMSO saline solution and 
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intraperitoneally administered. The other compounds were dissolved in saline solution for 
subcutaneous and intraperitoneal administrations, in CMC 1 % for oral administrations and in 
PBS for intrathecal injections. All the substances were injected 15 min before the test (n=5).  
  
4. Assessment of visceral sensitivity by Viscero Motor Response (VMR) 
The visceromotor response (VMR) to colorectal balloon distension were used as objective 
measure of visceral sensitivity in animals. Two EMG electrodes were sutured into the external 
oblique abdominal muscle under deep anaesthesia and exteriorised dorsally (Christianson and 
Gebhart, 2007). VMR assessment were carried out under light anaesthesia (Isoflurane 2%). A 
lubricated latex balloon (length: 4.5 cm), assembled to an embolectomy catheter and 
connected to a syringe filled with water was used to perform colo-rectal distension. The 
baloon was inserted into the colon and positionated 6.5 cm from the anus and and was filled 
with increasing volumes of water (0.5, 1, 2, 3 mL). A smaller balloon (length: 2 cm), was 
used to perform rectal distension by positioning it in the rectum and by filling it with 1.5 mL 
of water. The electrodes were relayed to a data acquisition system and the corresponding 
EMG signal consequent to colo-rectal stimulation were recorded, amplified and filtered 
(Animal Bio Amp, ADInstruments, USA), digitised (PowerLab 4/35, ADIinstruments, USA), 
analysed and quantified using LabChart 8 (ADInstruments, USA). To quantify the magnitude 
of the VMR at each distension volume, the area under the curve (AUC) immediately before 
the distension (30 s) was subtracted from the AUC during the balloon distension (30 s) and 
responses were expressed as percentage increase from the baseline. The time elapsed between 
two consecutive distension was 5 min. The measurements were carried out before (pretest) 
and 7, 14 and 21 days after DNBS administration (control group n=10, DNBS group n=10).  
 
5. Assessment of visceral sensitivity by Abdominal Withdrawal Reflex (AWR) 
The behavioural responses to CRD were assessed in the animals by measuring the Abdominal 
Withdrawal Reflex (AWR), a semi-quantitative score described previously in conscious 
animals (Chen et al., 2014). Briefly, rats were anesthetized with isoflurane, and a lubricated 
latex balloon (length: 4.5 cm), attached to polyethylene tubing, assembled to an embolectomy 
catheter and connected to a syringe filled with water was inserted through the anus into the 
rectum and descending colon of adult rats. The tubing was taped to the tail to hold the balloon 
in place. Then rats were allowed to recover from the anaesthesia for 30 min. AWR 
measurement consisted of visual observation of animal responses to graded CRD (0.5, 1, 2, 3 
mL) blinded observers who assigned AWR scores: No behavioral response to colorectal 
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distention (0); Immobile during colorectal distention and occasional head clinching at 
stimulus onset (1); Mild contraction of the abdominal muscles but absence of abdomen lifting 
from the platform (2); Observed strong contraction of the abdominal muscles and lifting of 
the abdomen off the platform (3); Arching of the body and lifting of the pelvic structures and 
scrotum (4). The measurements were carried out once week for 7 weeks after DNBS 
administration (control group n=10, DNBS group n=10). 
 
6. Assessment of depression-related behaviour by Forced Swim Test (FST) 
The FST was carried out as previously described (Slattery and Cryan, 2012). All experimental 
animals were first habituated to the testing room 30 minutes prior to testing. A pre-swim (15 
min) was conducted 24 hours prior to the test. On test day, all animals were introduced again 
to the Plexiglas cylinder (46 cm tall; 21 cm in diameter) filled with water (24 °C) to a depth of 
30 cm. Test sessions (5 min) were recorded by video camera positioned directly above the 
cylinder. Animals were removed from their home-cage and placed into the tank. After 5 min, 
animals were removed from the tank, dried and replaced back into their home-cage. The tank 
was then emptied, and fresh water was replaced into the tank between animals. The 
parameters of interest were the time mobile and the distance travelled. Data acquisition and 
analysis were performed automatically using ANY-maze Software® (Stoelting Co., USA) 
(control group n=10, DNBS group n=10). 
 
7. Assessment of anxiety-related behaviour by Open Field Test (OFT) 
The open field paradigm was performed as previously described by O‘ Mahony et al. (2011). 
The open field arena was brightly lit (1000 lux). This is considered to be stressful to rats as 
they are not given the opportunity to retreat into dark corners. The arena 90 cm in diameter 
was placed on the floor. A video tracking system was fixed above the experimental platform. 
All rats were habituated to the testing room for 30 min. Rats were placed gently into the 
centre of the arena: the total distance travelled and the time they spent in the centre of the 
field within 5 min was recorded. The arena was cleaned between each rat with 30% ethanol to 
avoid leaving an abnormal odour. Data acquisition and analysis were performed automatically 
using ANY-maze Software® (Stoelting Co., USA) (control group n=10, DNBS group n=10). 
 
8. Assessment of anxiety-related behaviour by Elevated Plus Maze Test (EPMT) 
The elevated plus maze test was performed as previously reported by Bissiere et al. (2006). 
Briefly, the apparatus consisted of two open arms (50 cm x 10 cm), two closed arms (50 cm x 
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10cm x 30 cm) and a central platform (10 cm x 10 cm) on a stand that was 70 cm high off the 
floor. A video tracking system was fixed above the experimental platform. All animals were 
habituated to the testing room for 30 min. Then rats were placed in the central platform of the 
maze and allowed to explore the maze for 5 min. The percentage of time spent in the open 
arms, in the closed arms and in the centre were measured. The maze was cleaned between 
each rat with 30% ethanol to avoid leaving an abnormal odour. Data acquisition and analysis 
were performed automatically using ANY-maze Software® (Stoelting Co., USA) (control 
group n=10, DNBS group n=10). 
 
9. Histological evaluation of colon damage  
The evaluation of colon damage was performed both macroscopically and histologically, in 
accordance with the criteria previously reported by Antonioli et al. (2007). The macroscopic 
criteria were: presence of adhesions between colon and other intra-abdominal organs (0-2); 
consistency of colonic faecal material (indirect marker of diarrhoea; 0-2); thickening of 
colonic wall (mm); presence and extension of hyperaemia and macroscopic mucosal damage 
(0-5). Microscopic evaluations were carried out on haematoxylin/eosin-stained sections of 
formalin-fixed full-thickness samples obtained from the distal colon. The microscopic damage 
was evaluated in accordance with the criteria reported previously by Antonioli et al. (2010): 
1) mucosal architecture loss (0-3); 2) goblet cell depletion (0, absent; 1, present); 3) crypt 
abscess (0, absent; 1, present); 4) cellular infiltration (0-3); 5) tunica muscularis thickening 
(0-3). Data obtained were used to calculate mean values ± SEM for each experimental group, 
which were plotted in graphs. The significance of differences was evaluated by one-way 
ANOVA followed by Tukey‘s multiple comparison test. P values ≤0.05 were considered 
significantly different compared to controls (n=4).  
 
10. Evaluation of collagen deposition and inflammatory cells in the colon wall 
Collagen deposition was localized by the Sirius Red/Fast Green (SR/FG) staining, which 
allowed to distinguish collagen and non-collagen proteins as red and green deposits, 
respectively, as described in detail by Segnani and colleagues (2015). Mast cells (MCs) and 
eosinophils were detected by histochemical toluidine blue and haematoxylin/eosin staining, 
respectively, and quantified as previously reported (Pellegrini et al., 2016). Activated 
macrophages were revealed by immunofluorescence staining of the MHC-II antigen as 
previously reported by Mowat and Bain (2013) and described in the following paragraph 
(control group n=4, DNBS-Day 14 group n=4). 
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11. Immunodetection of SP-positive fibres and MHC-II-positive macrophages in the colon 
Immunoenzymatic histochemistry. Colonic sections were processed as previously described 
(Pellegrini et al., 2016). Briefly, after an overnight incubation at 4°C with rabbit anti-SP 
immunoglobulins, biotinylated immunoglobulins, peroxidase-labelled streptavidin complex, 
3.3‘-diaminobenzidine tetrahydrochloride and eosin-staining were employed.  
Confocal immunofluorescence histochemistry. SP-positive fibres and MHC-II-positive 
macrophages were detected by means of double immunofluorescence protocols. Colonic 
sections were unmasked with heat and incubated overnight at 4°C with the combined primary 
antibodies anti-SP and anti-MHC class II. The sections were then exposed to appropriate 
fluorophore-conjugated secondary antibody or biotinylated secondary antibody followed by 
fluorophore-conjugated streptavidin and nuclear counterstaining with TO-PRO3 as previously 
described (Ippolito et al., 2015). Sections were examined under a Leica TCS SP8 confocal 
laser-scanning microscope (Leica Microsystems, Mannheim, Germany) (control group n=4, 
DNBS-Day 14 group n=4). 
 
12. Image analysis for the histochemical and immunohistochemical staining of the colon 
The sections were examined by a Leica DMRB light microscope, equipped with a DFC480 
digital camera (Leica Microsystems, Cambridge, UK), and quantitatively analysed using the 
Image Analysis System ‗L.A.S. software version 4.5‘ (Leica Microsystems, Cambridge, UK), 
as previously described. Two blind investigators (C.I. and C.S.) independently evaluated the 
eosinophil and MC density (cell number / respective analysed areas [mm
2
]) as well as the SR- 
and SP-positivity expression (positive pixels percentage [PPP]) as previously described 
(Segnani et al., 2015; Pellegrini et al., 2016). Data obtained were used to calculate mean 
values ± SEM for each experimental group, which were plotted in graphs. The significance of 
differences was evaluated by Student‘s t test for unpaired data. P values ≤0.05 were 
considered significantly different compared to controls (control group n=4, DNBS-Day 14 
group n=4).  
 
13. Analysis of spinal cord Iba-1 and GFAP positive cells by immunofluorescence 
The lumbar segments of rat spinal cord were exposed from the vertebral column via 
laminectomy and formalin-fixed by standard protocols previously described (Di Cesare 
Mannelli et al., 2013). Cryostat sections (5 μm) were washed thrice with phosphate-buffered 
saline (PBS), permeabilized with 0.3% Triton X-100 in PBS (PBST) for 10 min and then 
were incubated, at room temperature, for 1 h in blocking solution (1% bovine serum albumin 
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in PBST). Slices were incubated overnight at 4°C in PBST containing rabbit primary 
antibodies. The primary antibody used was directed against Iba1 (ionized calcium binding 
adapter molecule 1; rabbit, 1:250; Wako, Richmond, VA, USA) for microglial staining or 
against GFAP (glial fibrillary acidic protein; rabbit, 1:500; DAKO, Carpinteria, CA, USA) for 
astrocyte staining. The following day, slides were washed thrice with PBS, and then 
incubated, for 1 hour, with blocking solution in goat anti-rabbit IgG secondary antibody 
labeled with Alexa Fluor 488 or 568 respectively (1:200; Life Technologies-ThermoFisher 
Scientific, Milano, Italy) and DAPI (4‘, 6-diamidin-2-fenilindolo; 1:2000; Life Technologies-
ThermoFisher Scientific), a nuclei marker, in PBST for 5 min., at room temperature in the 
dark. After three washed in PBS and a final wash in distilled water, slices were mounted using 
ProLong Gold (Life Technologies-ThermoFisher scientific) as a mounting medium. Negative 
control sections (no exposure to the primary antibody) were processed concurrently with the 
other sections for all immunohistochemical studies, to exclude the presence of non-specific 
immunofluorescence staining or cross-immunostaining. Digitalized images were collected at 
100×, 200× or 400× total magnification by a motorized Leica DM6000B microscope 
equipped with a DFC350FX. Quantitative analysis of GFAP- and Iba1-positive cells was 
performed by collecting independent fields in the dorsal and ventral horn of each mouse 
spinal cord. GFAP and Iba1-positive cells were counted using the ―cell counter‖ plugin of 
ImageJ (NIH, Bethesda, Maryland, USA). Values were expressed as means ± S.E.M. and the 
statistical analysis was performed by t-test. Each value represents the mean of 8 field per 
spinal cord, both dorsal and ventral horn (control group n=4, DNBS-Day 14 group n=4).  
 
14. Adenosine A3 receptor agonists administration 
The selective A3 receptor agonist, 2-Chloro-N
6
-(3-iodobenzyl)-adenosine-5′-N-
methyluronamide (Cl-IB-MECA; Tocris Bioscience, Bristol, UK), and the selective A3 
receptor antagonist, 3-Propyl-6-ethyl-5-[(ethylthio)carbonyl]-2 phenyl-4-propyl-3-pyridine 
carboxylate (MRS1523; Sigma-Aldrich, Milan, Italy), were dissolved in 5% DMSO and 5% 
TWEEN 20 saline solution for in vivo administration. The new, highly selective (10,000-fold 
vs each of the other 3 receptor subtypes), A3 receptor agonist, MRS5980, (1S,2R,3S,4R,5S)-
4-(2-((5-Chlorothiophen-2-yl)ethynyl)-6-(methylamino)-9H-purin-9-yl)-2,3-dihydroxy-N-
methylbicyclo[3.1.0]hexane-1-carboxamide, recently synthetized by the research group of 
Prof. Kenneth Jacobson, NIDDK, NIH, Bethesda, US (Fang et al., 2015)  was dissolved in 5% 
DMSO saline solution for in vivo administration. N-[[4-(1,1-dimethylethyl)phenyl]methyl]-N-
methyl-L-leucyl-N-(1,1-dimethylethyl)-O-(phenylmethyl)-L-tyrosinamide (PD173232) was 
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purchased from Alomone labs (Jerusalem, Israel; https://www.alomone.com) and dissolved in 
5% DMSO and 5% TWEEN 20 saline solution for in vivo administration. Linaclotide 
(Allergan, UK) was dissolved in water and orally administered 1 h before starting the 
behavioural tests (Eutamene et al., 2010). Cl-IB-MECA, MRS5980 and PD173232 were 
administered i.p. 15 min before the test. MRS1523 was administered i.p. 15 min before Cl-IB-
MECA and MRS5980 (n=5).  
 
15. Faecal Microbiota Transplantation (FMT) 
First experimental set: Faecal material was collected from controls and DNBS treated animals 
(between 14 and 21 days after the intra-rectal injection of the inflammatory agent) and placed 
into tubes containing freezing solution (sterile saline solution with 12.5% glycerol), tubes 
were left on ice for 60 min and later homogenized for two min on ice using a hand-held pellet 
pestle device with sterile, re-usable pestles. When fully homogenized, the suspended pellets 
were frozen and stored at -80°C until utilized for the FMT procedure. To this end, rats were 
randomized into the following treatment groups (n=5): control (no antibiotic treatment, no 
FMT); abx + FMT from CTR (antibiotic treatment followed by FMT from controls); abx + 
FMT from DNBS (antibiotic treatment followed by FMT from DNBS treated animals). 
Antibiotic mix was prepared in autoclaved drinking water and provided in 500 ml clear glass 
slippers or were suspended in 1% carboxymethylcellulose sodium salt (CMC; Sigma-Aldrich) 
and administered by oral gavage. The antibiotic/anti-fungal regime was as follows: day 1-3 
rats received a daily oral gavage of amphotericin B (1 mg kg
-1
), day 4-17 rats received a daily 
gavage of metronidazole 100 mg kg
-1





 and neomicin 1 g L
-1
 was added to drinking water), day 18-24 daily oral gavage with 
ampicillin 1 g L
-1
, vancomycin 0.5 g L
-1
, neomicin 1 g L
-1
, metronidazole 100 mg kg
-1
, 
amphotericin B 1 mg kg
-1
. FMT was carried out via oral gavage with a faecal suspension (50 
mg ml
-1
) in a final volume of 3 ml. FMT was performed six times on days 24-28 and 35 from 
the beginning of antibiotic regime. Behavioural tests were performed 10, 17 and 24 days after 
the last FMT (n=5). 
Second experimental set: Faecal material was collected from controls and DNBS treated 
animals (between 14 and 21 days after the intra-rectal injection of the inflammatory agent) 
and placed into tubes containing sterile saline solution, tubes were left on ice for 60 min and 
later homogenized for two min on ice using a hand-held pellet pestle device with sterile, re-
usable pestles. When fully homogenized, the suspended pellets were directly utilized for the 
FMT procedure. To this end, rats were randomized into the following treatment groups (n=5): 
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control (no antibiotic treatment, no FMT); abx + vehicle (antibiotic treatment followed by 
vehicle administration); abx + FMT from CTR (antibiotic treatment followed by FMT from 
controls); abx + FMT from DNBS (antibiotic treatment followed by FMT from DNBS treated 
animals). Antibiotic mix was prepared in autoclaved drinking water and provided in 500 ml 
clear glass slippers or were suspended in 1% carboxymethylcellulose sodium salt (CMC; 
Sigma-Aldrich) and administered by oral gavage. The antibiotic/anti-fungal regime was as 
follows: day 0-6 rats received a daily oral gavage of amphotericin B (1 mg kg
-1
) and 
metronidazole (100 mg kg
-1
) while the antibiotic mix (ceftazidime 1 g L
-1
, vancomycin 0.5 g 
L
-1
 and neomicin 1 g L
-1
 was added to drinking water). FMT was carried out via oral gavage 
with a faecal suspension (50 mg ml
-1
) in a final volume of 3 ml. FMT was daily performed ten 
times on days 7-11 and 20-24 from the beginning of antibiotic regime. Behavioural tests were 
performed at the end of the antibiotic treatment, 24h and 7 days after each FMT set and once 
week after the last treatment.  
Third experimental set: Faecal material was collected from controls animals and placed into 
tubes containing sterile saline solution, tubes were left on ice for 60 min and later 
homogenized for two min on ice using a hand-held pellet pestle device with sterile, re-usable 
pestles. When fully homogenized, the suspended pellets were directly utilized for the FMT 
procedure. To this end, rats were randomized into the following treatment groups (n=6): 
controls; DNBS + vehicle (intrarectal injection of DNBS 30 mg followed by vehicle 
administration); DNBS + FMT from CTR (intrarectal injection of DNBS 30 mg followed by 
FMT from controls). FMT was carried out via oral gavage with a faecal suspension (50 mg 
ml
-1
) in a final volume of 3 ml. Four set of 5 consecutive FMT were performed on days 7-11, 
14-18, 21-25 and 28-32 after DNBS injection. Behavioural tests were performed 7 day after 
DNBS injection, 3 days after each FMT set and once week after the last treatment (n=5).  
 
16. Detection of DNBS in faecal samples by Liquid Chromatography – Mass Spectrometry 
(LC-MS) 
The LC-MS/MS analysis was carried out using a Varian 1200L triple quadrupole system 
(Palo Alto, CA, USA) equipped by two Prostar 210 pumps, a Prostar 410 autosampler and an 
Electrospray Source (ESI) operating in negative ions. Raw-data were collected and processed 
by Varian Workstation vers. 6.8 software. The column used was a Pursuit XRs C18 30 mm 




employing a binary mobile phases elution gradient. The solvents used were 10 mM formic 
acid solution (solvent A) and 10 mM formic acid in acetonitrile (solvent B) according to the 
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elution gradient as follows: initial at 90 % solvent A, which was then decreased to 10 % in 4.0 
min, kept for 3.0 min, returned to initial conditions in 0.1 min and maintained for 3.0 min for 
reconditioning, to a total run time of 10.0 min. The column temperature was maintained at 30 
°C and the injection volume was 5 μL. The analyses were acquired in Multiple Reaction 











ISTD 262 183 [25] 122 [30] 
DNBS 247 109 [40] 183 [20] 
 
Stock solutions of DNBS and ISTD were prepared in acetone at 1.0 mg mL
-1
 and stored at 4 
°C. Working solutions of analyte were freshly prepared by diluting stock solution up to a 
concentration of 1.0 μg mL
-1
 and 0.1 μg mL
-1
 (working solution 1 and 2 respectively) in 
mixture of mQ water:acetonitrile 50:50 (v/v). The ISTD working solution was prepared in 
acetonitrile at 10 μg mL
-1
 (ISTD solution). A five levels calibration solutions were prepared in 
mQ water:acetonitrile 50:50 (v/v) by adding proper volumes of working solution (1 or 2) of 
each analyte and 10 μL of ISTD solution. Final concentrations of calibration levels were: 0, 
5.0, 10.0, 25.0 and 50.0 ng mL
-1
 of analyte in the sample. All calibration levels were analyzed 
six times by LC-MS/MS method described above. The calibration curve of analyte was 
obtained by plotting the peak area ratios (PAR), between analyte and ISTD quantitation ions, 
versus the nominal concentration of the calibration solution. A linear regression analysis was 
applied to obtain the best fitting function between the calibration points. In order to obtain 
reliable limit of detection (LOD) and limit of quantitation (LOQ) values, the standard 
deviation of response and slope approach was employed. The estimated standard deviation of 
response of analyte was obtained by the calculated standard deviation of y-intercept (SDY-I) 
of regression line. The calculated values of LOD and LOQ were 2.0 ng mL
-1
 and 6.0 ng mL
-1
 
respectively. The sample was obtained by suspending the rat/mouse faeces (about 1.7 g) in 16 
mL of phosphate buffer solution. An aliquot of 1 mL of sample solution was transferred in 
microcentrifuge tube, added of 10 μL of ISTD solution and then centrifuged (room 
temperature for 5 min at 800 g). The supernatants were transferred in autosampler vials and 
analysed by the LC-MS/MS method described above. In order to verify the evaluated limit of 
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quantitation in real sample, an aliquot of control sample was added of 5 ng mL
-1
 of DNBS and 
analysed by the LC-MS/MS method. 
 
17. Plasma Lipopolysaccharide Binding Protein (LBP) dosage by ELISA 
Plasma LBP concentrations were determined using the Enzyme Immunoassay Kit (Enzo
®
, 
Life Sciences). Rat blood samples were collected in heparinized tubes after decapitation. 
Samples were centrifuged immediately at 14000 rpm for 15 minutes and the resulting plasma 
was frozen at -80
o
C until analysis. LBP concentrations were determined using the Enzyme 
Immunoassay Kit for free mouse and rat LBP as per manufacturers‘ instruction (Enzo®, Life 
Sciences). Sensitivity: Range 1-50 ng/ml (n=4-6).  
 
18. Monoamines analysis by High Performance Liquid Chromatography (HPLC)   
Rat colons or faecal pellets were placed into chilled mobile phase spiked with N-methyl-
serotonin, an internal standard (N-methyl-5-HT; 4 ng/20 µl; Sigma-Aldrich, Ireland). Samples 
were weighed, individually sonicated in 500 µl buffer and centrifuged (14 000 rpm, 4°C, 20 
min). Supernatant was collected and diluted 1/2 in HPLC mobile phase. The supernatants 
derived from faecal pellets were filtered by 0.22 µm filter before the anlysis. The mobile 
phase contained 0.1 M citric acid, 0.1 M sodium dihydrogen phosphate, 0.01 mM EDTA 
(Sigma-Aldrich, Ireland), 5.6 mM octane-1-sulphonic acid (Sigma) and 11% (v/v) methanol 
(Sigma-Aldrich, Ireland) and was adjusted to pH 2.8 using 1M sodium hydroxide (Sigma-
Aldrich, Ireland). The monoamines and metabolites DA, homovanillic acid (HVA), 
dihydroxyphenylacetic acid (DOPAC), 5-HT, 5-hydroxyindoleacetic acid (5-HIAA) and 
noradrenaline (NA) were measured using HPLC with electrochemical detection. Twenty 
microlitres of supernatant was injected onto the HPLC system which consisted of a SCL 10-
Avp system controller, LC-10AS pump, SIL-10A autoinjector (with sample cooler maintained 
at 4°C), CTO-10A oven, LECD 6A electrochemical detector (Shimadzu) and an online 
Gastorr Degasser (ISS, UK). A reverse-phase column (Kinetex 2.6u C18 100× 4.6 mm, 
Phenomenex) maintained at 30°C was employed in the separation (flow rate 0.9 ml/min), the 
glassy carbon working electrode combined with an Ag/AgCl reference electrode (Shimdazu) 
was operated at +0.8 V and the chromatograms generated were analysed using Class-VP 5 
software (Shimadzu). Monoamines were identified by their characteristic retention times as 
determined by standard injections which were run at regular intervals during the sample 
analysis. Concentrations were calculated using analyte: internal standard peak height ratios 
and expressed as nanograms of neurotransmitter per gram of tissue weight (n=4-6). 
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19. Kynurenine/Tryptophan analysis by High Performance Liquid Chromatography 
(HPLC)  
Plasma samples were spiked with internal standard (3-Nitro l-tyrosine) prior to being 
deproteinised by the addition of 20 μl of 4M perchloric acid to 200 μl of sample. Samples 
were centrifuged at 12000 rpm for 20 minutes at 4°C and 100 μl of supernatant transferred to 
a HPLC vial for analysis on the HPLC system (UV and FLD detection). All samples were 
injected onto a reversed phase Luna 3 μm C18 (2) 150 × 2 mm column (Phenomenex), which 
was protected by Krudkatcher disposable pre-column filters (Phenomenex) and SecurityGuard 
cartridges (Phenomenex). The mobile phase consisted of 50 mM acetic acid, 100 mM zinc 
acetate with 2.5% (v/v) acetonitrile and was filtered through sterile 0.45µm polyvinylidene 
fluoride (PVDF) Stericup™ Millipore filter unit and vacuum degassed prior to use. 
Compounds were eluted isocratically over a 30-minute runtime at a flow rate of 0.3 mls/min 
after a 20 μl injection. The column was maintained at a temperature of 30°C and 
samples/standards were kept at 8°C in the cooled autoinjector prior to injection. The 
fluorescent detector was set at an excitation wavelength of 254 nm and an emission 
wavelength of 404 nm. The UV detector was set to 330 nm. L-tryptophan and kynurenine 
were identified by their characteristic retention times as determined by standard injections 
which were run at regular intervals during the sample analysis. Analyte: Internal standard 
peak height rations were measured and compared with standard injections and results were 
expressed as ng/ml of plasma (n=4-6). 
 
20. Gene expression analysis by quantitative RT-PCR (qRT-PCR)  
Total RNA was extracted using the mirVana
TM
 miRNA Isolation kit (Ambion/life 
technologies) according to the manufacturer‘s recommendations. For each group, 4–6 animals 
were used. RNA concentration and quality were determined using a Nanodrop 1000 (Thermo 
Scientific). Quantitative PCR was carried out in a LightCycler480 System using PowerUp™ 
SYBR
®
 Green Master Mix (Applied Biosystems) and specific probes designed by Applied 
Biosystems to rat occludin, ZO-1, TNF-α, IL6, IL10 and Tgf-β, while using β-Actin as an 
endogenous control. Experimental samples were run in triplicate with 4 µL cDNA per 
reaction. To check for amplicon contamination, each run contained no template controls in 
triplicate for each probe used. Cycle threshold (Ct) values were recorded. Data was 
normalised using β-Actin and transformed using the 2
−ΔΔCt
 method. No significant differences 
were observed in the mRNA expression levels of β-Actin between groups (n=4-6).   
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21. Statistical analysis  
Behavioural measurements were performed on 5-10 animals for each treatment carried out in 
2 different experimental sets. All the experimental procedures were performed by a researcher 
blind to the treatment.  Results were expressed as mean ± S.E.M. The analysis of variance of 
behavioural data was performed by one-way ANOVA with Bonferroni's significant difference 
procedure used for post-hoc comparisons. Statistics of electrophysiological data was 
performed by Student‘s paired or unpaired t-test or by one-way ANOVA followed by 
Bonferroni's post-test, as appropriate. P values of less than 0.05 were considered significant.  






























1. Setting up and analysis of a rat model of persistent abdominal pain 
 
1.1 Assessment of visceral sensitivity after the intra-rectal injection of DNBS  
Colitis was induced in rats by the intra-rectal injection of DNBS (30 mg dissolved in 0.25 mL 
EtOH 50%). Control animals were administered with saline solution. Visceral sensitivity was 
assessed in the animals by measuring the viscero-motor response to colo-rectal distension 
before (Pretest) and 7, 14 and 21 days after DNBS injection (Fig 1A). No difference were 
found in the experimental groups before the treatments (Fig 1, pretest). The injection of 
DNBS caused a huge and persistent increase of visceral sensitivity in the animals. In fact, 
DNBS-treated animals showed a viscero-motor response to colo-rectal distension induced by 
2 and 3 mL significantly higher than vehicle-treated animals up to 21 days after the injection 
(Fig 1A). On day 14, DNBS-treated animals were also responsive to 1 mL, showing a visceral 
sensitivity threshold further lowered (Fig 1A). The abdominal contraction in response to a 
rectal stimulus was measured in the same animals (Fig 1B). A smaller balloon (2 cm) was 
positionated at rectal level and filled with 1.5 mL of water to specifically induce rectal 
distension. The response of DNBS-treated animals resulted significantly augmented in 
comparison to that of controls at each time tested (Fig 1B). The nocifensive response of 
animals to colorectal distension was measured by assigning a score to their abdominal 
withdrawal response (AWR) to colo-rectal distension (Fig 1C). The behavioural response of 
vehicle-treated animals to colo-rectal distension was constant over time and proportional to 
the stimulus applied. DNBS-treated animals showed an abdominal response significantly 
higher than that of controls, resulting responsive also to low volume of distension (0.5-1 mL). 
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Figure 1. Measurements of the visceral sensitivity in the animals after DNBS injection. A) Viscero-
motor response to colo-rectal distension; B) Viscero-motor response to rectal distension; C) 
Abdominal withdrawal reflex in response to colo-rectal distension. Each value represents the mean ± 
S.E.M. of 10 animals per group. *P < 0.05 and **P < 0.01 vs vehicle treated animals. 
 
1.2. Assessment of behavioural alteration in DNBS-treated animals  
The behavioural alterations frequently associated with the presence of spontaneous pain, as 
depression, anxiety and reduction of locomotor activity were investigated trhought the Forced 
Swim Test (FST), the Open Field Test (OFT) and the Elevated Plus Maze Test (EPMT). FST 
is used to highlight depressive-like behaviours in the animals. Control rats swim, struggle and 
climb the wall of the tank to stay afloat in the water. This behaviour was expressed both as the 
time the animals spent moving and as the distance travelled. DNBS-treated animals showed a 
decreased motility in comparison with controls on Day 7, 14 and 21, pointing out a depressive 
disorder in these animals (Fig 2A). OFT was performed to evaluate the locomotor activity and 
the explorative behaviour (expressed as distance travelled and wall rearings, respectively) of 
DNBS-treated animals in comparison to controls (Fig 2B). Both the distance travelled and the 
number of walls rearings performed by DNBS-treated animals were significantly lower than 
that of controls 7 days after damage induction. By contrast, no difference was relieved 
between the experimental groups on Day 14 and 21 (Fig 2B). EPMT was used to evaluate 
anxiety-like behaviour in the animals. DNBS-treated animals did not show significant 
C)  
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differences in the % of time spent in the open arms, in the closed one and in the centre with 
respect to the controls. In both the groups, the animals preferred to spend their time in the 
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Figure 2. Measurements of the depressive and anxiety related behaviours in DNBS-treated animals. 
A) Forced Swim Test; B) Open Field Test; C) Elevated Plus Maze Test. Each value represents the 
mean ± S.E.M. of 10 animals per group. *P < 0.05 and **P < 0.01 vs vehicle treated animals. 
 
1.3. Histological assessment of colon damage  
The animals were sacrificed 3, 7, 14 and 21 days after DNBS injection and the colon was 
harvested and processed for both macroscopic and microscopic analysis (Figure 3A and 3B, 
respectively). The Macroscopic Damage Score was used to quantify the tissue damage degree 
(Fig. 3A). Macroscopically, the damage induced by DNBS showed a peak 3 days after the 
injection and progressively decreased between 7 and 21 days after DNBS injection. In fact, 
though the Macroscopic Damage Score of DNBS-treated animals on Day 21 resulted still 
significantly higher than that of controls, it appeared considerably lowered than that of Day 3 
(Fig. 3A). The Microscopic Damage Score followed the trend of the Macroscopic Damage 
Score at the respective time points (3, 7, 14 and 21 days; Figure 3b and Figure 3C). 
Colitis had a peak 3 days after DNBS injection, the colon appearing extensively inflamed, 
infiltrated and thickened with diffuse ulcerations and necrosis, and loss of its main layers. 
After 7 days from DNBS injection colonic samples still showed a considerable epithelial 
injury. The tissue largely recovered its primary structures, though there were many ulcers and 
areas with surface epithelium loss, transmural immune cell infiltration (predominantly 
neutrophils, lymphocytes, and MCs), crypt abscesses, altered goblet cells and oedema. At day 
14 after DNBS treatment the colon appeared still significantly thick with inflammatory 
infiltration. The tunica mucosa resulted mostly restored apart from spot loss of epithelial 
surface, probably resulting from healing processes on previous deep ulcers. The crypts were 
elongated with irregular diameters and shapes. On day 21, although the thickening of the 
colonic wall persisted, the presence of inflammatory infiltrate was reduced and almost 
exclusively limited to the submucosa. No hyperplasia of the epithelial cells was detected, and 
the structure of the crypts was comparable to that of controls (Figure 3C).  
On the base of these results, the optimal timing for studying persistent visceral 
hypersensitivity in the presence of significantly restored intestine morphology was established 
at day 14. The subsequent behavioural and histological evaluations on DNBS-treated animals 











Figure 3. Histological evaluation of colon damage after DNBS injection. A) Macroscopic damage 
score; B) Microscopic damage score. C) Representative pictures of haematoxylin/eosin-stained 
sections of full-thickness colon. Original magnification: 5x (left column), 10x (right column). Each 
value represents the mean ± S.E.M. of 4 animals per group. **P < 0.01 vs vehicle treated animals. 
^^
P<0.01 vs DNBS day 3 treated animals. 
°




1.4. Effect of the systemic administration of reference drugs 
To characterize the type of pain observed, we evaluated the effect of the acute systemic 
administration of different drugs on visceral hypersensitivity 7, 14 and 21 days after the 
injection of DNBS (Fig 4A, B and C respectively). Visceral sensitivity was assessed by 
measuring the viscero-motor response to the colorectal distension 15 min after compounds 
administration (Fig 4). The acute administration of morphine (5-10 mg kg
-1
 s.c.) and 




completely suppressed the viscero-motor response to colorectal 
distension in DNBS-treated animals 7, 14 and 21 days after colitis induction (Fig 4A-C). 
Otilonium bromide (20 mg kg
-1
 p.o.) significantly reduced visceral hypersensitivity induced 
by DNBS on day 7 (Fig 4A), while on day 14 and 21 the drug resulted less effective (Fig 4 B 
and C). On the contrary, pregabalin (30 mg kg
-1
), which was ineffective in reducing visceral 
hypersensitivity on day 7 (Fig 4A), became progressively active starting from Day 14 (Fig 4 
B and C). Ibuprofen (100 mg kg
-1 
p.o.) was not able to significantly reduce visceral pain 
induced by DNBS (Fig 4A-C). In line with ibuprofen, also dexamethasone (0.6 mg kg
-1
 i.p.) 
resulted ineffective (Fig 4A-C). The administration of vehicles did not elicit any effect in 
DNBS-treated animals (Fig 4A-C). Considering that there was no substantial difference 
between the effect of drugs on day 14 and 21, hereinafter we reported only the results 
gathered on Day 14, as representative of the post-inflammatory phase. Figure 5 shows the 
effect of the acute systemic administration of the same reference drugs on the abdominal 
withdrawal reflex in DNBS-treated animals. This measure allows to evaluate also the 
affective component of visceral pain, since it was performed in awake animals, unlike the 
EMG recording. Control animals showed a gradually response to the increasing stimuli and 
this response was significantly augmented in DNBS treated animals. The systemic 
administration of morphine was able to make DNBS-treated animals completely insensitive to 
the colorectal distension. In fact, the animals treated with morphine (10 mg kg
-1
) showed a 
responsiveness even lower than that of controls. On the other hand, amitriptyline (15 mg kg
-1
) 
and otilonium bromide (20 mg kg
-1
) conserved their efficacy on visceral hypersensitivity 
without affecting the normal intestinal sensitivity. Dexamethasone (0.6 mg kg
-1
 i.p.) resulted 
ineffective also in this case while ibuprophen (100 mg kg
-1
) became partially effective. By 
contrast pregabalin (30 mg kg
-1
) lost some of its effectiveness on visceral pain in conscious 
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Figure 4. Effect of the systemic drugs administration on viscero-motor response to colo-rectal distension. The 
tests were performed 7(A), 14(B) and 21(C) days after DNBS injection. All the drugs were administered 15 min 
before starting the test. Each value represents the mean ± S.E.M. of 5 animals per group performed in 2 
experimental sets. *P < 0.05 and **P < 0.01 vs vehicle + vehicle treated animals. ^P<0.05 and ^^P<0.01 vs 
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Figure 5. Effect of the systemic drugs administration on abdominal withdrawal reflex in response  to colo-
rectal distension. The tests were performed 14 days after DNBS injection. All the drugs were administered 15 
min before starting the test. Each value represents the mean ± S.E.M.  of 5 animals per group performed in 2 
experimental sets. *P < 0.05 and **P < 0.01 vs vehicle + vehicle treated animals. ^P<0.05 and ^^P<0.01 vs 
DNBS + vehicle. 
 
1.5. Effect of the intrathecal administration of reference drugs  
In Figure 6 it is shown the effect of the intrathecal administration of morphine, amitriptyline 
and pregabalin on both the viscero-motor response (Fig 6A) and the abdominal withdrawal 
reflex (Fig 6B) to colorectal distension in DNBS-treated animals. The intrathecal 
administration of pregabalin (100 µg) strongly reduced the viscero-motor response to 
colorectal distension in the animals under anaesthesia (Figure 6A), while resulted ineffective 
in reducing visceral pain in awake animals (Fig 6B). Amitriptyline (60 µg), intrathecally 
administered, showed a partial effect on the abdominal withdrawal response of animals to 
colo-rectal distension (Fig 6B) and no significant effects on their viscero-motor response (Fig 
6A). Likewise, morphine (1 µg i.t.) significantly reduced the abdominal withdrawal reflex in 
DNBS-treated animals, without showing any effect on the viscero motor response to 















Figure 6. Effect of the intrathecal drugs administration on visceral hypersensitive induced by 
DNBS in the animals. The effect of the drugs was evaluated on both the viscero-motor response (A) 
and the abdominal withdrawal reflex (B) to colo-rectal distension. The tests were performed 14 days 
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after DNBS injection. All the drugs were administered 15 min before starting the test. Each value 
represents the mean ± S.E.M.  of 5 animals per group performed in 2 experimental sets. *P < 0.05 and 
**P < 0.01 vs vehicle + vehicle treated animals. ^P<0.05 and ^^P<0.01 vs DNBS + vehicle. 
 
1.6. Histological evaluation of inflammatory cells, fibrosis and SP-immunostained fibres  
At day 14 from DNBS treatment the partial restitution of the tunica mucosa was associated 
with inflammatory cell infiltration and significant transmural deposition of SR-positive 
collagen fibres (Fig 7A). MCs, occasionally found in controls along the colonic submucosal 
vessels and rarely within the tunica muscularis, were significantly increased in density in the 
whole wall of colon from DNBS-treated rats (Fig 7B). Eosinophil density significantly rose 
throughout the inflamed colonic wall, as compared with the low amount of eosinophils 
registered at mucosal and submucosal levels in controls (Fig 8). Several eosinophils (Figure 
8) and macrophages expressing MHC-II antigen (Fig 9) were found in close proximity with 
SP-immunostained fibres in the lamina propria and tunica muscularis, where the SP-fibres 
resulted upregulated and mainly localized in the myenteric ganglia and circular layer of 




Figure 7. Histologic evaluation of colonic fibrosis and mast cell (MC) infiltration  
Representative pictures of (A) Sirius Red-Fast Green (SR/FG)-, and (B) toluidine blue-stained colonic 
sections obtained from controls or animals treated with DNBS at day 14. The column graphs display 
the mean values of the positive pixels percentage (PPP) of SR-stained fibres, and MC density per mm
2
 
of colonic areas (cells/mm
2
) ± S.E.M. obtained from 4 animals for each group. *P≤0.05, 






Figure 8. Eosinophil infiltration of the colonic wall in close contiguity with SP-positive fibres  
Representative pictures of colonic sections stained with haematoxylin/eosin and SP 
immunoperoxidase. The right panel shows pictures captured from tunica mucosa (up) and muscularis 
(down). The column graphs display the mean values of eosinophil density per mm
2
 of colonic wall 
areas (cells/mm
2
), and positive pixels percentage (PPP) of SP-reactive fibres ± S.E.M. obtained from 













Figure 9. MHC-II cell infiltration of the colonic wall along with SP-immunostained fibres  
Confocal microscopy representative images of SP/MCHII double-immunolabelled colon from control 
rats and inflamed rats (n=4 animals for each group). Original magnification: 80x (tunica mucosa), 





1.7. Evaluation of glial activation in the spinal cord 
Fourteen days after DNBS injection the animals were sacrificed and the morphology and the 
number of astrocytes and microglial cells at spinal level was evaluated by performing an 
immunofluorescent analysis on lumbo-spinal sections (Fig 10 and 11). Both the dorsal and the 
ventral horn (Fig 10B and 11B, respectively) of DNBS treated animals were characterized by 
astrocyte (GFAP-positive cells) activation, highlighted by the significant increase in number 
(about 30%) as well as by the expansion of cellular body and processes, denoting their typical 
activated status (Di Cesare Mannelli et al., 2013), in comparison to control. On the other 
hand, microglia (Iba1-positive cells) did not change in number but underwent well-defined 
morphological alterations, detectable on both the dorsal and the ventral horn (Fig. 10A and 
11A). The percentage of morphological activated Iba-1 positive cells was significantly 
increased in DNBS-treated animals in comparison to control. The activated status of 
microglial cells was recognized by the loss of the processes that are peculiar of resting 
conditions (Fernández-Arjona et al., 2017). 
  
 
Figure 10. Evaluation of microglia and astrocytes activation in the dorsal horn of spinal cord. A) 
Iba1-positive cell density in the dorsal horn of the spinal cord of animals 14 days after DNBS 
injection; Representative images of merged Iba1-labeled microglia cells (red), plus DAPI-labeled cell 
nuclei (blue), scale bar: 50 μm. B) GFAP-positive cell density in the dorsal horn of the spinal cord of 
animals 14 days after DNBS injection; Representative images of merged GFAP-labeled microglia 
cells (red), plus DAPI-labeled cell nuclei (blue), scale bar: 50 μm. Each value represents the mean ± 
S.E.M. of 4 rats, performed by analysing 4 independent fields for both the sides of the spinal cord.  





Figure 11. Evaluation of microglia and astrocytes activation in the ventral horn of spinal cord. A) 
Iba1-positive cell density in the ventral horn of the spinal cord of animals 14 days after DNBS 
injection; Representative images of merged Iba1-labeled microglia cells (red), plus DAPI-labeled cell 
nuclei (blue), scale bar: 50 μm. B) GFAP-positive cell density in the ventral horn of the spinal cord of 
animals 14 days after DNBS injection; Representative images of merged GFAP-labeled microglia 
cells (red), plus DAPI-labeled cell nuclei (blue), scale bar: 50 μm. Each value represents the mean ± 
S.E.M. of 4 rats, performed by analysing 4 independent fields for both the sides of the spinal cord.  
**P<0.01 vs control animals. 
 
2. Evaluation of the efficacy of adenosine A3 receptor agonists on post-inflammatory 
visceral pain induced by DNBS 
 
2.1. Efficacy of adenosine A3AR agonist MRS5980 against visceral hypersensitivity induced 
by DNBS  
The viscero-motor and the abdominal withdrawal responses (VMR and AWR) to the 
progressive increase in colorectal distension (CRD) were measured using increasing filling 
volumes (highest volume: 3 ml, to avoid tissue damage). Fourteen and 21 days after DNBS 
injection, VMR was significantly higher in comparison to controls (vehicle + vehicle; Fig 
12A and 12C) starting from 2 ml whereas AWR was already altered by 1 ml (Fig 10B and 
12D). The effects of the acute i.p. administration of MRS5980 (0.3, 1.2, 2.4 µmol kg
-1
) were 
evaluated (Fig 12). On day 14, MRS5980 dose-dependently reduced the post-inflammatory 
visceral hypersensitivity induced by DNBS; the magnitude of the reduction was similar for 
VMR and AWR. The highest dose (2.4 µmol kg
-1
) completely reversed the sensitivity 
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alteration back to the value of control rats. MRS5980 1.2 µmol kg
-1
 partially, but significantly 
reduced the response of the animals to CRD. The lowest dose of MRS5980 (0.3 µmol kg
-1
) 
was ineffective in both tests (Fig 12A and 12B). On day 21, the effect of MRS5980 (0.3, 1.2, 
2.4 µmol kg
-1
) was confirmed (VMR and AWR to CRD, Figures 10C and 10D, respectively). 
Unlike VMR, the assessment of AWR allows the evaluation of DNBS-induced 
hypersensitivity for a long time. This behavioural response was still altered 28 and 35 days 
after the colonic irritation (Fig 13A and 13B, respectively), reflecting the peculiar tendency of 
this type of pain to become chronic. Hence, we used this test to evaluate the effect of 
MRS5980 on visceral pain in a more delayed phase after the initial insult. The chronic 
hypersensitivity in the rat is likely to be similar to the clinical condition. On Day 28 and 35, 
the pain-relieving effect of MRS5980 (0.3, 1.2, 2.4 µmol kg
-1
) was as potent as that seen 
earlier. The effect on chronic hypersensitivity was dose-dependent, and with the AWR 
measure, the highest dose (2.4 µmol kg
-1
) was again able to reverse the pain threshold of 
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Figure 12. Effect of MRS5980 on post-inflammatory visceral pain induced by DNBS. Effect of 
MRS5980 (0.3, 1.2, and 2.4 µmol kg
-1
; i.p.) on viscero-motor response (VMR) to CRD (left column) 
and abdominal withdrawal response (right column) on day 14 (A, B) and day 21 (C, D) after DNBS-
induced colonic inflammation.  Each value is the mean ± S.E.M. of 5 rats per group. ^^P < 0.01 vs. 




Figure 13. Effect of MRS5980 on persistent visceral pain induced by DNBS injection. Effect of 
MRS5980 (0.3, 1.2, and 2.4 µmol kg
-1
; i.p.) was observed 28 days (A) and 35 days (B) after DNBS 
treatment. The compound was administered 15 min before the first colo-rectal distension (CRD). 
Visceral pain was assessed by measuring the animal abdominal withdrawal response (AWR) to CRD. 
Each value is the mean ± S.E.M. of 5 rats per group. ^^P < 0.01 vs. vehicle-treated normal controls 
(blue). *P < 0.05 and **P < 0.01 vs DNBS + vehicle treated group (red).  
 
2.2. Involvement of A3A Receptor in the MRS5980 effect on visceral hypersensitivity  
Figure 14A shows the result of the pre-treatment with the selective A3AR antagonist 
MRS1523 on the anti-hyperalgesic effect of MRS5980 on day 14. MRS1523 (5 µmol kg
-1
) 
completely abolished the pain-relieving effect of MRS5980 (2.4 µmol kg
-1
). Furthermore, the 
pain-relieving effect evoked by A3AR stimulation was confirmed by using another selective 
A3AR agonist, Cl-IB-MECA. On day 14, the acute administration of Cl-IB-MECA dose-
dependently relieved visceral pain in DNBS treated animals, reducing their VMR to the value 
of controls (dosed at 1.2 µmol kg
-1
, Fig 14B). The lower dose of 0.3 µmol kg
-1
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weaker effect only with the 3 ml stimulus. The Cl-IB-MECA (1.2 µmol kg
-1
) effect was 
blocked by MRS1523 (5 µmol kg
-1

























Figure 14. Evaluation of the role of adenosine A3ARs in visceral pain relief and comparison with 
the effect of the reference compound.  Tests were performed 14 days after DNBS treatment by 
measuring the viscero-motor response (VMR) to colo-rectal distension (CRD) after compound 
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administration. (A) Effect of pre-treatment with the selective A3 antagonist MRS1523 (5 µmol kg
-1
) on 
the visceral pain relieving effect of the highly-selective A3AR agonist, MRS5980 (5 µmol kg
-1
).  (B) 
Effect of the selective A3 agonist, Cl-IB-MECA (0.03, 0.3, and 2.4 µmol kg
-1
; i.p.). Each value is the 
mean ± S.E.M. of 5 rats per group.  ^^P < 0.01 vs. vehicle-treated normal controls (blue). *P < 0.05 
and **P < 0.01 vs DNBS + vehicle treated group (red).  °°P < 0.01 vs DNBS + MRS 5980 (2.4 µmol 
kg
-1
, black triangles in A) or Cl-IB-MECA (1.2 µmol kg
-1
, black triangles in B).  
    
2.3. Effect of N-type voltage-gated Ca
2+
 channel blocking on visceral pain induced by 
DNBS  
A3AR agonists have been recently reported to inhibit Cav2.2-mediated currents in DRG 
neurons, thus suggesting a possible mechanism for pain relief (Coppi et al., 2018). On this 
basis, we evaluated the effect of acute administration of the selective N-type Cav2.2 blocker 
PD173212 (Hu et al., 1999) in our visceral pain model. The test (VMR assessment) was 
performed on day 14 after DNBS injection. As shown in Figure 3C, PD173212 0.001-1 mg 
kg
-1
 (0.0017 – 1.7 µmol kg
-1
, i.p.) dose-dependently reduced the visceral hypersensitivity 





) and completely relieved abdominal pain when administered at a ten-fold higher 
















Figure 15. Effect of blocking N-type voltage-gated calcium channels on post-inflammatory visceral 
pain.  Tests were performed 14 days after DNBS treatment by measuring the viscero-motor response 
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(VMR) to colo-rectal distension (CRD) after the administration of the selective N-type voltage-gated 
calcium channel (Cav2.2) blocker, PD173212 (1-1000 µg kg
-1
). Each value is the mean ± S.E.M. of 5 
rats per group. ^^P < 0.01 vs. vehicle-treated normal controls (blue). *P < 0.05 and 
**P < 0.01 vs DNBS + vehicle treated group (red).      
 
2.4. Comparative effect of the clinically-used compound linaclotide in the DNBS model  
The effects induced by MRS5980 against the post-inflammatory hypersensitivity induced by 
DNBS were compared with the effects of linaclotide, the reference drug in the management of 
pain in IBS-C patients. On day 14, 0.2 and 0.066 nmol kg
-1 
(0.3 and 0.1 µg kg
-1
, respectively) 
linaclotide, strongly reduced the VMR to CRD in DNBS-treated animals, while the ten-fold 















Figure 16. Effect of the reference drug linaclotide on post-inflammatory visceral pain.  Tests were 
performed 14 days after DNBS treatment by measuring the viscero-motor response (VMR) to colo-
rectal distension (CRD) after the administration of linaclotide (0.01- 0.3 µg kg
-1
).  Each value is the 
mean ± S.E.M. of 5 rats per group.  ^^P < 0.01 vs. vehicle-treated normal controls (blue). *P < 0.05 
and **P < 0.01 vs DNBS + vehicle treated group (red).   
 
2.5. Effect of adenosine A3R agonists on N-type voltage-gated Ca
2+
 channels in DRG 
neurons isolated from control or DNBS-treated rats (Data not shown)  
Thanks to the collaboration with Dr. Elisabetta Coppi (Dept. of Neurofarba, University of 
Florence), we gained insight into mechanisms underlying the anti-hyperalgesic role of 
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A3ARs, by exploring electrophysiological properties and Cl-IB-MECA effects in DRG 
primary sensory neurons isolated from vehicle-injected (control group) or DNBS-treated rats 
(14 days after treatment; data not shown). 
Whole-cell patch-clamp recordings were performed as previously described (Coppi et al., 
2018; Coppi et al., 2012). Briefly, cells were transferred to a 1 ml recording chamber mounted 
on the platform of an inverted microscope (Olympus CKX41, Milan, Italy) and superfused at 
a flow rate of 1.5 ml/min by a three-way perfusion valve controller (Harvard Apparatus) by 
the following extracellular solution (mM): NaCl 147; KCl 4; MgCl2 1; CaCl2 5; HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) 10; D-glucose 10 (pH 7.4 with NaOH). 
Borosilicate glass electrodes (Harvard Apparatus, Holliston, MA) were pulled with a Sutter 
Instruments puller (model P-87) to a final tip resistance of 1.5–3 ΩM. Passive membrane 
properties of DRG neurons isolated from control or DNBS-treated rats were investigated 
under physiological-like conditions by using the following K-gluconate- based pipette 
solution (mM): KGlu 130; NaCl 4.8; KCl 10; MgCl2 2; CaCl2 1; Na2-ATP 2; Na2-GTP 0.3; 
EGTA 3; HEPES 10 (pH 7.4 with KOH). Resting membrane potential (Vm) was measured 
immediately after seal break-through by switching the amplifier to the current-clamp mode. 
The calculated liquid junction potential for K-gluconate pipettes in our experimental 
conditions was 15.0 mV and Vm values reported in the present research have been corrected 
accordingly. Voltage-dependent Ca
2+
 currents (VDCCs) were recorded by using a Cs
+
-based 
pipette solution of the following composition (mM): CsCl (130); NaCl (4.8); KCl (10); MgCl2 
(2); CaCl2 (1); Na2-ATP (2); Na2-GTP (0.3); EGTA (3); and HEPES (10 - pH 7.4 with 
CsOH). The extracellular solution was (in mM): NaCl (147); CsCl (4); MgCl2 (1); and CaCl2 
(5); HEPES (10); D-glucose (10); pH 7.4 with NaOH. Tetrodotoxin (TTX; 1 µM) and 5-(4-
butoxy-3-chlorophenyl)-N-[[2-(4-morpholinyl)-3-pyridinyl]methyl]-3-pyridinecarboxamide 
(A887826; 200 nM) were added to the extracellular solution to block TTX-sensitive Nav1.1, 
1.2, 1.3, 1.4, 1.6, 1.7 channels and TTX-resistant Nav1.8, respectively. VDCC currents were 
evoked by a 0 mV step depolarization (200 ms) once every 30 s to minimize Ca
2+
 current run 
down. The current-to-voltage relationship (I-V plot) of Ca
2+
 currents was obtained by eliciting 
10 depolarizing voltage steps (200 msec duration, 10 mV increments, 5 s interval) from -50 to 
+50 mV starting from a holding potential (Vh) of -65 mV. Data were acquired with an 
Axopatch 200B amplifier (Axon Instruments, CA), low-pass filtered at 10 kHz, and stored 
and analysed with pClamp 9.2 software (Axon Instruments, CA). Membrane resistance (Rm), 
and membrane capacitance (Cm) were routinely measured by fast hyperpolarizing voltage 
pulses (from -60 to -70 mV, 40 ms duration). Averaged currents were normalized to cell 
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capacitance and expressed as pA/pF.Cell capacitance was used to estimate neuronal diameter 
by assuming an approximated spherical cell shape according to the calculated Cm for all 
biological membranes of 1 µF/cm
2




Concerning passive membrane properties, DNBS neurons presented a more depolarized Vm 
in comparison to those from the vehicle-treated animals (from - 61.4 ± 2.2 mV in control to - 
52.0  ± 2.6 mV in DNBS group, n=23 and n=33 respectively, P=0.0143, unpaired Student‘s t-
test), whereas no obvious differences were found in Rm or Cm. Of note, VDCCs, activated by 
a depolarizing voltage step protocol (from -50 to +40 mV, 200 ms), showed some differences 
in DNBS-treated versus control rats. Although if total peak currents were unchanged, either in 
amplitude or time to peak, Ca
2+
 currents measured at the steady-state in DNBS neurons were 
significantly smaller in amplitude (from -21.5 ± 8.1 pA/pF in control to -1.4 ± 4.0 pA/pF in 
DNBS group, n=15 and n=14 respectively, P=0.0393, unpaired Student‘s t-test). Consistent 
with our previous work (Coppi et al., 2019), we confirmed that Cl-IB-MECA (30 nM) 
inhibited PD173232-sensitive N-type Ca
2+
 currents in DRG neurons isolated either from 
control or DNBS-treated rats and the effect was blocked by the A3AR antagonist, MRS1523 
(100 nM). No difference was found in the percentage of Cl-IB-MECA-inhibited Ca
2+
 current 
in control or DNBS neurons (from 20.0 ± 4.1 to 22.5 ± 6.1 % inhibition, n=7 in both groups; 
P=0.7332 unpaired Student‘s t-test). Similar results were obtained in the presence of the 
newly synthetized highly-selective A3AR agonist, MRS5980 (30 nM): the compound 
inhibited, to a similar extent, Ca
2+
 currents either in control or DNBS neurons and the effect 
was prevented by MRS1523 and by the N-type channel blocker, PD173232 (1 µM). 
 
3. Study of the role of gut microbiota in post-inflammatory visceral pain induced by 
DNBS 
 
3.1. Effect of long-term antibiotic treatment and Faecal Microbiota Transplantation (FMT) 
from DNBS-treated animals on visceral sensitivity of naïve recipients 
The animals were treated as reported in the scheme below: in order to deplete the gut 
microbiota, rats were subjected to a combination of antibiotics for 24 days. A control group 
was treated with the vehicle. On day 25 the antibiotics-treated animals were divided in 2 
groups, respectively receiving the control-derived faecal microbiota (FMT from CTR) or the 
DNBS-derived faecal microbiota (FMT from DNBS). The Faecal Microbiota Transplantation 
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(FMT) was performed for 5 consecutive days and repeated once after 7 days. Behavioural 
tests were performed 10, 17 and 24 days after the last FMT. The viscero-motor and the 
abdominal withdrawal responses (VMR and AWR) to the progressive increase in colorectal 
distension (CRD) were measured (Fig 17, respectively A and B).  
Visceral pain threshold of antibiotic-treated animals appeared significantly lowered during the 
assessment of the abdominal withdrawal response to CRD (Fig 17B), In particular the animals 
treated with the antibiotics showed a greater sensitivity to the lower volume stimuli (1-2 mL) 
in respect to vehicle treated animals. Nevertheless, the long-term antibiotic treatment did not 
cause a significant increase in the viscero-motor response to CRD (Fig 17B). No difference 
was observed between the different groups treated with the antibiotics before FMT (Day 25, 
Fig 17). The transplant of the microbiota derived from controls attenuated visceral 
hypersensitivity induced by the long-term antibiotic regime, though the animals did not come 
back to the value of controls (black bars, Day 46-60). By contrast the animals receiving the 
microbiota of DNBS donors showed no recovery from the antibiotic-induced visceral 
hypersensitivity, which persists at least 24 days after the interruption of the treatments (Day 
60 Fig 17B). Moreover, these animals showed an increase in the viscero motor response to 
CRD, which was significantly higher in respect to the other groups 10 and 17 days after the 
FMT (Day 46 and 53, Fig 17A). In these experimental conditions, it was difficult to discern 










Figure 17. Effect of long-term antibiotic treatment and Faecal Microbiota Transplantation (FMT) 
from DNBS-treated animals on visceral sensitivity of naïve recipients. Rats were treated with a 
combination of antibiotics for 24 days; control group was treated with vehicle. On day 25 the 
antibiotics (abx- treated animals were divided in 2 groups, control-derived faecal material or DNBS-
derived faecal material was respectively administered per os for five consecutive days. One week after 
the administration was repeated. Behavioural tests were performed 10, 17 and 24 days after the last 
FMT. Visceral sensitivity was assessed in the animals by measuring the Viscero-Motor Response 
(VMR; A) and the Abdominal Withdrawal Response (AWR; B). Each value is the mean ± S.E.M. of 5 
rats per group.  *P<0.05 and **P<0.01 vs vehicle or vehicle + vehicle treated animals.  
 
3.2. Effect of short-term antibiotic treatment and Faecal Microbiota Transplantation 
(FMT) from DNBS-treated animals on visceral sensitivity of naïve recipients 
To reduce the impact of antibiotics on visceral sensitivity we repeated the previous 
experiment by shortening the antibiotic treatment. With the collaboration of Dr. Di Pilato 
(Clinical Microbiology and Virology Unit, Florence Careggi University Hospital) we 
ascertained that 7 days of antibiotic regime are enough to obtain a sufficiently microbiota 
depletion to performed FMT (data not shown). 
The animals were treated as reported in the scheme below: after 7 days of antibiotics, the 
animals were divided into 3 groups, respectively receiving the vehicle, the control-derived 
faecal microbiota (FMT from CTR) or the DNBS-derived faecal microbiota (FMT from 
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consecutive days and the same protocol was repeated one week after (I and II set of FMT). 
Behavioural tests were performed at the end of the antibiotic treatment, 24h and 7 days after 
each set of FMT and once week after that. The viscero-motor and the abdominal withdrawal 
responses (VMR and AWR) to the progressive increase in colorectal distension (CRD) were 
measured (Fig 18, respectively A and B). 
The short-term antibiotic treatment affected animals‘ visceral sensitivity. All the groups 
treated with the antibiotics showed a significantly augmented abdominal withdrawal response 
to CRD (Fig 18B). Also, in this case the antibiotic treatment did not cause a significant 
increase in the viscero-motor response to CRD (Fig 18B). No difference was observed among 
the different groups treated with the antibiotics before FMT (Day 7, Fig 18).  
The re-colonization of the intestine with the healthy microbiota was able to restore a normal 
visceral pain threshold in antibiotics-treated animals. In fact, visceral hyperalgesia induced by 
antibiotics was remarkably reduced after the I set of FMT (Day 12-18, Fig 18) and completely 
reverted after the II set of FMT from CTR (Day 25-32, Fig 18). The same effect was observed 
by administering the vehicle (Fig 18). By contrast, the animals receiving the FMT from 
DNBS donors showed no recovery from the antibiotic treatment, but a further increase of both 
the viscero-motor response and the abdominal withdrawal response to CRD (Day 12-18, Fig 
18A and B, respectively). This effect consolidated after the II set of FMT (Day 25-32, Fig 
18). The animals receiving the FMT from DNBS still manifest an increased abdominal 
withdrawal response to CRD 2 weeks after the last FMT (Day 39, Fig 18B). On Day 46, 3 
weeks after the interruption of the treatments, the effect of FMT from DNBS donors ended 
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Figure 18. Effect of short-term antibiotic treatment and Faecal Microbiota Transplantation (FMT) 
from DNBS-treated animals on visceral sensitivity of naïve recipients. Rats were treated with a 
combination of antibiotics for 7 days; control group was treated with vehicle. On day 7 the antibiotics 
(abx)-treated animals were divided into 3 groups, FMT from CTR donors, FMT from DNBS donors or 
vehicle were respectively administered per os for five consecutive days. One week after the 
administrations were repeated. Behavioural tests were performed at the end of the antibiotic 
treatment, 24h and 7 days after each cycle of FMT and once week after the last treatment. Visceral 
sensitivity was assessed in the animals by measuring the Viscero-Motor Response (VMR; A) and the 
Abdominal Withdrawal Response (AWR; B) to Colo-Rectal Distension (CRD; 0.5-3 mL). Each value is 
the mean ± S.E.M. of 5 rats per group repeated in 2 experimental set.  *P<0.05 and **P<0.01 vs 
vehicle or vehicle + vehicle treated animals. 
 
3.3. Detection of DNBS in faecal samples by Liquid Chromatography-Mass Spectrometry 
(LC-MS/MS) 
The determination of DNBS were carried out on sample solutions derived by both treated (30 
mg DNBS in 0.25 mL EtOH i.r.) and control rats. Each group of samples was composed at 
least by three solutions obtained by different rats. The obtained LC-MS/MS chromatographic 
profiles were very similar for the two groups of samples (Figure 19, left). This evidence 
establishes that the analyte in treated samples is minor than LOD of the method (2 ng ml
-1
). In 
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 of analyte. The result demonstrates that the DNBS was detected and, compared with 
5 ng mL
-1
 calibration solution, correctly quantified (Fig 19, right). 
Figure 19. Detection of DNBS in faecal samples by LC-MS/MS. Left: LC-MS/MS chromatographic 
profiles obtained by DNBS (Above) and control (Bottom) FMT donor animals. Right: LC-MS/MS 
chromatographic profiles obtained by control sample added with 5 ng mL
-1
 of DNBS (Above) and 5 ng 
mL
-1
 calibration solution (Bottom) samples. 
 
3.4. Effect of short-term antibiotic treatment and Faecal Microbiota Transplantation 
(FMT) on colon histology 
The animals were sacrificed on Day 7 (24h after the end of antibiotic treatment), Day 32 
(when the effect of FMT on pain was well established) and Day 46 (when the effect of FMT 
disappeared). The colon was harvested and processed for both macroscopic and microscopic 
analysis (Figure 20A and 20B, respectively). The Macroscopic Damage Score (MDS) was 
used to quantify the tissue damage degree (Fig 20A). The macroscopic examination highlight 
the presence of hyperaemia and a slight thickening of wall after the antibiotic treatment (Day 
7). These alterations dissipated as a result of the administration of vehicle as well as the FMT 
from CTR donors. The recovery was slower in the animals receiving the FMT from DNBS 
donors (Day 32). On Day 46 no macroscopic alterations were detected among the groups (Fig 
20A). These results were confirmed by microscopic analysis: an infiltration of neutrophils in 
mucosa and sub-mucosa were detected in the animals underwent the antibiotic treatment (Day 
7; black arrow; Fig 20B). This tissue alteration found in the colon recover consequently to the 
interruption of antibiotic. No microscopic differences were observed in the animals receiving 
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Figure 20. Histological evaluation of colon damage after the antibiotic regime and the FMT. A) 
Macroscopic Damage Score; B) Histological analysis on haematoxylin/eosin stained colon slices. 
Each value represents the mean ± S.E.M. of 5 animals per group. **P < 0.01 vs vehicle treated 
animals. 
A) Macroscopic Damage Score 
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3.5. Effect of short-term antibiotic treatment and Faecal Microbiota Transplantation 
(FMT) on gut permeability 
Animals‘ gut permeability was evaluated either by assessing the levels of Lipopolysaccharide 
Binding Protein (LBP) in the plasma and by measuring the expression of the tight junction 
related proteins, occludin and Zo-1, in the colon. The animals were sacrificed on Day 7 (24h 
after the end of antibiotic treatment), Day 32 (when the effect of FMT on pain was well 
established) and Day 46 (when the effect of FMT disappeared). Plasma and colon samples 
were collected from each experimental group. The results obtained in the animals underwent 
the FMT were compared with that obtained respectively in the CTR and DNBS donors. 
Plasma was analysed for LBP using an ELISA immunoassay. No significant alteration in the 
plasmatic levels of LBP was found among the experimental groups, only a tendency to 
increase after the antibiotic treatment was appreciable (Day 7; Fig 21A). On the other hand, 
no divergence was found in the levels of plasmatic LBP between CTR and DNBS donors (Fig 
21A). 
Accordingly, We analysed the expression of tight junctions related proteins in the colon by 
RT-qPCR. The expression of occludin tended to increase after the antibiotic treatment (Day 7; 
Fig 21B). On Day 46 occludin expression appeared significantly up regulated in all the groups 
which had received the antibiotics (Fig 21B). Similarly, the levels of Zo-1 mRNA resulted 
significantly increased on Day 7 after the antibiotic regime. By contrast, the expression of 
occludin and Zo-1 seems not to have been influenced by the FMT. A slight derangement in 
Zo-1 expression was observed in DNBS donors and FMT-DNBS recipients, though this effect 
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Figure 21. Effect of antibiotic regime and FMT on gut permeability. A) Elisa assay for 
Lipopolysaccharides Binding Protein (LBP) in plasma samples. B) Analysis of occludin and Zo-1 gene 
expression on colon samples by RT-qPCR. The mRNA expression was normalized to β-actin and fold 
changes were expressed in comparison with control group. Each value is the mean ± S.E.M. of 4-6 
rats per group.  *P<0.05 and **P<0.01 vs vehicle or vehicle + vehicle treated animals. 
 
3.6. Effect of short-term antibiotic treatment and Faecal Microbiota Transplantation 
(FMT) on gut cytokines profile 
The immune response of animals was investigated by analysing the pro- and anti-
inflammatory cytokine profile in the gut. The animals were sacrificed on Day 7 (24h after the 
end of antibiotic treatment), Day 32 (when the effect of FMT on pain was well established) 
and Day 46 (when the effect of FMT disappeared) and colon samples were collected from 
each experimental group. The results obtained in the animals underwent the FMT were 
compared with that obtained respectively in the CTR and DNBS donors.  
The gene expression of TNF-α, IL-6, IL-10 and Tgf-β was measured in the colon by RT-
qPCR. The antibiotic regime caused a long-lasting up regulation of both pro- and anti-
inflammatory cytokines expression (Day 7; Fig 22). This deregulatory effect of antibiotics 
was not fixed with the transplant of the microbiota (Day 32; Fig 22).  
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On the other hand, the cytokines profile of recipient animals did not follow the trend of the 
donors. In fact, the expression of both IL-6 and Tgf-β resulted augmented in FMT recipient 
animals, irrespective to the donors (CTR or DNBS; Day 32), though these cytokines were 
overexpressed only in DNBS donors (Fig 22). Unlike DNBS donors, TNF-alfa expression 
was drastically down-regulated in FMT-DNBS recipients, while the expression of IL-10 was 
remarkably increased (Day 32; Fig 22). On Day 46 all the cytokines were still upregulated in 
the abx + vehicle group and in the abx + FMT from CTR group. By contrast, in the abx + 
FMT from DNBS all the cytokines, with exception of Tgf-β, come back to the value of 
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Figure 22. Effect of antibiotic regime and FMT on gut cytokines profile. Analysis of TNF-α, IL-6, 
IL-10 and Tgf-β gene expression on colon samples by RT-qPCR. The mRNA expression was 
normalized to β-actin and fold changes were expressed in comparison with control group. Each value 
is the mean ± S.E.M. of 4-6 rats per group.  *P<0.05 and **P<0.01 vs vehicle or vehicle + vehicle 
treated animals. 
 
3.7. Effect of short-term antibiotic treatment and Faecal Microbiota Transplantation 
(FMT) on tryptophan metabolism 
The plasmatic levels of tryptophan (TRP) and kynurenine (KYN) were investigated by 
performing a HPLC analysis. The animals were sacrificed on Day 7 (24h after the end of 
antibiotic treatment), Day 32 (when the effect of FMT on pain was well established) and Day 
46 (when the effect of FMT disappeared) and plasma samples were collected from each 
experimental group. The results obtained in the animals underwent the FMT were compared 
with that obtained respectively in the CTR and DNBS donors.  
The levels of both TRP and KYN resulted significantly decreased in the plasma of DNBS 
donors in respect to controls (grey background; Fig 23). The levels of TRP were not affected 
by the antibiotic treatment, while the levels of KYN tended to increase (Day 7, Fig 23). 
Anyway, on Day 32 all the groups treated with the antibiotics, irrespective to the microbiota 
transplant, showed a significant reduction of TRP. On the other side, the levels of KYN did 
not change, leading to an increase in the TRP/KYN ratio (Day 32; Fig 23).  
On Day 46 the levels of TRP were still lowered in abx + vehicle and abx + FMT from CTR 
animals. At the same time, the levels of KYN resulted increased in abx + vehicle animals and 
decreased in abx + FMT from CTR animals. Regarding the group treated with abx + FMT 
from DNBS, the amount of TRP rised up back to the controls value, while that of KYN 













Figure 23. Effect of antibiotic regime and FMT on tryptophan and kynurenine plasmatic levels. 
Concentrations of tryptophan (TRP) and kynurenine (KYN) and their ratio (KYN/TRP) assessed by 
HPLC in plasma samples. Each value is the mean ± S.E.M. of 4-6 rats per group.  *P<0.05 and 
**P<0.01 vs vehicle or vehicle + vehicle treated animals. 
 
3.8. Effect of short-term antibiotic treatment and Faecal Microbiota Transplantation 
(FMT) on gut monoamines 
The levels of monoamines in the colon were investigated by using HPLC. The animals were 
sacrificed on Day 7 (24h after the end of antibiotic treatment), Day 32 (when the effect of 
FMT on pain was well established) and Day 46 (when the effect of FMT disappeared) and 
colon samples were collected from each experimental group. The results obtained in the 
animals underwent the FMT were compared with that obtained respectively in the CTR and 
DNBS donors.  
The amount of 5-HT, but not that of the metabolite 5-HIAA, were significantly higher in the 
colon of DNBS donors than controls (grey background; Fig 24A). On the other hand, the 
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The levels of 5-HT and 5-HIAA were not significantly affected by the antibiotic treatment 
(Day 7), neither by the microbiota transplant (Day 32, Fig 24A). Only a slight lowering of 5-
HIAA was noticed in the animals underwent the FMT, irrespective to the donors (Day 32). 
The same framework was observed on Day 46 (Fig 24A).  
Although not significant, a persistent lowering of DA was observed as a consequence of the 












the end of antibiotic regime   
Day 32 
 7 days after the II set of FMT  
Day 46 








































































































































 vehicle + vechicle
 abx + vehicle
 abx + FMT from CTR




















 vehicle + vechicle
 abx + vehicle
 abx + FMT from CTR






















 vehicle + vechicle
 abx + vehicle
 abx + FMT from CTR






















 vehicle + vechicle
 abx + vehicle
 abx + FMT from CTR














 vehicle + vechicle
 abx + vehicle
 abx + FMT from CTR














 vehicle + vechicle
 abx + vehicle
 abx + FMT from CTR
 abx + FMT from DNBS
FMT Donors 
Day 7 
the end of antibiotic regime   
Day 32 
 7 days after the II set of FMT  
Day 46 









































































 vehicle + vechicle
 abx + vehicle
 abx + FMT from CTR























 vehicle + vechicle
 abx + vehicle
 abx + FMT from CTR





Figure 24. Effect of antibiotic regime and FMT on monoamines levels in the gut. A) Concentrations 
of  serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) and their ratio (5-HIAA/5-HT) assessed 
by HPLC in colon samples. B) Concentrations of  dopamine (DA) assessed by HPLC in colon samples. 
Each value is the mean ± S.E.M. of 4-6 rats per group.  *P<0.05 and **P<0.01 vs vehicle or vehicle 
+ vehicle treated animals. 
 
3.9. Effect of short-term antibiotic treatment and Faecal Microbiota Transplantation 
(FMT) on faecal monoamines 
The levels of monoamines in the colon lumen were investigated by processing the faecal 
pellets with HPLC. The faecal pellets were collected from each experimental group on Day 7 
(24h after the end of antibiotic treatment), Day 32 (when the effect of FMT on pain was well 
established) and Day 46 (when the effect of FMT disappeared). The results obtained in the 
animals underwent the FMT were compared with that obtained respectively in the CTR and 
DNBS donors. In the faecal pellets, no differences in 5-HT and DA levels were found 
between DNBS and CTR donors (grey background; Fig 25A and B, respectively). The 
concentration of 5-HT was appreciably reduced as a result of the antibiotic treatment, by 
contrast DA amount considerably increased (Day 7, Fig 25A and B, respectively). After the 
FMT, the amount of 5-HT in the lumen significantly augmented, irrespective to the donor 
(Day 32; Fig 25A). This effect persisted on Day 46, when the levels of 5-HT were still high in 
both the groups receiving the FMT (Fig 25A). On the other hand, the DA increase caused by 
the antibiotic regime was reverted by the FMT as well as by the spontaneous re-colonization 
of the intestine due to the vehicle administration (Day 32; Fig 25B). 
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Figure 25. Effect of antibiotic regime and FMT on monoamines levels in the faeces. A) 
Concentrations of  serotonin (5-HT; A) and dopamine (DA; B) assessed by HPLC in faecal samples. 
Each value is the mean ± S.E.M. of 4-6 rats per group.  *P<0.05 and **P<0.01 vs vehicle or vehicle 
+ vehicle treated animals. 
 
3.10. Effect of the antibiotic treatment and the Faecal Microbiota Transplantation (FMT) 
on gut microbiota composition (Data not shown) 
Thanks to the collaboration with Dr. Vincenzo Di Pilato (Dept. of Surgery and Translational 
Medicine, University of Florence) we performed a gut microbiota analysis. 
In order to identify potential signatures in the gut microbiota of animals subjected to FMT 
using stools collected from both controls and DNBS-treated donors, the fecal microbiota of 
recipient animals was characterized through a 16S metagenomic sequencing approach. Four 
faecal samples of different animals for each experimental group were collected on Day 0 
(before the treatments), Day 7 (24h after the last antibiotic treatment), Day 18 (7 days after 
the the first set of FMT) Day 32 (7 days after the second set of FMT) and on Day 46 (21 days 
after the last FMT). The microbiota characterization was also performed on the preparations 
used for the repeated fecal transfers from both CTR and DNBS donors. In particular the faecal 
supernatant utilized for the first and the last transfer of each set of FMT was analysed. 
Fecal pellet and fecal suspensions were processed for the total DNA extraction using a 
commercial kit (DNeasy PowerLyzer PowerSoil Kit - Qiagen, Hilden, Germany). The gut 
microbiota was characterized by next generation sequencing technology using the Illumina 
MiSeq platform and the 16S ribosomal RNA gene as target (V3-V4 region) on amplified 
genomic DNA, according to the Illumina 16S Metagenomic Sequencing Library Preparation 
protocol (Part # 15044223 Rev. B; URL: http://www.illumina.com/content/dam/illumina-
support/documents/documentation/chemistry_documentation/16s/16s-metagenomic-library-
prep-guide-15044223-b.pdf). Sequencing results were analyzed using the QIIME 2 suite 
(Quantitative Insights Into Microbial Ecology) (Bolyen et al., 2019).  
Microbial diversity was estimated by evaluating alpha- and beta-diversity metrics using 
specific tools implemented in the QIIME 2 pipeline. The alpha-diversity, representing the 
measure of mean diversity within a sample, was analyzed evaluating the Shannon diversity 
index. The beta-diversity, which consists in comparison of diversities between samples, was 
evaluated using the Principle Coordinates Analysis (PCoA) and the Bray-Curtis metric to 
inspect a potential clustering of samples according to the study groups. Statistical analysis 
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was performed through QIIME 2 and GraphPad Prism 6 using nonparametric tests (e.g. 
Kruskal-Wallis, ANOSIM, PERMANOVA). 
Preliminary analysis of alpha-diversity revealed an overall lower microbial diversity in 
samples from antibiotic-treated animals not subjected to a subsequent fecal transfer, an 
observation consistent with the antibiotic treatment performed to deplete the resident 
microbiota. Conversely, the microbial diversity was overall stable in control samples over the 
examined timepoints and showed an increase trend in samples from animal subjected to fecal 
transfer, either using stool from control or DNBS-treated animals.  
The analysis of beta-diversity showed that samples from antibiotic-treated animals clustered 
away from controls, confirming a different structure of their gut microbiota which is 
maintained over time.  
Differences in microbial taxonomic profiles were identified in preparations of the fecal 
material used for the repeated fecal transfers, obtained either from control or DNBS-treated 
animals, indicating that alterations of the gut ecosystem mediated by DNBS can directly 
impact on the resident microbial communities and persist until later stages following the acute 
inflammatory response. 
Concerning the experimental groups of animals treated with antibiotics and then subjected to 
FMT, defined clusters in PCoA plots were observed for samples collected after the second 
series of repeated fecal transfers (Day 32), suggesting that major modifications in the 
composition and structure of the gut microbiota might have occurred at this stage. Evaluation 
of taxonomic profiles confirmed that marked differences between the animals underwent the 
FMT from CTR or DNBS were identifiable after the second series of repeated fecal transfers 
at phylum and family level for major members of the gut microbiota, including also protective 
microbial taxa known to be associated with gastrointestinal health.  
 
 
3.11. Therapeutic effect of Faecal Microbiota Transplantation (FMT) on post-
inflammatory visceral pain persistence 
The animals were treated as reported in the scheme below. Colitis was induced in the animals 
by the intra rectal injection of DNBS (30 mg in 0.25 mL EtOH 50%). A control group was 
intra-rectally administered with saline solution. Seven day after DNBS injection the animals 
were split into 2 groups, respectively receiving the vehicle or the controls-derived faecal 
microbiota (FMT from CTR). The Faecal Microbiota Transplantation (FMT) was performed 
for 5 consecutive days and the same protocol was repeated for 4 weeks (I-IV set of FMT). 
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Behavioural tests were performed 7 day after DNBS injection, 3 days after each set of FMT 
and once week after the end of the treatment. The abdominal withdrawal responses (VMR and 
AWR) to the progressive increase in colorectal distension (CRD) was measured (Fig 26).  
As expected, 7 days after the induction of the damage, the abdominal withdrawal response to 
CRD was significantly higher in both the groups treated with DNBS (Fig 26). The transplant 
of the microbiota derived from healthy donors (FMT from CTR) into DNBS treated animals 
led to a progressive reduction of visceral hypersensitivity which became significant after the 
third transplant cycle (Day 28) end consolidated after the fourth one (Day 35; Fig 26). The 
beneficial effect of FMT on post-inflammatory visceral pain caused by DNBS lasts up to 17 
days after the treatment interruption (Day 49). Starting from Day 56, the behavioural response 
of animals to CRD increase again. On Day 63, irrespectively of the received treatment, both 
the DNBS groups showed a significantly higher visceral sensitivity in respect to controls 






















































Figure 26. Therapeutic effect of FMT on DNBS-induced post-inflammatory visceral pain. Rats were intra-
rectally injected with DNBS (30 mg in 0.25 mL EtOH 50%). On day 7 DNBS-animals were divided into 2 groups 
respectively administered with the vehicle or the FMT from CTR donors per os for five consecutive days. The 
FMT set was weekly repeated for 4 times. Behavioural tests were performed at the end of the antibiotic 
treatment, 3 days after each cycle of FMT and once week afterwards. Visceral sensitivity was assessed in the 
animals by measuring the Abdominal Withdrawal Response (AWR) to Colo-Rectal Distension (CRD; 0.5-3 mL). 
Each value is the mean ± S.E.M. of 5 rats per group. *P<0.05 and **P<0.01 vs vehicle or vehicle + vehicle 
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The first part of this work provides a comprehensive pharmacological and histological 
characterization of the persistent visceral pain caused by intestinal inflammatory damages. 
We found that this kind of chronic pain is related to a persistent immune activation as well as 
to abnormalities in the nervous system signalling. Interestingly these alterations, which likely 
originate in the periphery as a consequence of the intestinal damage, reverberate at central 
level where they trigger mechanisms of chronicization, such as a marked activation of 
microglia and astrocytes. 
The similarities between the animal model of post-inflammatory visceral pain induced by 
DNBS and the clinical manifestations showed by patients affected by both IBS and IBDs (Qin 
et al. 2011; Antonioli et al., 2011; Brierley and Linden, 2014; Greenwood-Van Meerveldet al., 
2015; Spiller and Major, 2016) allowed us to deepen into the pathophysiological mechanisms 
involved in pain development and maintenance. DNBS induced a local inflammatory 
response with a peak between 3 and 7 days after its intra-rectal injection with a subsequent 
progressive remission already detectable after 2 weeks as previously reported by Ippolito et 
al. (2015). After colitis resolution, the animals developed a visceral hypersensitivity which 
persisted ~ 3 months, in accordance to previous reports by Adam et al. (2006) and 
Gschossmann et al.  (2004).  
The measure of the viscero-motor response to colo-rectal distension gave a quantitative 
measure of the visceral sensitivity, since the entity of the abdominal contraction is directly 
proportional to the intrinsic sensibility of the animals (Arvidsson et al.,  2006; Christianson 
and Gebhart, 2007). Despite its usefulness as quantitative measure, the assessment of this 
viscero-motor response needed the animals to be asleep, excluding the cognitive and 
emotional component of pain. We complete the puzzle, by coupling this test to the measure of 
the abdominal withdrawal response to the colo-rectal distension in awake animals as 
described by Chen et al. (2014) which allowed to further analyse the different aspects of this 
type of pain. 
Regarding the emotional aspect, we found that DNBS treated animals, along with pain, 
present also persistent depresive-like behaviours. By contrast, no significative anxiety or 
motor disorders were detected, though chronic colitis-induced visceral pain has been recently 
associated with increased anxiety during quiescent phase (Salameh et al., 2019). A high 
comorbidity of chronic pain with stress-related psychiatric disorders including anxiety and 
depression occurs also at clinical level, despite the mechanisms linking visceral pain with 
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these overlapping comorbidities remain to be elucidated (Elsenbruch et al., 2010a; Moloney et 
al., 2015). These behavioural disorders can be caused by the presence of spontaneous pain or 
discomfort in the animals. On the other hand, long term stress facilitates pain perception and 
sensitizes pain pathways, leading to a feed-forward cycle promoting chronic visceral pain 
disorders such as IBS (Greenwood-Van Meerveld and Johnson, 2017). This also explains the 
benefit provided by antidepressants in these patients (Camilleri and Boeckxstaens, 2017).  
From a pharmacological point of view, we observed that the drugs with spasmolytic effect on 
the gut were effective in visceral pain relief, likely inhibiting perception of the stimulus. On 
the other hand, we found that anti-depressant and anti-epileptic drugs, able to restore the 
normal neuronal activity, as pregabalin, work better than anti-inflammatory drugs. This is 
similar to what usually happens in neuropathic pain conditions (Attal and Bouhassira, 2015). 
Nevertheless, though inflammation seems not be responsible for the persistence of visceral 
pain, it represents the driving force for the induction of neuroplasticity in the periphery which 
lead to altered motility and nociceptors sensitization (Brierley and Linden, 2014; Mawe et al., 
2015).   
In the study of the mechanisms it is important to consider that the emotional component has 
an important role in the perception of visceral pain (Elsenbruch et al., 2010b; Van 
Oudenhove, 2010; Schmid et al., 2015), which therefore cannot be considered only the result 
of a peripheral altered nervous signalling. The systemic administration of morphine was able 
to make DNBS-treated animals completely insensitive to the colorectal stimulus, an effect that 
cannot be traced back only to the muscular relaxation of the intestine walls, otherwise all the 
compounds with spasmolytic activity should have shown the same effect. Yet, we cannot 
consider this effect solely due to the inhibition of the painful signal transmission from the 
periphery to central nervous system. In fact, the intrathecal injection of morphine partially 
relief pain in awake animals but not in unconscious rats, confirming that an important 
regulatory component may reside in the supraspinal centres where morphine exerts a 
dissociative effect on pain perception (Mayer, 2000; Harton et al., 2017). Similarly 
amitriptyline, able to activate the descending inhibitory signal on pain pathways (Obata et al., 
2017), once intrathecally administered resulted effective only in conscious animals. 
Conversely, pregabalin, a blocker of the alpha2-delta subunit of voltage-gated calcium 
channels, was more active in unconscious animals after the intrathecal infusion. Overall the 
pharmacological data demonstrate the complex nature of this kind of persistent pain in which 
inflammatory, neuropathic and emotional components intertwined.  
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Looking more thoroughly the colon, we found an augmented production and deposition of 
collage fibres in DNBS treated animals as previously reported by Ippolito et al. (2015). This 
process which starts as a mechanism of repair, inevitably alters the tissue physiology (Rieder 
and Fiocchi, 2009). On the other hand, we found a widespread increase in the production of 
substance P, a neurotransmitter involved in the regulation of local nervous signalling as well 
as in the modulation of painful perception (Von Boyen et al., 2002; Vergnolle, 2003). 
As previously mentioned, the intestinal inflammation leads to significative neuroplastic 
alterations in the enteric nervous system resulting in the chronicization of enteric neuropathy-
related symptoms, like visceral pain and intestinal dysmotility (Mawe et al., 2015). During 
inflammation resident and immune cells recruited to the inflamed or damaged site secrete 
inflammatory mediators that act on peripheral nerves innervating the affected tissue. Some of 
the signals triggered by the peripheral immune activation have been reported to migrate 
toward the dorsal root ganglia and the spinal cord, modulating pain maintenance (Raoof et al., 
2018).  
Among the inflammatory mediators, those mainly involved in modifying peripheral neurons 
activities are histamine, proteases, polyunsaturated fatty acid metabolites, and tachykinins 
(Corsetti et al., 2015; Wouters et al., 2016b; Cenac et al., 2015; Delvalle et al., 2018). In 
particular, histamine produced by MCs is increased in the gut of patients affected by IBS 
playing a key role in visceral sensitivity regulation, given its ability to directly enhance 
neuron excitability (Wouters et al., 2016b; Traina et al., 2019). Similarly, we found an 
increase in the number of MCs in the mucosa and in the submucosa of DNBS animals which 
is likely triggered by the disruption of the intestinal barrier consequent to the damage which 
determines the passage of luminal antigens into the mucosa. This evidence, along with that 
discussed below, suggests the persistence of an immune system activation after the resolution 
of inflammation that inevitably affect the enteric nervous signalling (Albert-Bayo et al., 
2019).  
In line with the hypothesis of a persistent immune activation, one interesting aspect we 
observed in DNBS rats at day 14 is the increase in eosinophils and MHC-II-positive 
macrophages detected throughout the colonic wall. Of interest, these cells accumulated 
consistently in the proximity of SP-positive fibres, indicating a neuro-immune interaction also 
during the post-inflammatory phase of colitis. Indeed, abundant eosinophils have been 
previously described in close apposition to enteric nerves in IBD patients, this pattern being 
probably mediated by the upregulated production of ICAM-1 and eotaxin-3 by enteric 
neurons after their damage (Smyth et al., 2013). Besides eosinophils, also activated MCH-II-
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positive macrophages were previously described in inflamed intestinal tissues (Mowat and 
Bain, 2013). In line with this, a pivotal role of activated intestinal macrophages has been 
suggested in the immune-mediated pathogenesis of inflammatory-associated functional 
disturbances in experimental and clinical IBD (German et al., 2001, Franzè et al., 2013), as 
well as in enteric neuron aging (Phillips et al., 2013) and parasitic infection (Galeazzi et al., 
2000), both the latter conditions being characterized by a close contiguity of these cells with 
intestinal dystrophic neurites. On the other hand, the MHC-class-II seems also expressed by 
enteroglial cells in the ganglia of the submucous and myenteric plexuses and on the 
enteroglial sheaths of the nerve extensions in patients with Crohn‘s Disease (Geboes et al., 
1992). Furthermore, an inflammatory response can induce MHC-II up-regulation in both 
astrocytes and neuronal stem cells in vitro (Vagaska et al., 2016). So that, it becomes 
interesting to further characterized these neurons surrounding MHC-II positive cells. 
In addition to hematogenous macrophage infiltration, other non-neuronal cells that surround 
the somata of sensory neurons, like the satellite glia, can react to the injury and participate to 
the local neuroinflammatory processes (Ippolito et al., 2015; Delvalle et al., 2018). In 
particular, the intestinal inflammation induced by DNBS seems to alter the functionality of 
the enteric nervous system by affecting the interaction between enteric neurons, nociceptors 
and enteric glia. In this context the activation of glia seems to be actively involved in visceral 
hypersensitivity (Delvalle et al., 2018). Interestingly, the glia activation persists even in the 
remission phase of colitis, spreading vertically to the dorsal root ganglion where it was found 
an increased coupling between satellite cells and neurons that was correlated with visceral 
pain (Hanani et al., 2010; Huang et al., 2013). 
Like in the periphery, also in the central nervous system, neurons are surrounded by different 
type of glial cells which can be activated by excitatory neurotransmitters released from nearby 
neurons (Winkelstein et al., 2001; Watkins et al., 2002). Two of them, microglia and 
astrocytes, are particularly important because they play a strategic role in central sensitization 
as well as in the remodelling of synaptic plasticity responsible for the chronicization of 
painful state (Auld
 
and Robitaille, 2003; Di Cesare Mannelli et al., 2013; Di Cesare Mannelli 
et al., 2014).  
The present results showed a significant activation of both microglia and astrocytes (as well 
as an increased number of astrocytes) in the spinal cord dorsal horn of DNBS treated animals, 
where sensitive afferents reach the second order neuron in the spino-thalamic pain pathway. 
Anyway, a similar cellular framework was observed also in the ventral horn, indicating a 
diffuse activation of glia over the spinal cord. This feature has been detected in other pain 
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syndromes associated with hyperreflexia, as nerve injury (De Luca et al., 2016; Cirillo et al., 
2016; Qian et al, 2018). Motor neurons of ventral horn project to abdominal muscles and 
intestine (Qian et al, 2018), so the overactivation of astrocytes and microglia in this district 
may be related to the increased spinal reflex that we observed in response to the colo-rectal 
distension as for intestinal dysmotility. It is indeed known that the dorsal and ventral horn of 
the spinal cord have quite different morphological and functional profiles: the dorsal horn 
contains interneurons and receives the sensory terminals from the peripheral nerve, while the 
ventral horn neurons distribute outgoing (efferent) motor impulses. The incoming information 
is processed at spinal level by complex circuits involving excitatory and inhibitory 
interneurons in the dorsal horn, and transmitted to projection neurons for relay to several brain 
areas. In addition, nociceptive information is conveyed to the ventral horn and contributes to 
spinally-mediated nocifensive reflexes (Todd et al., 2010). Interestingly, a research group of 
Pittsburgh recently demonstrated that extrinsic primary afferent neurons (as pain-sensing 
neurons) of the colon influence myenteric neuron activity through a spinal reflex in mice, 
providing an explanation on how pain and dysmotility co-occur in GI disorders (Smith-
Edwards et al., 2019). Our results, showing a sequential activation of microglia and astrocytes 
along the reflex arc of the spinal cord, support the idea that glia activation along this circuit 
may contribute to prolong intestinal dysregulation and pain, as previously supposed in the 
animal model of chronic fatigue syndrome (Ji et al., 2013; Yasui et al., 2019). Moreover, this 
vicious circle is probably strengthened by the persisting immune activation in the periphery 
which can modulate signal propagation (Grace et al., 2014; Murphy et al., 2014). 
In the second part of my work, I studied the role of A3AR as possible new pharmacological 
target for relieving visceral pain. The novel A3AR agonist, MRS5980, as well as the classical 
agonist, Cl-IB-MECA, resulted effective against post-inflammatory visceral hypersensitivity 
in rats.  
The administration of A3AR agonists in the DNBS model of post-inflammatory visceral pain 
showed an efficacy equivalent to that of linaclotide, an approved treatment for adult patients 
suffering from IBS with predominant constipation (IBS-C; Chey et al., 2012). Linaclotide, a 
selective agonist of the guanylate cyclase–C receptor that is expressed on the luminal surface 
of intestinal enterocytes, reduces intestinal pain in animal models (Potter, 2011; Eutamene et 
al., 2010).  The use of linaclotide has been associated with the development of diarrhoea in 
20% of patients. This adverse effect makes linaclotide unsuitable for patients affected by 
diarrhoea-predominant IBS or IBS with alternating constipation and diarrhoea (Thomas and 
Allmond, 2013).  
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Adenosinergic signalling is known to contribute to pain control (Zylka, 2011; Sawynok, 2016; 
Janes et al., 2016) and to modulate intestinal functionality (Antonioli et al., 2014; Asano et 
al., 2017; Asano and Takenaga, 2017). We were especially interested in a potential role for 
A3AR agonists as a rapidly growing body of evidence shows that these compounds give pain 
relief in diverse models of chronic pain without significant adverse side effects (Fishman et 
al., 2012; Janes et al., 2016; Salvemini and Jacobson, 2017). This latter feature is of particular 
importance because of the cardiovascular side effects produced by A1AR agonists (Zahn et 
al., 2011; Zhang et al., 2009).  
The pharmacology of adenosine receptor subtypes displays significant inter-species 
differences. In the rat, the relative selectivity vs A3 for Cl-IB-MECA is:  A1/A3 = 848, A2A/A3 
= 1424, and A2B:/A3 = <10,000 (Borea et al., 2015).  It is thus unlikely but not impossible that 
the effects we saw with Cl-IB-MECA may have been partly due to activity at the A1 and/or 
A2A receptor subtypes. However, in the rat MRS5980 is greater than 10,000-fold selective for 
the A3 receptor subtype vs each of the other three subtypes and we can thus be confident that 
the effects seen with this agonist were entirely due to activity at the A3AR.  This conclusion is 
consistent with our data showing that both the Cl-IB-MECA the MRS5980 effects were 
blocked by the A3AR antagonist MRS1523, whose selectivity ratios in the rat are: A1/A3 = 
140 and A2A/A3 = 18 (the ratio for A2B is undetermined but is almost certain to be greater than 
10,000/1) (Borea et al., 2015). The analgesic effects of A3AR agonists in other pain models 
have been shown to be absent in A3AR knockout mice (Little et al., 2015).   
The efficacy of A3AR agonists against visceral pain is consistent with data showing that the 
A3AR is involved with multiple pain mechanisms (Janes et al., 2016) at peripheral, spinal and 
supraspinal levels (Little et al., 2015; Janes et al., 2016). There is evidence that A3AR 
agonists are analgesic against neuropathic pain via inhibition of the astrocyte-associated 
neuroinflammatory response in the spinal cord (Janes et al., 2014; Janes et al., 2015), a 
phenomenon strongly involved in pain persistence (Di Cesare Mannelli et al., 2013; Di Cesare 
Mannelli et al., 2014). A3AR activation has been reported to enhance the formation of anti-
inflammatory cytokines (Hasko et al., 1996; Janes et al., 2014; Janes et al., 2015; Wahlman et 
al., 2018) and the production of glial-derived neuroprotective substances (Wittendorp et al., 
2004). Furthermore, in vitro and in vivo studies demonstrate that A3AR produces its effects by 
inhibiting the p38 MAPK and NF-κB signalling pathways (Madi et al.,2007; Varani et al., 
2010; Varani et al.,2011; Janes et al.,2014). All these mechanisms may contribute to the relief 
of visceral pain evoked by colitis. This is consistent with the reports of Ren et al. who 
described that A3AR activation reduced colitis-induced tissue injury by modulating the NF-
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kB signalling pathway (Ren et al., 2015) and through inhibiting NLRP3 inflammasome 
activation and pyroptosis in colonic epithelial cells (Ren et al., 2019). 
A3ARs may limit excitatory neurotransmission, which is altered in neuropathic pain (Gwak et 
al., 2012) as well as in visceral pain (Willert et al., 2004; Lapointe et al., 2015; Gebhart and 
Bielefeldt, 2016). For example, the protective role of A3ARs in the first phase of ischemia 
appears to be at least partly related to a decrease in synaptic transmission (Pugliese et al., 
2003; Pugliese et al 2006; Rivera-Oliver and Diaz-Rios, 2014). Moreover, A3AR activation 
protects against the neurotoxic intra-cellular Ca
2+
 rise mediated by P2X7 or NMDA receptors 
(Zhang et al., 2006 and 2010).  
As already demonstrated (Coppi et al., 2019), the selective stimulation of adenosine A3 
receptors inhibits the N-type Cav2.2 opening and decreases electrically-evoked excitation in 
isolated rat DRG neurons. Here, we found that both Cl-IB-MECA and MRS5980 significantly 
inhibited Cav2.2 activation in DRG neurons. The effect was prevented by the selective A3AR 
antagonist, MRS1523, and by the Cav2.2 blocker, PD173212, confirming the involvement of 
Cav2.2 in the A3AR-mediated effect. We did not measure significant difference between 
A3AR-mediated inhibition in DRG neurons isolated from DNBS-treated vs vehicle-treated 
animals. However, alterations in passive membrane properties and steady-state Ca
2+
 currents 
were observed between the two groups. The resting membrane potential was significantly 
more depolarized in DRG neurons isolated from DNBS-treated animals, suggesting a 
hyperexcitable state in inflamed animals. Interestingly, steady-state Ca
2+
 currents, but not 
peak Ca
2+
 currents, were markedly reduced in DRG neurons isolated from DNBS animals. In 
an attempt to explain the relationship between steady-state Ca
2+
 current reduction in DRG 
neurons and visceral hypersensitivity, we hypothesize that a decrease in Ca
2+
 influx into the 





 channels (KCa) opening (Pagadala et al., 2013; Zhang et al., 2007; for 




 channels are known to stabilize the membrane 
potential and participate in repolarizing neurons after action potential firing, thus avoiding 
bursting activity. 
Moreover, a recent publication demonstrates that Cav2.2 induces a voltage-dependent, but 
Ca
2+ 
independent secretion of ATP from the soma of DRG neurons (Chai et al., 2017). ATP is 
a powerful mediator of pain, for example, ATP-induced activation of the P2X3 receptor is 
involved in visceral pain, as shown by the ability of the P2X3 antagonist, A-317491, to 
potently reduce hypersensitivity (Deiteren et al., 2015). 
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The hypothesis that Cav2.2-mediated modulation contributes to A3AR-mediated anti-
hyperalgesia is supported by other evidence. Modulation of Cav2.2 channel activity is seen 
with other pain-relieving, Gi-coupled receptor agonists, e.g., opioids, cannabinoids, 
neuropeptides Y, and substance P (Beedle and Zamponi, 2004; Shapiro and Hille, 1993; 
Soldo and Moises, 1996; Twitchell et al., 1997; Sun and Miller, 1999).  Also, the neuropathic 
pain analgesics, gabapentin and pregabalin (Finnerup et al., 2015), inhibit synaptic 
transmission mediated by Cav2.2 (Sutton et al., 2002; Bauer et al., 2009). The gabapentinoids 
are effective in reducing visceral pain and preventing spinal neuronal activation associated 
with colorectal distension in animals (Ohashi et al., 2008; Ravnefjord et al., 2008; Sikandar 
and Dickenson, 2011) and have been suggested to be treatments for irritable bowel syndrome 
(Camilleri and Boeckxstaens, 2017). A direct inhibitor of Cav2.2 channel activity, ziconotide, 
is a clinically-approved pain therapy, although it is limited to the intrathecal route (McDowell 
and Pope, 2016). In our hands, the i.p. administration of the specific Cav2.2 inhibitor 
PD173212 (Hu et al., 1999; Ryder et al., 1999; McDowell and Pope, 2016) significantly 
decreased visceral hypersensitivity in DNBS-treated animals, confirming the effectiveness of 
modulating this channels to obtain visceral pain relief.  
In the third part of the work, I studied the role of gut microbiota in the development and the 
persistence of post-inflammatory visceral pain induced by DNBS.  
Microbial composition can shape the environment in the colon as metabolites produced by 
microbiota can be involved in signalling, immune system modulation or have antibiotic 
activity (McHardy et al., 2013; Dorrestein et al., 2014; Wu et al., 2014). The dysbiosis of gut 
microbiota is one of the mechanisms proposed to contribute to the initiation, exacerbation and 
persistence of visceral pain (De Palma et al., 2014; Hyland et al., 2014; O‘Mahony et al., 
2017; Foster et al., 2017). It has been demonstrated that disturbance of the gut microbiota in 
adult mice and rats affects the local immune response and enhances pain signalling (Verdu et 
al., 2006; Hoban et al., 2016; Luczynski et al., 2017). However, the most well-documented 
line of evidence linking disruption of gastrointestinal microbial homeostasis to the 
development of chronic visceral hypersensitivity comes from the literature on post-infectious 
IBS (Thabane et al., 2007; Klem et al., 2017).  
Previous studies at clinical level showed major shifts in the gut microbial composition of 
patients with IBD (Morgan et al., 2012; Haberman et al., 2014; Blander et al., 2017; Imhann 
et al., 2018). Recently, a broad metabolic shift of microbiota has been also correlated with 
inflammation in these patients (Franzosa et al., 2018). Differences in microbial taxonomic 
profiles were identified in preparations of the fecal material used for the repeated fecal 
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transfers, obtained either from control or DNBS-treated animals, indicating that alterations of 
the gut ecosystem mediated by DNBS persist in the remission phase of colitis.  
Despite all the evidences, a cause-effect relationship between dysbiosis and post-
inflammatory visceral pain has not yet been proved. In this regard, Hadizadeh et al., (2018) 
provide evidence linking faecal microbiota composition to the occurrence of abdominal pain 
and its frequency, duration and intensity in the general population and, therefore proposed 
microbiota as risk factor for the development of functional gastrointestinal disorders. Studies 
in experimental animals showed that sensitivity to colonic distension of IBS patients can be 
transferred to rats by the fecal microbiota, without the occurrence of mucosal alterations 
(Crouzet et al., 2013). Additionally, alterations of visceral sensitivity and expressions of 
BDNF, GFAP and substance P in colon of mice in the presence or absence of IBS fecal 
supernatants stimulation were observed (Wang et al., 2016). In the majority of the studies, 
animals were transplanted with the microbiota from human, introducing another confounding 
factor which could be avoid using specie-specific transplants, as in our case. 
We found that the transplant of the faecal microbiota derived from DNBS rats in naïve rats is 
able to directly transfer visceral hypersensitivity to naïve animals. This effect was not 
imputable to an inflammatory response, neither to changes in gut permeability or serotonin 
increase. Besides, the transplant of a healthy microbiota in DNBS-treated animals counteract 
the persistence of visceral pain after the colitis resolution, confirming an active involvement 
of microbiota in post-inflammatory visceral pain.    
In a similar experiment, Yang et al. (2019) found a correlation between an abnormal 
composition of gut microbiota and susceptibility to anhedonia post spinal nerve injury (SNI) 
surgery. In fact, they observed that faecal microbiota transplantation from SNI rats with or 
without anhedonia altered pain, depression-like and anhedonia-like phenotypes in the pseudo-
germ-free mice, suggesting a general control of microbiota on pain perception. 
Despite all the evidences attesting a modulatory effect of faecal material transplantation on 
visceral sensitivity, no-one of these studies provided a strong correlation between the 
microbiota composition and the behavioural trends. Particularly, there are poor evidence 
investigating the evolution of microbiota over time after the FMT. In this work we 
demonstrated a strict temporal correlation between the animal‘s behaviour and the evolution 
of microbiota composition. Concerning the experimental groups of animals treated with 
antibiotics and then subjected to FMT, defined clusters in PCoA plots were observed for 
samples collected after the second series of repeated faecal transfers (Day 32) from CTR 
donors and DNBS donors, suggesting that major modifications in the composition and 
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structure of the gut microbiota might have occurred at this stage. On Day 46 (when the 
difference of pain disappeared) the microbiota belonging to the two different groups got 
closer again. Evaluation of taxonomic profiles confirmed that marked differences between the 
animals underwent the FMT from CTR or DNBS were identifiable on Day 32 at phylum and 
family level for major members of the gut microbiota, including also protective microbial taxa 
known to be associated with gastrointestinal health. 
The fact that the effect of the transplant was not decisive, demonstrated the presence of a 
continuous bidirectional influence between the microbiota and the gut, which can be only 
temporarily modulated by FMT. Establishing and maintaining beneficial interactions between 
the host and its associated microbiota are key requirements for host health. On one hand, 
microbiota composition modulates gut physiology (Sommer and Bäckhed, 2013; Contijoch et 
al., 2019), on the other hand, substances released from the gut can exert a selective pressure 
on different microbiota bacterial strains (Hevia et al., 2015; Fung et al., 2019).  
In an altered GI physiology, like that occurs after a major intestinal damage, the microbiota 
transplanted could somehow stem the pathogenic mechanisms underlying pain persistence, 
e.g., by metabolizing pain mediators or by producing analgesic substances, or even through a 
modulation of gene expression in the gut. This effect may last until the ―new‖ microbiota is 
able to survive in the new environment. Afterwards the selective pressure exerted by the host 
determine further alterations in the composition of microbiota, with loss of the effects. All 
these hypotheses need to be tested. 
Another point that need to be discussed is the employ of the antibiotics to prepare the animals 
to the FMT. In the first set of the experiments, we adopted a 24 days-antibiotic treatment in 
order to deplete the resident microbiota and therefore favor the establishment of the new one 
derived from CTR and DNBS animals, respectively. Although the protocols for preparing the 
animals to the FMT are quite heterogeneous in literature, long treatments which employ a 
combination of antibiotics, like this, are commonly used (Hintze et al., 2014; Staley et al., 
2017). However, most of the studies have only shown the feasibly of this approach, but they 
have been seldom used in a disease context (Kelly et al., 2016; Routy et al., 2017). Actually, 
antibiotics should be used with caution, depending on the disease that is studied. For example, 
the use of antibiotics can be problematical when studying some diseases, as they may be 
improved in rodent models by the antibiotics themselves (Adachi et al., 1995; Bigorgne et al., 
2008; Dapito et al., 2012). 
In our case, an important bias was represented by the fact that a long antibiotic treatment 
directly affects visceral sensitivity, as reported in many studies (Verdu et al., 2006; 
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O‘Mahony et al., 2014, Hoban et al., 2016; Luczynski et al., 2017), becoming a confounding 
factor in the study of FMT effect on visceral pain. As expected, the long antibiotic treatment 
increased visceral sensitivity in the animals, though the effect was significant only in the 
AWR test. In particular the antibiotic treatment lowered the threshold at which the animals 
respond to the colo-rectal stimulus. Microbial re-colonization restored normal visceral pain 
responsiveness and threshold, as previously observed (Luczynski et al., 2017). By contrast, 
the animals receiving the FMT from DNBS donors showed a partial and slow recovery from 
the antibiotic effect. This led us to question if the increased visceral sensitivity observed after 
the FMT from DNBS donors was imputed to an active effect of the established microbiota or 
to a slow recovery from the antibiotic effect, as the new microbiota was incapable to restore 
the normal gut physiology. To reduce the impact of the antibiotics on visceral sensitivity we 
shortened the length of the antibiotic treatment to 7 days, time needed to obtain a sufficient 
antibiotic depletion. Also the shortened antibiotic treatment caused a significant increase in 
the AWR response to CRD, confirming that visceral sensitivity is directly modulated by the 
resident microbiota. Anyway, in this case, the effect of the antibiotic was completely reverted 
by the FMT from CTR donors as well as by administering the vehicle, indicating a beneficial 
effect of a spontaneous re-colonization of the intestine. On the other hand, the pro-algesic 
effect mediated by FMT from DNBS donors was confirmed even after the shortened 
antibiotic treatment.  
The visceral hyperalgesia induced by the transplant of the faecal material derived from DNBS 
animals was evident already 24h after the first set of FMT, suggesting the presence of pain 
mediators in the supernatant obtained from the faeces, as supposed in other studies (Buhner  
et al., 2019; Wang et al., 2015; Hevia et al., 2015; Wang et al., 2016). About that, we 
excluded the presence of residual DNBS in the faecal supernatant utilized for FMT. We 
cannot exclude instead the presence of cytokine, enzymes, neurotransmitters or other 
secondary metabolites (maybe not known yet) in these preparations. Regarding the protein 
content, it is likely digested through the stomach, unless the microbiota someway protects 
them from the enzymatic actions or continue producing them once transplanted.   
The presence of pain mediators in the faecal medium might explain the acute effect of FMT. 
By contrast, the long-lasting hyperalgesia observed in these animals can not be imputed to 
this acute stimulation, as well as to a local irritation, since by colon histological analysis, no 
macroscopic or microscopic signs of damage were observed on Day 32 (7 days after the last 
FMT). These evidences increasingly strengthened the idea of an active role of microbiota in 
pain modulation mediated by FMT. Moreover, the fact that the visceral hyperalgesia induced 
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by the microbiota transplant from DNBS donors extinguished earlier in the VMR test in 
respect to AWR test, suggested a possible central sensitization to the painful stimulus induced 
by CRD. Similarly, in the animals treated with DNBS, VMR response is significantly 
decreased after 4 weeks, while the augmented AWR response persists up to 13 week after 
DNBS injection. 
The integrity of the intestine was also confirmed by investigating its permeability. A slight 
increase in gut permeability was denotable only after the antibiotic treatment, with an increase 
in the expression of Zo-1. The up-regulation of Zo-1 expression and its augment at plasma 
level has been in fact related to a leaky gut (Sapone et al., 2006; Fasano t al., 2012; Sturgeon 
and Fasano, 2016). This result is in line to the previous findings showing a positive effect of 
microbiota on tight junctions‘ expression and gut barrier integrity maintenance (Kelly et al., 
2015b; Desai et al., 2016; Stevens et al., 2018).  
The analysis of gene expression in the gut confirmed a derangement of cytokines as a result of 
both the antibiotic treatment and the FMT, but no significant correlations were found between 
the cytokines profiles among the groups and the observed differences in visceral pain. 
However, it appears difficult to associate a behavioural phenotype to the alteration of few 
cytokines. In fact, the immune response is very finely orchestrated with many co-factors 
intervening. Frequently the augment of pro-inflammatory cytokines is followed by an 
increased release of anti-inflammatory cytokines in a circular regulatory loop where the final 
outcome is the result of the balance between all the actors involved, including the microbiota 
(Round et al., 2009; Maslowski et al., 2010; Cicchese et al., 2018). This is evident in the 
DNBS donors wherein an increase in both pro- and anti- inflammatory cytokines occurred. 
Concerning the immune response, contradictory evidences were revealed in patients affected 
by IBS. In fact, although the evidence for aberrant immune activation seems overwhelming in 
PI‐IBS, various research groups found no differences in immune cell numbers or cytokine 
mRNA expression in mucosal biopsies of PI‐IBS and IBS patients compared with healthy 
volunteers (Mearin et al., 2009; Braak  et al., 2012; Wouters et al., 2016a; Bennett et al., 
2016). Noteworthy, in the animals receiving the FMT from DNBS donors we found a 
decrease in TNF-α and an increase in IL-10. The opposite has been observed in the animals 
receiving the FMT from CTR. There are no data in literature that can explain this 
phenomenon, whereby it would be interesting to investigate further the inflammatory 
response in the gut by an extensive mRNA microarray analysis on the tissue.  
Searching for other possible mechanisms, I focused the attention on tryptophan metabolism, 
which is one of the most important molecules at the interface between the microbiota, the gut 
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and the nervous system: its metabolism, which is under the strict control of the microbiota, 
can lead to different compounds with neuromodulator functions like serotonin and kynurenine 
(Agus et al., 2018). Alterations in tryptophan metabolism have been documented to be 
involved in different GI disorders, such as IBS-D, IBS-C and IBDs (Fitzgerald et al., 2008; 
Clarke et al., 2012; Lamas et al., 2016; Nikolaus et al., 2017). In the DNBS donors we found 
a decrease in the plasmatic levels of tryptophan that could account for an increase 
biosynthesis of serotonin, as confirmed by the HPLC analysis on the gut. The augment in the 
serotonin production and release is a characteristic consequence of intestinal damages. In fact, 
the enterochromaffin cells respond to a gut insult through the release of this neurotransmitter, 
which can directly act on visceral afferents (Nozawa et al., 2009; Cremon et al., 2011; Mawe 
et al., 2013; Nikolaus et al., 2017).  In the animals underwent the antibiotic treatment and then 
subject to FMT we found a common decrease in the plasmatic levels of tryptophan, but in this 
case no changes in serotonin levels were observed in the gut tissue. By contrast, the animals 
underwent the FMT showed a massive and long-lasting increase of serotonin in the faeces, 
irrespective to the donor.  
In the animals treated with the antibiotics+vehicle the decrease in tryptophan instead combine 
with an increase in the production of kynurenine. Interestingly, the metabolism of kynurenin 
in the different tissues leads to both neuromodulator compounds, like kynurenic acid and 
quinolinic acid (Stone, 2000; Vamos et al., 2009). Kynurenic acid account for the 
neuroprotective effects of kynurenine derivatives. Through the activation of GPR35 receptors, 
it also showed pain relief properties in animal models of pain (Zhao et al., 2010; Cosi et al., 
2011; Resta et al., 2016), while neurotoxicity is usually ascribed to quinolinic acid 
(Guillemin, 2012). Preclinical evidence demonstrated direct and indirect mechanisms by 
which the gut microbiota can regulate tryptophan availability for kynurenine pathway 
metabolism, with downstream effects on gut and brain functions (Kaszaki et al., 2012; 
Kennedy et al., 2017). Also other metabolites of tryptophan, like aryl hydrocarbon receptors 
(AhR) agonists, were found to be important in neuromodulation, e.g., by the control of 
microglial activation (Rothhammer et al., 2018) as well as by modulating intestinal immune 
response (Hubbard et al., 2015; Metidji et al., 2018). Anyway, the increase in the production 
of these molecules and their involvement in visceral pain has to be explored yet.  
As mentioned above, since the microbiota is able to directly influence the levels of 5-HT, I 
measured serotonin levels also in the faeces. Interestingly the faecal content did not reflect 
what observed in the gut tissue. In fact, in the faeces we observed a decrease in serotonin 
consequent the antibiotics treatment, as previously reported (Hata et al., 2017). On the other 
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hand, serotonin increased after the FMT. Interestingly, Fung et al. (2019) demonstrated that 
an increase of 5-HT in the gut lumen selectively modulate the colonization of bacteria species 
in the gut. Nevertheless, no difference was found between the animals receiving the FMT 
from CTR or from DNBS donors, demonstrating again that 5-HT is not involved in the 
transfer of pain mediated by FMT from DNBS donors into naïve rats. Furthermore, I found a 
decrease of dopamine in the gut as consequence of the antibiotic treatment and the FMT in all 
the experimental groups. In accordance, it was reported that the clearance of gut microbiota 
by antibiotic cocktail reduced synthesis of dopamine (DA) in intestines and exacerbated liver 
damage. Anyway, the alteration in dopamine levels were restored by recovery of gut 
microbiota (Xue et al., 2018; Strandwitz et al., 2018), unlike what we have observed. 
Physiological studies suggest that dopaminergic mechanisms are important in the regulation 
of gastrointestinal motility (Vieira-Coelho et al., 1993; Walker et al., 2000; Li et al., 2006). 
Moreover, dopamine is the metabolic precursor of noradrenaline (NA), which is another 
important regulator of gut functionalities (Musacchio et al., 2013; Mittal et al., 2017). The gut 
levels of dopamine were reduced also in DNBS donors, which reported alterations in the GI 
motility (Antonioli et al., 2011).  
Regarding the therapeutic potential of FMT, current evidences from randomized clinical trials 
do not suggest a benefit of FMT for global IBS symptoms, though there remain discrepant 
results among the trials (Xu et al., 2019). Actually, the therapeutic effect of FMT could be 
empowered by adjusting the protocols. In fact, up to now it has been considered a good 
protocol to maintain a low number of FMT with a single donor. This protocol could not be 
effective in particular conditions like IBDs. Indeed, recent clinical studies highlighted the 
efficacy of a multiple donor and repeated treatment based therapy in patients affected by UC, 
chronic intestinal pseudo-obstruction and IBS (Paramsothy,et al., 2017; Gu et al., 2017; El-
Salhy et al., 2019). In our animal model of colitis-induced visceral pain, we obtained a good 
relief from pain after 4 cycles of FMT, utilizing different donors. In fact, is likely that the 
―inflammatory‖ environment wherein the microbiota is transplanted obstacles the 
establishment of some species compared to others. In this case, the repetition of the FMT 
could force the system to accept the new microbiota. 
In conclusion, this work highlighted the complex nature of post-inflammatory visceral pain 
whose study required a multidisciplinary approach. On one side, these findings could suggest 
the possibility to employ complementary therapies for modulating the different actors 
involved in the persistence of pain. On the other side, understanding the molecular 
mechanisms that regulate the interaction between the periphery and the central nervous 
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system in the maintenance of this hyperactivated system could represent the key to identify 
new therapeutic targets. Within this scenario, A3AR agonists appear to be a promising 
resource for visceral pain management. Regarding the microbiota, the results obtained in vivo 
strengthen the hypothesis of a direct involvement of microbiota in post-inflammatory visceral 
pain and so encourage to further study the therapeutic effect of microbiota transplantation. 
Even if the question about the mechanism by which the microbiota influences visceral 
sensitivity remain still open, this work contributed to exclude some hypothesis. It is however 
necessary to continue investigating the mechanisms by which the microbiota can modulate 
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